0001213809-20-000024.txt : 20200514 0001213809-20-000024.hdr.sgml : 20200514 20200514161017 ACCESSION NUMBER: 0001213809-20-000024 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200514 DATE AS OF CHANGE: 20200514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DYADIC INTERNATIONAL INC CENTRAL INDEX KEY: 0001213809 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 450486747 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32513 FILM NUMBER: 20877831 BUSINESS ADDRESS: STREET 1: 140 INTRACOASTAL POINTE DRIVE STREET 2: SUITE 404 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: 561-743-8333 MAIL ADDRESS: STREET 1: 140 INTRACOASTAL POINTE DRIVE STREET 2: SUITE 404 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: CCP WORLDWIDE INC DATE OF NAME CHANGE: 20030110 10-Q 1 dyai-20200331.htm 10-Q dyai-20200331
0001213809March 31, 20202020Q1false140 Intracoastal Pointe DriveSuite 404JupiterFlorida☒☐--12-31P2YP2YP3YP2YP3YP6M00012138092020-01-012020-03-31xbrli:shares00012138092020-05-13iso4217:USD00012138092020-03-3100012138092019-12-31iso4217:USDxbrli:shares00012138092019-01-012019-03-310001213809us-gaap:CommonStockMember2019-12-310001213809us-gaap:TreasuryStockMember2019-12-310001213809us-gaap:AdditionalPaidInCapitalMember2019-12-310001213809us-gaap:RetainedEarningsMember2019-12-310001213809us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001213809us-gaap:CommonStockMember2020-01-012020-03-310001213809us-gaap:RetainedEarningsMember2020-01-012020-03-310001213809us-gaap:CommonStockMember2020-03-310001213809us-gaap:TreasuryStockMember2020-03-310001213809us-gaap:AdditionalPaidInCapitalMember2020-03-310001213809us-gaap:RetainedEarningsMember2020-03-3100012138092018-12-3100012138092019-03-310001213809dyai:DuPontDaniscoMemberdyai:IndustrialTechnologyBusinessMember2015-12-312015-12-31dyai:segmentdyai:customer0001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-03-310001213809us-gaap:NonUsMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001213809us-gaap:NonUsMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-31xbrli:pure0001213809us-gaap:NonUsMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-03-310001213809us-gaap:NonUsMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-03-310001213809us-gaap:NonUsMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001213809us-gaap:NonUsMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-12-310001213809dyai:ContractResearchOrganizationsMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001213809dyai:ContractResearchOrganizationsMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-03-310001213809dyai:ContractResearchOrganizationsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsPayableMember2020-03-310001213809dyai:ContractResearchOrganizationsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsPayableMember2020-01-012020-03-310001213809dyai:ContractResearchOrganizationsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsPayableMember2019-12-310001213809dyai:ContractResearchOrganizationsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsPayableMember2019-01-012019-12-310001213809us-gaap:BilledRevenuesMember2020-03-310001213809us-gaap:BilledRevenuesMember2019-12-310001213809us-gaap:UnbilledRevenuesMember2020-03-310001213809us-gaap:UnbilledRevenuesMember2019-12-310001213809us-gaap:TaxYear2018Member2020-01-012020-03-310001213809us-gaap:CashMember2020-03-310001213809us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-03-310001213809us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-03-310001213809us-gaap:CashMember2019-12-310001213809us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2019-12-310001213809us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310001213809us-gaap:CorporateDebtSecuritiesMember2020-01-012020-03-310001213809us-gaap:CorporateDebtSecuritiesMember2019-01-012019-03-310001213809us-gaap:CorporateDebtSecuritiesMember2019-01-012019-12-3100012138092017-06-302017-06-30iso4217:EUR0001213809dyai:ResearchServicesAgreementMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMemberdyai:BDIHoldingsMember2017-06-302017-06-300001213809dyai:VLPbioMemberdyai:ResearchServicesAgreementMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMemberdyai:BDIMember2017-12-310001213809dyai:ResearchServicesAgreementMemberdyai:BDIMember2017-06-302017-06-300001213809srt:MinimumMemberdyai:ResearchServicesAgreementMember2017-06-302017-06-300001213809srt:MaximumMemberdyai:ResearchServicesAgreementMember2017-06-302017-06-300001213809srt:MinimumMemberdyai:ResearchServicesAgreementMemberdyai:BDIMember2017-06-302017-06-300001213809srt:MaximumMemberdyai:ResearchServicesAgreementMemberdyai:BDIMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMember2017-12-310001213809dyai:ServiceFrameworkAgreementMember2017-12-310001213809dyai:ServiceFrameworkAgreementMember2017-06-302017-06-300001213809dyai:NovovetMember2019-04-260001213809dyai:AlphazymeMember2019-05-050001213809dyai:AlphazymeMemberus-gaap:CollaborativeArrangementMember2019-05-052019-05-05dyai:antibody_and_vaccine0001213809us-gaap:CollaborativeArrangementMemberdyai:SerumMember2019-05-07dyai:protein0001213809us-gaap:CollaborativeArrangementMemberdyai:SerumMember2019-05-072019-05-070001213809us-gaap:CollaborativeArrangementMemberdyai:SerumMember2020-01-012020-03-310001213809us-gaap:CollaborativeArrangementMemberdyai:SerumMember2020-03-31utr:sqft0001213809dyai:JupiterFloridaHeadquartersLeaseMember2020-03-310001213809dyai:JupiterFloridaHeadquartersLeaseMember2020-01-012020-03-310001213809dyai:NetherlandsOfficeLeaseMember2020-01-012020-03-310001213809dyai:VTTTechnicalResearchCentreofFinlandLtdMember2019-06-280001213809dyai:VTTTechnicalResearchCentreofFinlandLtdMember2019-06-282019-06-280001213809dyai:VTTTechnicalResearchCentreofFinlandLtdMember2019-10-250001213809dyai:VTTTechnicalResearchCentreofFinlandLtdMember2019-10-252019-10-250001213809dyai:VTTTechnicalResearchCentreofFinlandLtdMember2020-03-230001213809dyai:VTTTechnicalResearchCentreofFinlandLtdMember2020-03-232020-03-230001213809dyai:A2006PlanMember2020-03-310001213809dyai:A2011PlanMember2020-03-310001213809dyai:A2011PlanMember2019-01-012019-01-010001213809dyai:A2011PlanMember2020-01-012020-01-010001213809dyai:A2011PlanMember2019-12-310001213809dyai:A2011PlanMemberus-gaap:EmployeeStockOptionMember2020-01-012020-03-310001213809dyai:A2011PlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:EmployeeStockOptionMemberus-gaap:ChiefExecutiveOfficerMember2020-01-012020-03-310001213809dyai:A2011PlanMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberdyai:ContractorMember2020-01-012020-03-310001213809dyai:A2011PlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:EmployeeStockOptionMemberdyai:ContractorMember2020-01-012020-03-310001213809us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001213809srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-03-310001213809srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-03-3100012138092019-01-012019-12-310001213809us-gaap:EmployeeStockOptionMemberdyai:ExecutivesandKeyPersonnelMember2020-01-022020-01-020001213809dyai:ExecutivesandKeyPersonnelMember2020-01-022020-01-020001213809us-gaap:DirectorMember2020-01-022020-01-020001213809dyai:EmployeeMember2020-01-022020-01-020001213809us-gaap:EmployeeStockOptionMemberdyai:EmployeeMember2020-01-022020-01-020001213809us-gaap:EmployeeStockOptionMemberdyai:ConsultantMember2020-01-022020-01-020001213809dyai:ConsultantMember2020-01-022020-01-020001213809us-gaap:EmployeeStockOptionMemberdyai:ContractorMember2020-03-220001213809dyai:ContractorMember2020-03-222020-03-220001213809us-gaap:SubsequentEventMember2020-05-012020-05-140001213809us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-310001213809us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-03-310001213809us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310001213809us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-03-310001213809us-gaap:CommonStockMember2018-12-310001213809us-gaap:TreasuryStockMember2018-12-310001213809us-gaap:AdditionalPaidInCapitalMember2018-12-310001213809us-gaap:RetainedEarningsMember2018-12-310001213809us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001213809us-gaap:RetainedEarningsMember2019-01-012019-03-310001213809us-gaap:CommonStockMember2019-03-310001213809us-gaap:TreasuryStockMember2019-03-310001213809us-gaap:AdditionalPaidInCapitalMember2019-03-310001213809us-gaap:RetainedEarningsMember2019-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended March 31, 2020
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to ______
Commission File Number: 000-55264
dyai-20200331_g1.jpg DYADIC INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 45-0486747
State or Other Jurisdiction of Incorporation or Organization I.R.S. Employer Identification No.
140 Intracoastal Pointe Drive, Suite 404
 Jupiter, Florida
 33477
Address of Principal Executive OfficesZip Code

(561) 743-8333
Registrant’s Telephone Number, Including Area Code
N/A
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
 
Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareDYAIThe NASDAQ Stock Market LLC
The number of shares outstanding of each of the registrant’s Common Stock as of May 13, 2020 was 27,469,157.






CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Information (other than historical facts) set forth in this Quarterly Report contains forward-looking statements within the meaning of the Federal securities laws, which involve many risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements generally can be identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” and other similar terms or variations of them or similar terminology. Such forward-looking statements are included under Item 2 “Management’s Discussion and Analysis”. Dyadic International, Inc., and its subsidiaries cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking statements involve many risks, uncertainties or other factors within and/or beyond Dyadic’s control. These factors include, but are not limited to (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic’s and third parties’ research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on our key customers and collaborators; (8) the pharmaceutical and biotech industry, governmental regulatory and other agencies’ willingness to adopt, utilize and approve the use of the C1 gene expression platform; (9) the risk of theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological materials owned by us and/or Danisco US, Inc. and VTT Technical Research Centre of Finland Ltd; (10) speculative nature and illiquidity of equity securities received as consideration from sub-licenses; (11) the impact of the novel coronavirus identified as “COVID-19” on our business and operating results; and (12) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in this Form 10-Q and our Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 30, 2020. We caution you that the foregoing list of important factors is not exclusive. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, considering the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Moreover, we operate in a highly regulated, competitive and rapidly changing environment. Our competitors have far greater resources, infrastructure and market presence than we do which makes it difficult for us to enter certain markets, and/or to gain or maintain customers. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Before investing in our common stock, investors should carefully read the information set forth under the caption “Risk Factors” in this Form 10-Q and elsewhere in our Form 10-K filed with the SEC on March 30, 2020 which could have a material adverse effect on our business, results of operations and financial condition.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations.
We qualify all our forward-looking statements by these cautionary statements. In addition, with respect to all our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

PART I

Item 1.Financial Statements

3

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Assets
Current assets:
Cash and cash equivalents$4,696,831  $4,823,544  
Short-term investment securities26,587,752  29,399,146  
Interest receivable227,146  329,711  
Accounts receivable518,601  558,530  
Income tax receivable500,616  250,308  
Prepaid expenses and other current assets288,495  277,999  
Total current assets32,819,441  35,639,238  
Non-current assets:
Long-term investment securities2,518,160  1,511,636  
Long-term income tax receivable—  250,308  
Other assets50,489  51,314  
Total assets$35,388,090  $37,452,496  
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$653,373  $943,378  
Accrued expenses240,003  566,003  
Deferred research and development obligations242,443  78,644  
Total current liabilities1,135,819  1,588,025  
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $.0001 par value:
Authorized shares - 5,000,000; none issued and outstanding
—  —  
Common stock, $.001 par value:
Authorized shares - 100,000,000; issued shares - 39,722,659 and 39,612,659, outstanding shares - 27,469,157 and 27,359,157 as of March 31, 2020 and December 31, 2019, respectively
39,713  39,613  
Additional paid-in capital96,707,690  96,105,851  
Treasury stock, shares held at cost - 12,253,502
(18,929,915) (18,929,915) 
Accumulated deficit(43,565,217) (41,351,078) 
Total stockholders’ equity34,252,271  35,864,471  
Total liabilities and stockholders’ equity$35,388,090  $37,452,496  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended March 31,
20202019
Revenues:
Research and development revenue$315,372  $402,527  
Costs and expenses:
Costs of research and development revenue278,182  327,903  
Research and development755,453  692,370  
Research and development - related party—  389,473  
General and administrative1,653,392  1,428,067  
Foreign currency exchange loss (gain), net10,867  6,034  
Total costs and expenses2,697,894  2,843,847  
Loss from operations(2,382,522) (2,441,320) 
Interest income168,383  266,962  
Loss before income taxes(2,214,139) (2,174,358) 
Provision for income taxes—  900  
Net loss$(2,214,139) $(2,175,258) 
Basic and diluted net loss per common share$(0.08) $(0.08) 
Basic and diluted weighted-average common shares outstanding27,452,490  26,713,486  
The accompanying notes are an integral part of these unaudited consolidated financial statements.

5


DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
Common StockTreasury StockAdditionalAccumulated
SharesAmountSharesAmountPaid-in CapitalDeficit Total
Balance at December 31, 201939,612,659   $39,613  (12,253,502) $(18,929,915) $96,105,851  $(41,351,078) $35,864,471  
Stock-based compensation—  —  —  —  426,939  —  426,939  
Exercise of stock options100,000  100  —  —  174,900  —  175,000  
Net loss—  —  —  —  —  (2,214,139) (2,214,139) 
Balance at March 31, 202039,712,659  $39,713  (12,253,502) $(18,929,915) $96,707,690  $(43,565,217) $34,252,271  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

6


DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended March 31,
20202019
Cash flows from operating activities
 Net loss $(2,214,139) $(2,175,258) 
 Adjustments to reconcile net loss to net cash used in operating activities:
 Stock-based compensation expense 426,939  309,563  
 Amortization of held-to-maturity securities, net 107,256  32,201  
 Foreign currency exchange loss (gain), net10,867  5,148  
 Changes in operating assets and liabilities:
 Interest receivable102,565  3,981  
 Accounts receivable35,258  (106,781) 
 Income tax receivable—  6,249  
 Prepaid research and development—  83,112  
 Prepaid expenses and other current assets(10,529) 5,049  
 Accounts payable(292,361) 641,799  
 Accrued expenses(326,000) (96,606) 
 Deferred research and development obligation163,799  (117,978) 
 Net cash used in operating activities(1,996,345) (1,409,521) 
Cash flows from investing activities
 Purchases of held-to-maturity investment securities(11,652,385) (13,190,855) 
 Proceeds from maturities of investment securities13,350,000  16,197,000  
 Net cash provided by investing activities1,697,615  3,006,145  
Cash flows from financing activities
 Proceeds from exercise of options175,000  —  
 Net cash provided by financing activities175,000  —  
 Effect of exchange rate changes on cash(2,983) (7,177) 
 Net (decrease) increase in cash and cash equivalents(126,713) 1,589,447  
 Cash and cash equivalents at beginning of period4,823,544  2,386,314  
 Cash and cash equivalents at end of period$4,696,831  $3,975,761  
 Supplemental cash flow information
 Cash received from income tax refund$—  $6,249  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

7

Notes to Consolidated Financial Statements

Note 1: Organization and Summary of Significant Accounting Policies
Description of Business
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica (formerly Myceliophthora thermophila) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.
On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (“DuPont”), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.
After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is aiming to develop products such as innovative vaccines and drugs, biosimilars and/or biobetters.
Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”. Prior to the Company’s uplisting to the NASDAQ, the Company’s common stock traded on the OTCQX market.

Impact of COVID-19

The recent outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company’s employees, operations, and research projects.
To date, as a direct result of COVID-19, most of our employees are working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the response to curb its spread, currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.

8

The Company is currently working on several COVID-19 related vaccine and antibody opportunities. For example, the Israel Institute for Biologic Research (“IIBR”) is exploring the potential of Dyadic’s industrially proven C1 gene expression platform to express certain gene sequences and targets developed by IIBR into both an rVaccine candidate and mAbs that may potentially help combat the outbreak of the COVID-19 virus. The Company is also working with three scientists who are a part of the EU ZAPI initiative: Dr. Bosch at Utrecht University, Dr. Haagmans at Erasmus Medical Center, and Prof. Osterhaus at University of Veterinary Medicine Hannover, as well as with Dr. Erroba and Mr. Es-Sbai at clinical contract research organizations to develop and submit a proposal for funding to pharmaceutical organizations and governmental agencies. The objective of this proposal is to develop, and pre-clinically and clinically evaluate (in Phase I/II trials), a multimeric self-assembling SARS-CoV-2 Receptor Binding Domain vaccine candidate to rapidly respond to the COVID-19 pandemic. Another proposal was developed in conjunction with Ufovax, a spin-off vaccine company of Scripps Research, which was submitted to many of the same parties. In addition, the Company is pursuing other opportunities where it may be able to apply its C1gene expression platform to help combat the COVID-19 pandemic; however, there is no assurance that any of these opportunities will materialize or that the C1 technology or any product expressed from C1 or any of the various other steps in a vaccine or drug development process will perform, provide benefits, obtain governmental safety and regulatory approvals, be registered or gain market acceptance. In addition, our C1 technology has yet to be used to produce a vaccine, antibody or other biologic product that has entered the clinical trial phase, and we are competing with more experienced companies for grants or funding of this type. As a result, there is no assurance that we will receive these grants or funding resulting from these proposals.
We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs of our operations. We believe that we have sufficient cash, cash equivalents and investments to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing balances of cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.

Summary of Significant Accounting Policies

Basis of Presentation
The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2019, included in our Form 10-K which was filed with the SEC on March 30, 2020.
In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.
Use of Estimates
The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
9

Concentrations and Credit Risk
The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.
For the three months ended March 31, 2020 and 2019, the Company’s revenue was generated from five and six customers, respectively. As of March 31, 2020 and December 31, 2019, the Company’s accounts receivable was from eight and five customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations.
The Company generates a portion of its revenues from customers that are located outside of the United States. For the three months ended March 31, 2020, the Company had three customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 58.0% or $183,000 of total revenue. For the three months ended March 31, 2019, the Company had one customer outside of the United States (i.e. European customer) that accounted for approximately 69.7% or $281,000 of total revenue.
As of March 31, 2020, the Company had eight customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 72.9% or $378,000 of accounts receivable. As of December 31, 2019, the Company had four customers outside of the United States that accounted for approximately 69.5% or $388,000 of accounts receivable.
The Company uses a few contract research organizations (“CROs”) to conduct its research projects. For the three months ended March 31, 2020 and 2019, one CRO accounted for approximately 100% and 68.1% of total research services we purchased, respectively. As of March 31, 2020, approximately $596,000 or 91.2% of accounts payable was related to this CRO. At December 31, 2019, approximately $706,000 or 74.9% of accounts payable was to this CRO. The loss of business from this CRO or a combination of the Company’s CROs could adversely affect its operations.
Cash and Cash Equivalents
We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.

Investment Securities
The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).
The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of March 31, 2020 and December 31, 2019, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of March 31, 2020 or December 31, 2019.
Accounts Receivable
Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.
10

Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. There was no allowance for doubtful accounts as of March 31, 2020 and December 31, 2019.
Accounts receivable consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Billed receivable $405,101  $432,546  
Unbilled receivable113,500  125,984  
$518,601  $558,530  

Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Prepaid insurance$198,554  $173,890  
Prepaid expenses - various88,607  101,221  
Prepaid taxes1,334  2,888  
$288,495  $277,999  
Accounts Payable
Accounts payable consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Research and development expenses$590,452  $766,001  
Legal expenses9,782  26,994  
Other53,139  150,383  
$653,373  $943,378  
Accrued Expenses
Accrued expenses consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Employee wages and benefits$162,310  $474,388  
Research and development expenses20,035  69,795  
Other57,658  21,820  
$240,003  $566,003  

Revenue Recognition
11

The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to grants and fundings: The Company may receive grants and fundings from governments, agencies, and other private and not-for-profit organizations. These grants and fundings are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred
12

research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

Research and Development Costs
Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.
Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three months ended March 31, 2020 and 2019 were as follows:
Three Months Ended March 31,
20202019
(Unaudited)(Unaudited)
Outside contracted services$613,790  $585,487  
Contracted services - related party—  389,473  
Personnel related costs123,638  94,762  
Facilities, overhead and other18,025  12,121  
$755,453  $1,081,843  

Foreign Currency Transaction Gain or Loss
The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.
Fair Value Measurements
The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 – Quoted prices in active markets for identical assets or liabilities.
•Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.
13

The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
Income Taxes
The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from 35% to 21% and repeal of the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended December 31, 2019.
The TCJA repealed the corporate AMT but permitted unused AMT credit carryforwards to be used to reduce the regular tax obligation in future years. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Subsequently, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), which was signed into law in March 2020, accelerated the full refund of any unused AMT credits from 2021 (as provided for in the TCJA) to 2018 or 2019, at the taxpayer’s election.

Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of March 31, 2020, we have received 50% or approximately a $0.5 million refund for tax year 2018 and we expect to receive the remaining portion in 2020 pursuant to the CARES Act.

For the three months ended March 31, 2020, there were no provision for income taxes and unrecognized tax benefits recorded.

Deferred tax assets as of March 31, 2020 and December 31, 2019 were approximately $9.6 million and $7.2 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of March 31, 2020 and December 31, 2019.
On June 20, 2019, the Company received a letter from the United States Internal Revenue Service (the “IRS”) informing the Company that its 2016 federal tax return was selected for examination. In August 2019, the Company had a meeting with the IRS agent and provided the IRS with all requested information. Thus far, the Company has not been informed of any assessment and we are unable to predict when the audit will be concluded or whether any assessment will be proposed.
Comprehensive Income (Loss)
Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.

Stock-Based Compensation

We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Net Loss Per Share
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average
14

number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method.
For the three months ended March 31, 2020 and 2019, the effect of the potential exercise of options to purchase 4,663,390 and 4,541,890 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.
Recent Accounting Pronouncements Not Adopted as of March 31, 2020
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2023. The Company does not expect ASU 2016-13 to have material impact on our consolidated financial statements.
Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.
Recently Adopted Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The ASU was effective for the Company beginning in the first quarter of 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

Note 2: Cash, Cash Equivalent, and Investments
The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of March 31, 2020 and December 31, 2019:
March 31, 2020 (Unaudited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$523,626  $—  $—  $523,626  
Money Market Funds14,173,205  —  —  4,173,205  
Subtotal4,696,831  —  —  4,696,831  
Short-Term Investment Securities (2)
Corporate Bonds (4)
226,439,982  —  (147,770) 26,587,752  
Long-Term Investment Securities (3)
Corporate Bonds (4)
22,536,610  24,812  (6,362) 2,518,160  
Total$33,673,423  $24,812  $(154,132) $33,802,743  

15

December 31, 2019 (Audited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$1,010,510  $—  $—  $1,010,510  
Money Market Funds13,813,034  —  —  3,813,034  
Subtotal4,823,544  —  —  4,823,544  
Short-Term Investment Securities (2)
Corporate Bonds (4)
229,387,053  5,898  (17,991) 29,399,146  
Long-Term Investment Securities (3)
Corporate Bonds (4)
21,528,190  16,554  —  1,511,636  
Total$35,738,787  $22,452  $(17,991) $35,734,326  
_________________
Notes:
(1) Definition of the three-level fair value hierarchy:
•Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
•Level 2 - Other inputs that are directly or indirectly observable in the markets
•Level 3 - Inputs that are generally unobservable
(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.
(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.
(4) The premium paid to purchase held-to-maturity investment securities was $196,385 and $80,855 for the three months ended March 31, 2020 and 2019, respectively. The premium paid to purchase held-to-maturity investment securities was $233,550 for the year ended December 31, 2019.

The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. As of March 31, 2020, the Company does not consider any of its investments to be other-than-temporarily impaired.

Note 3: Research Collaboration and Sub-licensing Agreements
BDI Agreements
On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”).

The R&D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic’s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.

16

Upon closing of the BDI transaction, the Company paid EUR €1 million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR €936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR €1 million for a 50% share or EUR €8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR €1.5 million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million (the “SFA Commitment”) in contract research services specified by Dyadic over two years since the closing of the BDI transaction.

The Company has concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results.

The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1 million (EUR €1 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1 million paid by Dyadic were expensed as the related research services were performed by BDI. In June 2019, BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. As of December 31, 2019, Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA. However, the Company may in the future continue to provide funding to BDI for certain research and commercialization projects.

As of March 31, 2020 and December 31, 2019, there were no balances in the prepaid research and development collaboration related to BDI recorded on our consolidated balance sheets. For the three months ended March 31, 2020, and 2019, research and development expenses related to BDI recorded as research and development - related party in our consolidated statements of operations were none and approximately $0.4 million, respectively.

Novovet and Luina Bio Sub-License Agreement
On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.

In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic’s proprietary C1 gene expression platform.

The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet.

As of March 31, 2020, Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity
17

method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.

Alphazyme Sub-License Agreement
On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.

In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a 7.5% ownership interest in Alphazyme (“Alphazyme Up-Front Consideration”) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic’s proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of 18 months (“Exclusivity Period”) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period, Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional 2.5% ownership interest in Alphazyme.

The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme.

As of March 31, 2020, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded during the three months ended March 31, 2020.

Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.

Research and Commercialization Collaboration with Serum Institute of India
On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (“Serum”). Under the terms of this collaboration, Serum anticipates applying Dyadic’s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic’s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.
For the three months ended March 31, 2020, the Company recognized approximately $75,000 in research and research revenue from Serum. As of March 31, 2020, the Company recorded approximately $82,000 in deferred research and development obligations related to this agreement.

Note 4: Commitments and Contingencies
Leases
Jupiter, Florida Headquarters
The Company’s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700 in total. The lease expires on June 30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.
18

The Netherlands Office
The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies a flexible office space for an annual rental rate of approximately $4,000. The lease expires on January 31, 2021, and thereafter, the Company will reconsider the leased space to align with the future operations of the Company.
VTT Research Contract Extension
On June 28, 2019, the Company extended its research contract (“Contract”) through June 2022 with VTT Technical Research Centre of Finland Ltd. (“VTT”). Under the terms of this Contract, Dyadic will pay VTT a total of EUR €2.52 million over the next three years to continue developing Dyadic’s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR €450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR €690,000 over the next 1.5 years to reinforce the glycoengineering work. On March 23, 2020, the Company further expanded the Contract to pay an additional EUR €700,000 over the next 19 months to accelerate the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days’ notice.
Legal Proceedings
We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.

Note 5: Share-Based Compensation
Description of Equity Plans
The 2011 Equity Incentive Plan (the “2011 Plan”) was adopted by the Company’s Board of Directors on April 28, 2011 and approved by the Company’s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company’s 2006 Stock Option Plan (the “2006 Plan”). Since the effective date of the 2011 Plan, all equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company’s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provisions of the 2011 Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on January 1, 2019 and 2020.
As of March 31, 2020, the Company had 4,663,390 stock options outstanding and an additional 2,134,211 shares of common stock available for grant under the 2011 Plan. As of December 31, 2019, there were 3,860,390 stock options outstanding and 1,547,211 shares of common stock available for grant under the 2011 Plan.
Stock Options
Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan is ten years except for certain options granted to the CEO (five years) and contractors (two or three years).
The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting
19

portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:
Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.
Expected dividend yield. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.
Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure.
Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for certain options granted to the CEO (five years) and contractors (two or three years).
The assumptions used in the Black-Scholes option pricing model for stock options granted during the three months ended March 31, 2020 are as follows:
Risk-Free interest rate
0.25% - 1.72%
Expected dividend yield— %
Expected stock price volatility
39.94% - 51.22%
Expected life of options
1.75 - 6.25 Years

The following table summarizes the stock option activities during the three months ended March 31, 2020: 
SharesWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
Outstanding at December 31, 20193,860,390  $1.765.7$13,287,932
Granted (1)
913,000  5.24  
Exercised (2)
(110,000) 1.78  
Expired —  —  
Canceled —  —  
Outstanding at March 31, 20204,663,390  $2.446.4$13,017,190
Exercisable at March 31, 20203,167,983  $1.675.1$11,201,783
_________________
Notes:
(1) Represents the following stock options granted:
•Annual share-based compensation awards on January 2, 2020, including: (a) 525,000 stock options with an exercise price of $5.27 per share granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 325,000 stock options with an exercise price of $5.27 per share granted to the Board of Directors, vesting upon one year anniversary, (c) 23,000 stock options with an exercise price of $5.27 per share granted to employees, vesting annually in equal installments over four years, and (d) 15,000 stock options with an exercise price of $5.27 per share granted to a consultant, vesting upon one year anniversary.
•One-time awards on March 22, 2020, including 25,000 stock options to a contractor with an exercise price of $3.99 per share, vesting in six months from the date of grant.
(2) Represents the following stock options exercised:
•A total of 110,000 stock options exercised with a weighted average market price of $1.78, among which, 10,000 shares were issued in May 2020.
20


Compensation Expenses
We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Total non-cash stock option compensation expense was allocated among the following expense categories: 
Three Months Ended March 31,
20202019
General and administrative$380,251  $233,214  
Research and development46,688  76,349  
Total $426,939  $309,563  

Note 6: Shareholders’ Equity
Issuances of Common Stock
For the three months ended March 31, 2020, there were 100,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.78 per share. For the three months ended March 31, 2019, no shares were issued.
Three Months Ended March 31, 2020 (Unaudited)
Common StockTreasury StockAdditional Paid-In CapitalAccumulated DeficitTotal
January 1, 2020$39,613  $(18,929,915) $96,105,851  $(41,351,078) $35,864,471  
Stock-based compensation—  —  426,939  —  426,939  
Exercise of stock options100  —  174,900  —  175,000  
Net loss—  —  —  (2,214,139) (2,214,139) 
March 31, 2020$39,713  $(18,929,915) $96,707,690  $(43,565,217) $34,252,271  
Three Months Ended March 31, 2019 (Unaudited)
Common StockTreasury StockAdditional Paid-In CapitalAccumulated DeficitTotal
January 1, 2019$38,967  $(18,929,915) $94,385,230  $(33,043,113) $42,451,169  
Stock-based compensation—  —  309,563  —  309,563  
Net loss—  —  —  (2,175,258) (2,175,258) 
March 31, 2019$38,967  $(18,929,915) $94,694,793  $(35,218,371) $40,585,474  

Treasury Stock
As of March 31, 2020 and December 31, 2019, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.

Note 7: Subsequent Events
21

Management continues to actively monitor the COVID-19 pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce.
For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through May 14, 2020, the date the consolidated financial statements were available to be issued. Management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.


Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements appearing in this Quarterly Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, assumptions and uncertainties. Important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis include, but not limited to those set forth in “Item 1A. Risk Factors” in this Quarterly Report. All forward-looking statements included in this Quarterly Report are based on information available to us as of the time we file this Quarterly Report and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements.

Overview
Description of Business
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica (formerly Myceliophthora thermophila) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.
On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (“DuPont”), the industrial biosciences business of DuPont (NYSE: DD) for $75.0 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.
After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is aiming to develop products such as innovative vaccines and drugs, biosimilars and/or biobetters.

Recent Developments
In the first quarter of fiscal 2020, the Company continued to develop relationships with business and research partners in the biopharmaceutical industry and achieved the following:
22

•Data presented at the 15th European Conference on Fungal Genetics (“ECFG15”) demonstrated that C1 strain has been glyco-engineered to achieve a core human-like G2 glycan level over 76%. Data also showed excellent progress we made in reducing the extracellular protease background by 50 times in C1. The elimination of protease activity makes the C1 cell line more efficient and stable, leading to even higher expression levels and lower cost.

•Dyadic entered into a funded collaboration with another top four animal health company to engage in a feasibility study regarding the production of two proteins using our C1 platform. Three of the top four animal health companies are currently funding research programs to evaluate C1. The first two projects with one of these top three have been expanded with additional funding and have entered the second phase of development, and a new work proposal for a third project is under final review.

•Dyadic entered into a nonexclusive research license with WuXi Biologics, one of the leading global Contract Development Manufacturing Organizations.

•Dyadic entered into a new feasibility study with the University of Oslo on influenza vaccine.

•In connection with the COVID-19 pandemic, the Company has the following initiatives:

◦The Israel Institute for Biological Research (“IIBR”) has expanded its collaboration with the Company to explore the potential of C1 to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (“mAbs”) that may potentially help combat the outbreak of the COVID-19 virus.

◦Dyadic’s C1 gene expression platform is being used to express targets and vaccination candidates developed by Ufovax, a spin-off vaccine company of Scripps Research, as well as by a group of scientists who are part of the EU ZAPI initiative, from Erasmus Medical Center, Utrecht University, and the University of Veterinary Medicine Hannover (“TiHo"), and by scientists at clinical contract research organizations.


Impact of COVID-19

The recent outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company’s employees, operations, and research projects.
To date, as a direct result of COVID-19, most of our employees are working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the response to curb its spread, currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.
The Company is currently working on several COVID-19 related vaccine and antibody opportunities. For example, the Israel Institute for Biologic Research (“IIBR”) is exploring the potential of Dyadic’s industrially proven C1 gene expression platform to express certain gene sequences and targets developed by IIBR into both an rVaccine candidate and mAbs that may potentially help combat the outbreak of the COVID-19 virus. The Company is also working with three scientists who are a part of the EU ZAPI initiative: Dr. Bosch at Utrecht University, Dr. Haagmans at Erasmus Medical Center, and Prof. Osterhaus at University of Veterinary Medicine Hannover, as well as with Dr. Erroba and Mr. Es-Sbai at clinical contract research organizations to develop and submit a proposal for funding to pharmaceutical organizations and governmental agencies. The objective of this proposal is to develop, and pre-clinically and clinically evaluate (in Phase I/II trials), a multimeric self-assembling SARS-CoV-2 Receptor Binding Domain vaccine candidate to rapidly respond to the COVID-19 pandemic. Another proposal was developed in conjunction with Ufovax, a spin-off vaccine company of Scripps Research, which was submitted to
23

many of the same parties. In addition, the Company is pursuing other opportunities where it may be able to apply its C1gene expression platform to help combat the COVID-19 pandemic; however, there is no assurance that any of these opportunities will materialize or that the C1 technology or any product expressed from C1 or any of the various other steps in a vaccine or drug development process will perform, provide benefits, obtain governmental safety and regulatory approvals, be registered or gain market acceptance. In addition, our C1 technology has yet to be used to produce a vaccine, antibody or other biologic product that has entered the clinical trial phase, and we are competing with more experienced companies for grants or funding of this type. As a result, there is no assurance that we will receive these grants or funding resulting from these proposals.
We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs of our operations. We believe that we have sufficient cash, cash equivalents and investments to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing balances of cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.

Critical Accounting Policies, Estimates, and Judgments
The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:
Revenue Recognition
The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related
24

to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to grants and fundings:The Company may receive grants and fundings from governments, agencies, and other private and not-for-profit organizations.These grants and fundings are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates.
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.

Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which sales-based royalties relate, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

Accrued Research and Development Expenses
In order to properly record services that have been rendered but not yet billed to the Company, we review open contracts and purchase orders, communicate with our personnel and we estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly or quarterly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of accrued research and development expenses include amounts owed to contract research organizations, to service providers in connection with commercialization and development activities.
Stock-Based Compensation
We have granted stock options and restricted stock to employees, directors and consultants. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model considers volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options and restricted stock and applied a discount to reflect the lack of marketability due to the holding period restriction
25

of its shares under Rule 144 prior to the Company April 2019 uplisting to NASDAQ. We also used the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option (except in the case of our CEO, 5 years, and in the case of contractors, 2 or 3 years). The Company performs a review of assumptions used in the Black-Scholes option-pricing model on an annual basis. During the Company’s annual review of its volatility assumption in 2018, the Company determined that it would be appropriate to use the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure. The change in assumption was effective January 1, 2018 and only impacts new options granted in 2018 and thereafter.

The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. These estimates are neither predictive nor indicative of the future performance of our stock. As a result, if other assumptions had been used, our recorded share-based compensation expense could have been materially different from that reported. In addition, because some of the options and restricted stock issued to employees, consultants and other third-parties vest upon the achievement of certain milestones, the total ultimate expense of share-based compensation is uncertain.
In connection with board member and employee terminations, the Company may modify certain terms to outstanding share-based awards. We have recorded charges related to these modifications based on the estimated fair value of the share-based options immediately prior to and immediately after the modification occurs, with any incremental value being charged to expense. We have used the Black-Scholes pricing model in this valuation process, and this requires management to use various assumptions and estimates. Future modifications to share-based compensation transactions may result in significant expenses being recorded in our consolidated financial statements.
Accounting for Income Taxes
The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740 (“Topic 740”), “Income Taxes”. Under this method, income tax expense/(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.
In determining taxable income for the Company’s consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company’s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.
The Company is required to evaluate the provisions of Topic 740 related to the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents a company’s potential future obligation to the taxing authority for a tax position that was not recognized because of applying the provision of Topic 740.
The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The legislation included, among other things, a reduction of the U.S. federal corporate income tax rate from 35% to 21%, and a repeal of the corporate alternative minimum tax (the “AMT”). The TCJA repealed the corporate AMT but permitted unused AMT credit carryforwards to be used to reduce the regular tax obligation in future years. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Subsequently, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), which was signed into law in March 2020, accelerated the full refund of any unused AMT credits from 2021 (as provided for in the TCJA) to 2018 or 2019, at the taxpayer’s election .
26


Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of March 31, 2020, we have received 50% or approximately a $0.5 million refund for tax year 2018 and we expect to receive the remaining portion in 2020 pursuant to the CARES Act.

Fair Value Measurements
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
The Company bases its fair value estimates on assumptions it believes to be reasonable, but which are unpredictable and inherently uncertain. Actual future results may differ from those estimates.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Recent Accounting Pronouncements
See Note 1 to the Consolidated Financial Statements for information about recent accounting pronouncements.

Results of Operations
Three Months Ended March 31, 2020 Compared to the Same Period in 2019
Revenue and Cost of Revenue
The following table summarizes the Company’s revenue and cost of research and development revenue for the three months ended March 31, 2020 and 2019:
Three Months Ended March 31,
20202019
Revenue$315,372  $402,527  
Cost of research and development revenue$278,182  $327,903  

The decrease in revenue and cost of research and development revenue for the three months ended March 31, 2020 reflect five on-going research collaborations compared to six collaborations for the same period a year ago.
Research and Development Expenses
Research and development costs are expensed as incurred and primarily include salary and benefits of research personnel, third-party contract research organization services and supply costs.
Research and development expenses for the three months ended March 31, 2020 increased to approximately $755,000 compared to $692,000 for the same period a year ago. The increase primarily reflects the additional costs of accelerated glyco-engineering project conducted at VTT.
27

Research and development expenses - related party, for the three months ended March 31, 2020, was $0 compared to approximately $389,000 for the same period a year ago. The decrease was due to the completion of the Research Service Agreement with BDI in June 2019.
General and Administrative Expenses
General and administrative expenses for the three months ended March 31, 2020, increased 15.8% to approximately $1,653,000 compared to $1,428,000 for the same period a year ago. The increase principally reflects increases in insurance and other outside service costs of $101,000, noncash share-based compensation expenses of $97,000, business development and investor relations costs of $70,000, and other increases of $54,000 offset by reductions in executive compensation costs and accrued incentives of $74,000 and legal expenses of $23,000.
Interest Income
Interest income for the three months ended March 31, 2020, decreased 37.1% to approximately $168,000 compared to $267,000 for the same period a year ago. The decrease was primarily due to the lower interest rate and yield on the Company’s investment grade securities, which are classified as held-to-maturity.
Net Loss
Net loss for the three months ended March 31, 2020 was approximately $2,214,000 compared to $2,175,000 for the same period a year ago.

Liquidity and Capital Resources
Our primary source of cash has been the cash received from the DuPont Transaction in December 2015, interest income received from investment grade securities, and funding from our research collaboration agreements. Between January 2016 and August 2018, the Company repurchased a total of 14,390,254 shares of its common stock from its existing cash on hand, for an aggregate purchase price of $21,814,530 at a weighted average price of $1.52 per share. As of December 31, 2019, our investment balance includes $29.7 million short-term investments with contractual maturities of twelve (12) months of less, including interest receivable, and $1.5 million long-term investments with contractual maturities beyond twelve (12) months. In June 2019, the Company’s liquidity was further improved with the receipt of an approximately $0.5 million tax refund resulting from the elimination of corporate Alternative Minimum Tax (AMT) under the TCJA. An additional approximately $0.5 million AMT tax refund is expected to be received late in 2020 pursuant to the CARES Act AMT Provision.

Our ability to achieve profitability depends on a number of factors, including our scientific results and our ability to continue to obtain funded research and development collaborations from industry and government programs, as well as sub-license agreements. We may continue to incur substantial operating losses even if we begin to generate revenues from research and development and licensing. Our primary future cash needs are expected to be for general operating activities, including our business development and research expenses, as well as additional costs as an SEC reporting and NASDAQ listed company. We believe that our existing cash position and investments in short-term and long-term investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next twelve (12) months.
At March 31, 2020, cash and cash equivalents were approximately $4.7 million compared to $4.8 million at December 31, 2019. The carrying value of short-term and long-term investment grade securities, including accrued interest at March 31, 2020 was approximately $29.3 million compared to $31.2 million at December 31, 2019.
Net cash used in operating activities for the three months ended March 31, 2020 of approximately $2.0 million was principally attributable to a net loss of approximately $2.2 million and changes in operating assets and liabilities of approximately $0.3 million, offset by share-based compensation expenses of approximately $0.4 million and amortization of held-to-maturity securities of approximately $0.1 million.
Net cash used in operating activities for the three months ended March 31, 2019 of approximately $1.4 million was principally attributable to a net loss of $2.2 million, partially offset by share-based compensation expense of $0.3 million and changes in other operating assets and liabilities of $0.4 million.
Net cash provided by investing activities for the three months ended March 31, 2020 was approximately $1.7 million compared to $3.0 million for the three months ended March 31, 2019. Cash flows from investing activities during the three
28

months ended March 31, 2020 and 2019 were primarily related to proceeds from maturities and purchases of investment grade debt securities.
Net cash provided by financing activities for the three months ended March 31, 2020 was approximately $0.2 million compared to zero for the three months ended March 31, 2019. Cash flows from financing activities during the three months ended March 31, 2020 were primarily related to proceeds from exercise of options.

Item 3.Quantitative and Qualitative Disclosures about Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4.Controls and procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.
Changes in Internal Controls Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.
Inherent Limitation on Effectiveness of Controls
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II

Item 1.Legal Proceedings
29

We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.


Item 1A.Risk Factors
There have been no changes to our risk factors from those disclosed in our Form 10-K for the 2019 fiscal year filed on March 30, 2020, other than the updated risk factors set forth below.
We face risks related to health epidemics, pandemics and other widespread outbreaks of contagious disease, pandemics, epidemics or other biological threats, such as the ongoing COVID-19 pandemic, that could significantly disrupt our operations and have a material adverse effect on our business, employees, directors, consultants, collaborators and other third parties, including business development activities and research and development projects conducted by third party contract research organizations parties.

Significant outbreaks of contagious diseases, and other adverse public health developments, could have a material impact on our business operations, financial condition, and operating results. The ongoing COVID-19 pandemic has significantly impacted the operation of business in the United States and Europe, where several of our key executive management members and our third-party contract research organizations are located. The continuation of the COVID-19 pandemic and various governmental responses in the United States and Europe has adversely affected and may continue to adversely affect our business operations, including our ability to carry on business development activities, restrictions in business-related travel, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, among others.

In addition, we rely on third parties in the United States and Europe to conduct our research and development projects and to provide other services, and COVID-19 has affected and may continue to affect service providers of such third-party contract research organizations and therefore negatively affect the operations of our on-going research projects, which could materially and negatively affect our business, financial condition, and results of operations.

The COVID-19 pandemic has adversely affected and may continue to adversely affect the economies and financial markets worldwide, resulting in an economic downturn that could impact our business, financial condition and results of operations. As a result, our ability to fund through public or private equity offerings, debt financings, and through other means at acceptable terms, if at all, may be disrupted, in the event our financing needs for the foreseeable future are not able to be met by our existing balances of cash, cash equivalents and investments. The extent to which COVID-19 could impact our business and research and development activities will depend on future developments, which are highly uncertain and cannot be predicted with confidence, and will depend on many factors, including the duration of the outbreak, the effect of travel restrictions and social distancing efforts in the United States and other countries, the scope and length of business closures or business disruptions, and the actions taken by governments to contain and treat the disease. As such, we cannot presently predict the scope and extent of any potential business shutdowns or disruptions.

The Company is currently working on several COVID-19 related vaccine and antibody opportunities. However, there is no assurance that any of these opportunities will materialize or that the C1 technology or any product expressed from C1 or any of the various other steps in a vaccine or drug development process will perform, provide benefits, obtain governmental safety and regulatory approvals, be registered or gain market acceptance. In addition, our C1 technology has yet to be used to produce a vaccine, antibody or other biologic product that has entered the clinical trial phase, and we are competing with more experienced companies for grants or funding of this type. As a result, there is no assurance that we will receive these grants or funding resulting from these proposals.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
None.


30

Item 3.Defaults Upon Senior Securities
Not applicable.


Item 4.Mine Safety Disclosures
Not applicable.


Item 5.Other Information
None.


Item 6.Exhibits
Following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:

Exhibit No. Description
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Extension Labels Linkbase Document
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
31

 DYADIC INTERNATIONAL, INC.
   
May 14, 2020By:/s/ Mark A. Emalfarb
  Mark A. Emalfarb
  President and Chief Executive Officer
(Principal Executive Officer)
May 14, 2020By:/s/ Ping W. Rawson
 Ping W. Rawson
 Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

32
 EX-31.1 2 exhibit311certificatio.htm EX-31.1 Document

Exhibit 31.1
 
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
and Securities and Exchange Commission Release 34-46427
 
 
 I, Mark A. Emalfarb, certify that:
 
1.I have reviewed this quarterly report on Form 10-Q of Dyadic International Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

5.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

6.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and



a.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: May 14, 2020
By:  
          
Name:              
Title:                 		/s/   Mark A. Emalfarb

Mark A. Emalfarb
Chief Executive Officer
 


 EX-31.2 3 exhibit312certificatio.htm EX-31.2 Document

Exhibit 31.2
 
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
and Securities and Exchange Commission Release 34-46427
 
 
 I, Ping W. Rawson, certify that:
 
1. I have reviewed this quarterly report on Form 10-Q of Dyadic International Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 


Date: May 14, 2020
By:  
          
Name:              
Title:                 		/s/   Ping W. Rawson

Ping W. Rawson
Chief Financial Officer
 


 EX-32.1 4 exhibit321sec1350certi.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Dyadic International Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Mark A. Emalfarb, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Date:May 14, 2020
By:  
          
Name:              
Title:                 		/s/   Mark A. Emalfarb

Mark A. Emalfarb
Chief Executive Officer
 


 EX-32.2 5 exhibit322sec1350certi.htm EX-32.2 Document

Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Dyadic International Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Ping W. Rawson, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Date:May 14, 2020
By:  
          
Name:              
Title:                 		/s/   Ping W. Rawson

Ping W. Rawson
Chief Financial Officer
 


 EX-101.SCH 6 dyai-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2110102 - Disclosure - Cash, Cash Equivalent, and Investments link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Cash, Cash Equivalent, and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2113103 - Disclosure - Research Collaboration and Sub-licensing Agreements link:presentationLink link:calculationLink link:definitionLink 2414408 - Disclosure - Research Collaboration and Sub-licensing Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2115104 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - Commitments and Contingencies - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2318303 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Share-Based Compensation - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2420411 - Disclosure - Share-Based Compensation - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2421412 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2422413 - Disclosure - Share-Based Compensation - Stock Option Activity - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - Share-Based Compensation - Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2124106 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2325304 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2426415 - Disclosure - Shareholders' Equity - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2427416 - Disclosure - Shareholders' Equity - Changes in Shareholders’ Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2128107 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 dyai-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 dyai-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 dyai-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Commitment to pay, additional Commitment To Pay, Additional Commitment To Pay, Additional VLPbio VLPbio [Member] VLPbio [Member] Assets Assets [Abstract] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Preferred stock, par value (USD per share) Preferred Stock, Par or Stated Value Per Share Plan Name [Axis] Plan Name [Axis] City Area Code City Area Code Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Total current assets Assets, Current Common Stock Common Stock [Member] Title of 12(b) Security Title of 12(b) Security Vesting [Domain] Vesting [Domain] Current assets: Assets, Current [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Total costs and expenses Costs and Expenses Other Other Accrued Liabilities, Current Accounts payable Increase (Decrease) in Accounts Payable Basic and diluted net loss per common share (USD per share) Earnings Per Share, Basic and Diluted Expected life of options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Concentration risk, number of customers Concentration Risk, Number of Customers Concentration Risk, Number of Customers Personnel related costs Research And Development Expense, Personnel Related Costs Research And Development Expense, Personnel Related Costs Accounts payable Accounts payable Accounts Payable, Current Option to obtain exclusive commercial sub-license for number of proteins Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Aggregate intrinsic value, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Prepaid taxes Prepaid Taxes Current Fiscal Year End Date Current Fiscal Year End Date Deferred tax assets, valuation allowance coverage, percent Deferred Tax Assets, Valuation Allowance Coverage, Percent Deferred Tax Assets, Valuation Allowance Coverage, Percent RSA Research Services Agreement [Member] Research Services Agreement [Member] Organization and Summary of Significant Accounting Policies Business Description and Accounting Policies [Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Expected stock price volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Entity Address, Postal Zip Code Entity Address, Postal Zip Code Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Project [Domain] Project [Domain] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of stock option activity Share-based Compensation, Stock Options, Activity [Table Text Block] Exercise of stock options, common stock issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock Issued Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock Issued Foreign currency exchange loss (gain), net Foreign Currency Transaction Gain (Loss), before Tax Equity [Abstract] Equity [Abstract] Financial Instrument [Axis] Financial Instrument [Axis] Accounts receivable Accounts Receivable, Net Revenues: Revenues [Abstract] Foreign Currency Transaction Gain or Loss Foreign Currency Transactions and Translations Policy [Policy Text Block] Entity Shell Company Entity Shell Company Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transaction [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transaction [Line Items] Cover [Abstract] Outstanding (in shares) Outstanding, beginning (in shares) Outstanding, ending (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Document Type Document Type Consultant Consultant [Member] Consultant Cash and Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Prepaid research and development Increase (Decrease) in Prepaid Research and Development Increase (Decrease) in Prepaid Research and Development Revenue from collaborative arrangement, contract liability Revenue from Collaborative Arrangement, Contract Liability Revenue from Collaborative Arrangement, Contract Liability Deferred research and development obligation Increase (Decrease) in Contract with Customer, Liability Alphazyme Alphazyme [Member] Alphazyme [Member] Tax Period [Domain] Tax Period [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable SFA Service Framework Agreement [Member] Service Framework Agreement [Member] Number of operating segments Number of Operating Segments Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Commitment to pay, expanded Commitment To Pay, Expanded Commitment To Pay, Expanded Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Long term Investments, gross unrealized holding loss Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent Level 1 Fair Value, Inputs, Level 1 [Member] Research and development Research and Development Expense [Member] Cash and Investment, adjusted cost Investments and Cash, Amortized Cost Investments and Cash, Amortized Cost VTT Technical Research Centre of Finland Ltd VTT Technical Research Centre of Finland Ltd [Member] VTT Technical Research Centre of Finland Ltd [Member] Commitment to pay, additional coverage period Commitment To Pay, Additional Period Coveage Commitment To Pay, Additional Period Coveage Option to extend exclusivity period Collaborative Arrangement, Option To Extend Exclusivity Period Collaborative Arrangement, Option To Extend Exclusivity Period Award Type [Axis] Award Type [Axis] Cash, Cash Equivalent, and Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Investment Securities Investment, Policy [Policy Text Block] Expected dividend rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Exclusivity period Collaborative Arrangement, Exclusivity Period Collaborative Arrangement, Exclusivity Period Granted (in shares) Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Document Quarterly Report Document Quarterly Report Range [Domain] Range [Domain] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Risk-Free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Purchases of held-to-maturity investment securities Payments to Acquire Held-to-maturity Securities Financial Instruments [Domain] Financial Instruments [Domain] General and administrative General and Administrative Expense [Member] Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Total assets Assets Total liabilities and stockholders’ equity Liabilities and Equity Obligation for payment for research and development, minimum Collaborative Arrangement, Minimum Obligation For Research And Development Collaborative Arrangement, Minimum Obligation For Research And Development Approved (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Research and development revenue Revenues Revenue from Contract with Customer, Excluding Assessed Tax Income tax receivable Income Taxes Receivable, Current Vesting [Axis] Vesting [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Equity Components [Axis] Equity Components [Axis] Entity Emerging Growth Company Entity Emerging Growth Company Money Market Funds Money Market Funds [Member] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Provision for income taxes Income Tax Expense (Benefit) Schedule of Research and Development Costs Schedule of Research and Development Costs [Table Text Block] Schedule of Research and Development Costs [Table Text Block] Research and development expenses Accrued Research and Development in Process, Current Accrued Research and Development in Process, Current Other assets Other Assets, Noncurrent Common stock Common Stock, Value, Issued Stock-based compensation expense Share-based Compensation Research funding, milestone payments and royalties, period Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period Concentration Risk Type [Domain] Concentration Risk Type [Domain] Non-current assets: Assets, Noncurrent [Abstract] Weighted average exercise price, canceled (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Accumulated deficit Retained Earnings [Member] Document Fiscal Period Focus Document Fiscal Period Focus Investment, gross unrealized holding gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Income Statement [Abstract] Income Statement [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Research and development - related party Research and Development Expense, Related Party Research and Development Expense, Related Party New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Short-term investment securities Short term investments, adjusted cost Debt Securities, Held-to-maturity, Current Concentration risk, percentage Concentration Risk, Percentage Short term investments, gross unrealized holding gain Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Contractor Contractor [Member] Contractor [Member] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Revenue Sales Revenue, Net [Member] Outstanding commitment Collaborative Arrangement, Outstanding Commitment Collaborative Arrangement, Outstanding Commitment Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Common stock, par value (USD per share) Common Stock, Par or Stated Value Per Share Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Tax Period [Axis] Tax Period [Axis] Contracted services - related party Research And Development Expense, Contracted Services, Related Party Research And Development Expense, Contracted Services, Related Party Concentrations and Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Schedule of non-cash stock option compensation expense Share-based Compensation, Activity [Table Text Block] DuPont Danisco DuPont Danisco [Member] DuPont Danisco [Member] Cash received from income tax refund Proceeds from Income Tax Refunds Weighted average exercise price, expired (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Area of building rented Area of Real Estate Property Amendment Flag Amendment Flag Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Executives and Key Personnel Executives and Key Personnel [Member] Executives and Key Personnel [Member] Total current liabilities Liabilities, Current Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Commitment to pay Commitment To Pay Commitment To Pay Title of Individual [Axis] Title of Individual [Axis] Aggregate intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Weighted-average remaining contractual term, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Additional paid-in capital Additional Paid in Capital Revenue from collaborative arrangement, recognized Revenue from Collaborative Arrangement, Recognized Revenue from Collaborative Arrangement, Recognized Income Taxes Income Tax, Policy [Policy Text Block] Accounts Receivable Accounts Receivable [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Equity percentage Equity Method Investment, Ownership Percentage Project [Axis] Project [Axis] Schedule of Accounts Payable Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Commitments and contingencies (Note 4) Commitments and Contingencies Research Collaboration and Sub-licensing Agreements Collaborative Arrangement Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Employee Employee [Member] Employee [Member] Unbilled receivable Unbilled Revenues [Member] Ownership [Domain] Ownership [Domain] Local Phone Number Local Phone Number Proceeds from maturities of investment securities Proceeds from Sale and Maturity of Held-to-maturity Securities Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Billed receivable Billed Revenues [Member] General and administrative General and Administrative Expense Short term investments, fair value Debt Securities, Held-to-maturity, Fair Value, Current Debt Securities, Held-to-maturity, Fair Value, Current Cash and Investment, fair value Investments and Cash Commitments, right to terminate contract notice period Commitments, Right To Terminate Contract Notice Period Commitments, Right To Terminate Contract Notice Period Revenue sharing, percentage Collaborative Arrangement, Revenue Sharing, Percentage Collaborative Arrangement, Revenue Sharing, Percentage Disposal Group Name [Domain] Disposal Group Name [Domain] Expected stock price volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development Research and Development Expense Commitment to pay, expanded, period Commitment To Pay, Expanded, Period Commitment To Pay, Expanded, Period Foreign currency exchange loss (gain), net Foreign Currency Transaction Gain (Loss), Realized BDI Holdings BDI Holdings [Member] BDI Holdings [Member] Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Entity Address, Address Line One Entity Address, Address Line One Commitment development period Commitment Development Period Commitment Development Period Entity Address, Address Line Two Entity Address, Address Line Two Treasury Stock Treasury Stock [Member] Subsequent Events Subsequent Events [Text Block] Obligation for payment for research and development, maximum Collaborative Arrangement, Maximum Obligation For Research And Development Collaborative Arrangement, Maximum Obligation For Research And Development Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Ownership interest consideration receivable upon extension of exclusivity period Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounts receivable Accounts Receivable, Net, Current Entity Address, State or Province Entity Address, State or Province Prepaid insurance Other Prepaid Expense, Current Equity Award [Domain] Equity Award [Domain] Entity Current Reporting Status Entity Current Reporting Status Jupiter, Florida Headquarters Lease Jupiter, Florida Headquarters Lease [Member] Jupiter, Florida Headquarters Lease [Member] Short term investments, gross unrealized holding loss Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current Prepaid expenses - various Prepaid Insurance Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Loss from operations Operating Income (Loss) Relationship to Entity [Domain] Relationship to Entity [Domain] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Current liabilities: Liabilities, Current [Abstract] Rent expense Operating Leases, Annual Rental Rate Operating Leases, Annual Rental Rate Receivables Billing Status [Domain] Receivables Billing Status [Domain] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 2006 Plan 2006 Plan [Member] 2006 Plan [Member] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Income tax receivable Increase (Decrease) in Income Taxes Receivable Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Small Business Entity Small Business Corporate bonds Corporate Debt Securities [Member] Outside of the United States Non-US [Member] Stock-based compensation Allocated Share-based Compensation Expense Entity Interactive Data Current Entity Interactive Data Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Treasury stock, shares held at cost Treasury stock, shares held at cost Treasury Stock, Value Entity Filer Category Entity Filer Category Netherlands Office Lease Netherlands Office Lease [Member] Netherlands Office Lease [Member] Minimum Minimum [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of stockholders equity Schedule of Stockholders Equity [Table Text Block] Entity Address, City or Town Entity Address, City or Town Schedule of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Interest income Interest Income (Expense), Nonoperating, Net Accrued expenses Increase (Decrease) in Accrued Liabilities Level 2 Fair Value, Inputs, Level 2 [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Exercise of stock options (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Cash Cash [Member] Customer Concentration Risk Customer Concentration Risk [Member] Geographical [Domain] Geographical [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Commitment success bonus award Commitment Success Bonus Award Commitment Success Bonus Award Loss before income taxes Income (Loss) Attributable to Parent, before Tax Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Payment for research and development agreement Collaborative Arrangement, Payment for Research and Development Agreement Collaborative Arrangement, Payment for Research and Development Agreement Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Risk-Free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Subsequent Event Subsequent Event [Member] Geographical [Axis] Geographical [Axis] Weighted average exercise price, exercisable (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of valuation assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Research and development expenses Research And Development In Process, Current Research And Development In Process, Current Contract Research Organizations Contract Research Organizations [Member] Contract Research Organizations Tax Year 2018 Tax Year 2018 [Member] Counterparty Name [Domain] Counterparty Name [Domain] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Statement [Table] Statement [Table] Period two Share-based Compensation Award, Tranche Two [Member] Research and development expense, related party, net Research And Development Expense, Including Related Party Research And Development Expense, Including Related Party Employee wages and benefits Employee-related Liabilities, Current Treasury stock (in shares) Treasury Stock, Common, Shares Other Accounts Payable, Other, Current Held-to-maturity, premium paid on purchase Debt Securities, Held-to-maturity, Premium Paid on Purchase Debt Securities, Held-to-maturity, Premium Paid on Purchase Accumulated deficit Retained Earnings (Accumulated Deficit) Facilities, overhead and other Research And Development Expense, Facilities, Overhead and Other Research And Development Expense, Facilities, Overhead and Other Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Recent Accounting Pronouncements Not Adopted and Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Accounts Receivable Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Award requisite service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period 2011 Plan 2011 Plan [Member] 2011 Plan [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Investment, Name [Axis] Investment, Name [Axis] Outside contracted services Research And Development Expense, Outside Contracted Services Research And Development Expense, Outside Contracted Services Weighted average exercise price, granted (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Range [Axis] Range [Axis] Billing Status, Type [Axis] Billing Status, Type [Axis] Basic and diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Document Period End Date Document Period End Date Prepaid research and development Prepaid Research and Development Prepaid Research and Development Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Income Statement Location [Domain] Income Statement Location [Domain] Entity Registrant Name Entity Registrant Name Investment, gross unrealized holding losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Long term Investments, gross unrealized holding gain Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent Interest receivable Increase (Decrease) in Accrued Interest Receivable, Net Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Long term Investments, fair value Debt Securities, Held-to-maturity, Fair Value, Noncurrent Debt Securities, Held-to-maturity, Fair Value, Noncurrent Duration of agreement Collaborative Arrangement, Duration Of Agreement Collaborative Arrangement, Duration Of Agreement Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted-average remaining contractual term, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Accounting Policies [Abstract] Accounting Policies [Abstract] Number of antibodies and vaccines for development and commercialization Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Weighted average exercise price, outstanding, beginning (USD per share) Weighted average exercise price, outstanding, ending (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Maximum Maximum [Member] Statement [Line Items] Statement [Line Items] Proceeds from sales of business Proceeds from Sales of Business, Affiliate and Productive Assets BDI BDI [Member] BDI [Member] Plan Name [Domain] Plan Name [Domain] Schedule of Cash, Available-for-sale Securities, Short-term and Long-term Investment Securities Cash, Cash Equivalents and Investments [Table Text Block] Novovet Novovet [Member] Novovet [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Interest receivable Interest Receivable, Current Proceeds from exercise of options Proceeds from Stock Options Exercised Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Period one Share-based Compensation Award, Tranche One [Member] Security Exchange Name Security Exchange Name Investment, Name [Domain] Investment, Name [Domain] Entity Tax Identification Number Entity Tax Identification Number Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Accounts Payable Accounts Payable [Member] Costs and expenses: Costs and Expenses [Abstract] Industrial Technology Business Industrial Technology Business [Member] Industrial Technology Business [Member] Preferred stock Preferred Stock, Value, Issued Equity interest acquired Collaborative Arrangement, Equity Interest Acquired Collaborative Arrangement, Equity Interest Acquired Deferred research and development obligations Contract with Customer, Liability, Current Subsequent Events [Abstract] Subsequent Events [Abstract] Additional paid-in capital Additional Paid-in Capital [Member] Amortization of held-to-maturity securities, net Investment Income, Amortization of Premium Monthly rental rate Operating Leases, Monthly Rental Rate Operating Leases, Monthly Rental Rate Income tax benefit, valuation allowance reversal Income Tax Expense (Benefit), Valuation Allowance Reversal Income Tax Expense (Benefit), Valuation Allowance Reversal Accrued expenses Accrued expenses Accrued Liabilities, Current Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Trading Symbol Trading Symbol Ownership [Axis] Ownership [Axis] Document Transition Report Document Transition Report Payment for additional development and commercialization Collaborative Arrangement, Payment for Additional Development and Commercialization Collaborative Arrangement, Payment for Additional Development and Commercialization Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Deferred tax assets, net Deferred Tax Assets, Net Collaborative Arrangement Collaborative Arrangement [Member] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Subsequent Event Type [Axis] Subsequent Event Type [Axis] Unrecognized tax benefits Unrecognized Tax Benefits Costs of research and development revenue Cost of Goods and Services Sold Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Equity Component [Domain] Equity Component [Domain] Research and Development [Abstract] Research and Development [Abstract] Chief Executive Officer Chief Executive Officer [Member] Serum Serum [Member] Serum [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Long-term income tax receivable Income Taxes Receivable, Noncurrent Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Accounts payable Accounts Payable Stock Option Employee Stock Option [Member] Legal expenses Accrued Professional Fees, Current Net loss Net loss Net Income (Loss) Attributable to Parent Weighted average exercise price, exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Income Statement Location [Axis] Income Statement Location [Axis] Long-term investment securities Long term investments, adjusted cost Debt Securities, Held-to-maturity, Noncurrent Board of Directors Director [Member] EX-101.PRE 10 dyai-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 dyai-20200331_g1.jpg begin 644 dyai-20200331_g1.jpg M_]C_X 02D9)1@ ! 0$ > !X #_X1"617AI9@ 34T *@ @ ! $[ ( M , (2H=I 0 ! (5IR= $ 8 0=NH< < @, /@ M G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T M82!X;6QN&UL;G,Z&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT M"UN#IX;7!M971A M/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^ M_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L= M)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ_\ $0@ XP$= P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! M @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-1 M80'EZ@X2%AH>(B8J2DY25EI>8 MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;G MZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D* M"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1" MD:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6F MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V M]_CY^O_: P# 0 "$0,1 #\ ^D:*\-^-_C;Q'X9\6V%IH6JRV4$EB)'1%4Y; MS'&>0>P%>;?\+:\=?]#%<_\ ?"?_ !-;QH2DKW,W42=CZ[HKY$_X6UXY_P"A MBN?^^$_^)JQ;?&;QY;=-<,H]);>)O_9:KZO+N+VD3ZSHKQ'P)\?/MU]%IWC* M&&V,A"I?P_*@/^VIZ?[PX'ICFO;00R@J001D$'K6$X2@[,T33V%HKP'XO^)/ M&W@[QB?[/UNYBTN^3S;8!5(0C =,E>QY^C"N2T+XR>++'7[*XU;5Y[RQ24?: M(&1/G3HW0=<#_ BB:9/Y.J7\GEV[@ F-5P7?GCI@?\"KP7_A;7CG_H8K MC_OA/_B:VA1E-71$IJ+L?7E%UO?%%[+=7U[^_'F@ QQG[BX '; MG\:Z^LI*SL6M0HKQ+XW?$36/#^OV&D^'-0:S=(#- M8?\ "V?'7_0Q7'_?"?\ Q-;1H2DKD.HD['UY16)X-UP>)/!FEZL&W-7/[ M#JT:;GMF;*R#NR'N/;J/?K6R45\P>"OB9XQU+QUHEE?:[/-;7%[%'+&R)A ME+ $=*^GZJI3<'9BC)26@45B^*_%>F>#]"DU/5Y=J+\L<:_?F?LJCN?Y5\Y^ M)OC?XKUR>1=.N!H]F3\D5M_K,>\AYS],"G"E*>P2DH[GU-17Q--XEUVXF,L^ MM:A)(3GVA4O)+(V%4>YKCOAS\3].\>VK0^7]CU6!-TUJ3D,.F]# MW&3TZC/XU'\0(H]5\7^#M!U YTN\NIYKB(_=F:&,-&A]02>G>L.1\W*S2^ET M+_PMW0MGVD:=KATW=C^TQIS_ &?'][=UQ^%=GI^H6FJZ?#?:=<1W-K.N^.6- MLJPKP31]8UR;6=%A6]UB![S6)(5NKK4-UC+$DC!H1%SSMPH'&>U>A>#$&B>- M_&&B:4G_ !+;>>WN(H%^[ \T9:15]!D X[5I.FEL)-GF7[1O_(]:;_V#1_Z- M>O-?#F@W/B?Q#::/8/%'<73%4:8D*, GG )[>E>E?M&_\CUIO_8-'_HUZY7X M1?\ )6-"_P"NK_\ HMJZH.U*YA+69TA_9V\6@<7VDGV\Z3_XBL36_@SXTT2V M>X?3DO84Y9K*3S"!Z[>&/X"OK"BN98B9K[.)\)U]"_ 'QK-J6GW'AK4IO,EL M4$MHSG+&+."OOM.,>S>U<5\=?",'A[Q=%J5A$L5KJRM(448"S*1OP/?*GZDU MRGPZUH^'_B'H]]NVQ_:%BE/^P_R-^AS^%=,DJM.Z,HWA*Q]+_$[P>OC/P5U?(9!5B&!!!P0>U?==?+WQM\&?\ "->,#J5I M'MT_5BTJA1Q'+_&OXD[A]3Z5AAY_99I4CU/1_@#XM.K>%YM!NY-USI9!AR>6 MA8\?]\G(^A6O6Z^-? ?BF3P=XRLM67<8%;R[E%_CB;AA]1U'N!7T/\6_&T7A M[X>M)I\X:ZU=/)M'0_P,N6D'T4\'U84JM-\^G4<)>[J>#?%'Q8?%_CN[NHG+ M65L?LUH,\;%/WO\ @1R?Q'I4OPI\'_\ "8>.+>&XCW6%GBYN\]&4'A/^!' ^ MF:XFOJ_X/^#/^$1\%1O=Q[=1U'%QU+7(?%/6_[!^&NKW*.$FEA^SQ9ZEI#MX]P"3^%<$5=V M.AZ:GR_XVUT^)?&VJZKN+1SW#>3GM&ORI_XZ!6%2=*ZSQOX-E\)6^@R2 _\ M$QTY)Y"1]V7.67\ RUZFBLCDU>IZQ^SIX@\_1=2T&9_GM91P8# M_OJO::^2/A%KAT+XFZ6[/MANW-I+DX!#\#/_ +:?PKZWKAKQM._*5#@J17VQJ^DVFN:/=:9J4?F6MU&8Y%]CW'N.H/J*^ M+]=TF70?$%_I-P0TEG.\)8=&P< _B.:UI5/:*S)G'EU1]=^!/%47C'P?9ZN@ M5)779<1K_!*O##Z=Q[$5Y'^TG_R$M _ZY3?S2IOV<-:;S-8T.1B5PMW$,\+_ M /^?R?E4/[2?_(2T#_KE-_-*QA'EK6+D[PN>:?#S_DI7AW_ +",/_H8K['D M=8HV>1E1%!+,QP !W-?''P\_Y*5X=_[",/\ Z&*^C?C-KK:%\,;\PL5FOBMG M&1VW_>_\<#4ZZYII"INT6SY[^)'C.X\:^+KB[,A-A QBLHNRQ@_>QZMU/Y=J MRO#7A;5_%NJC3]"M3/-C<[$X2-?[S-T _GVK'KZX^%/A.'PIX#LT\M1>WJ+< MW3XY+,,A?^ @@8]<^M;5)*E'0B*YWJ>8Q?LW:D;/=/XAM4N\:NFK:'R)HFLWGA_6K75=,E,5S:R!T(/!]5/J M"."/0U]97EAIWQ+\$V%Y;SR6CR!+RRNX3^\M)AW'N#D$=^?K7SYH?P7\::UM M9M-&FQ'_ ):7[^7C_@(RWZ5]"?#?PK?^#/!\>CZG>Q7 M%8/"NER0+<27MY\O9O]9<2GJQ]!Z#M6]17-*;:L:V/G#]HW_D M>M-_[!H_]&O7*_"+_DK&A?\ 75__ $6U=5^T;_R/6F_]@T?^C7KE?A%_R5C0 MO^NK_P#HMJ[8_P +Y&#^,^N:***\\Z#R#]HRT63P5IMWCYH;\(#[,C9_]!%? M.:.8Y%=>"I##\*^EOVAR!\.+;/4ZE'C_ +XDKYG/2O0H? <]3XC[GLY_M5C! M=:L?X95Y'Y\K]&K9T(%?#NG!NHM8 M@?\ O@5?-<%^5W1T;GPI)&\4C1RJ4="596&"".H-7]2US4-6L].M;^?""Z'XKCUJS0+:ZMN:10.%G'WO^^@0?KNKRJO3C M)22D#T\(>" M+:&2,"_O +B[;'.XCA/^ C ^N?6NU%<%:?/(Z(1L@KP;]HWQ 3)I7AZ)N #> M3@'ZJG_L_P"8KWDU\^?'S01J?P^748ES+I4ZR? M]LV^5A^94_A7$?LZ:,+CQ+J>KR1AEL[=88V/9W.3C_@*D?C7OFL:9#K.BWFF MW(S%=P/"W&S5\0ZY_P C%J7_ %]R_P#H9K[> MKXAUS_D8M2_Z^Y?_ $,U&&W8ZNQ[?^S7_P @_P 0_P#7:#_T%Z]OKQ#]FO\ MY!_B'_KM!_Z"]>WUE6_B,N'PH*^4?C;;+;_%G4R@P)4AD./4QJ#^HKZNKY9^ M.Y!^*MT!VMH0?^^:K#_&*I\(_P" MTT'Q2AB4X%Q:S1M[@ -_P"RUTO[2?\ MR$M _P"N4W\TKD?@>"?BWIF.T<^?^_35UW[2?_(2T#_KE-_-*V?\9>A"_AGF MGP\_Y*5X=_[",/\ Z&*]=_:2NF32-!M ?EEGED(]U50/_0S7D7P\_P"2E>'? M^PC#_P"ABO4OVE0<^'&_A_T@?^BZQT'DW[2&HJFAZ+IH8;IKAYRN>R+M!_\ 'Z\$L;5[[4;: MTA7=)<2I$H'I\1]TT445YYT'.^/=?'AGP+JNJ!ML ML4!6$@\^8WRI^I!_"OC7KU.3ZU[Y^T;K_EV6E>'XFYFV<#\:\\BE>"9)H6*R1L'1AV(.0:OW9QLA:Q>I]U"OB'7/^1BU+_K[E_] M#-?9'A;6X_$?A73M7BQB[MUD8#HK8PP_!@1^%?&^N?\ (Q:E_P!?5_Y9QY&0?=BWY5@?M)_P#(2T#_ *Y3?S2GS7KA:U,\T^'G_)2O M#O\ V$8?_0Q7LO[1VGM-X6TF_496VNVC;VWK_BE>-?#S_DI7AW_L(P_^ABOJ M;Q_X<_X2OP-J6E(!Y\D6^ D?\M%.Y?IDC'XTZLN6I%B@KQ:/CF"8V]Q',GWH MW#CZ@YK[AT^]BU'3;:]MSF&YB69#ZJP!'Z&OAQD:-V212K*<,I'(/I7T#\$/ MB3:SZ7#X4UJ98+JV&VRED; F3/\ J\G^(9X]1].7B(MQNN@4W9V/:JK:E?1: M9I=U?7)Q#:PO,Y_V5!)_E5BO'/C=\1K2RT6X\+:3,LU]=#9=LC9%O'GE3_M' MICL,^U<<(NKZ)KVE^(] M-%_HE[%>6Q8KYD9Z,.H(/(/(X-?$5?7/PE\/-X;^&^G6\R[;BY4W4P/9GY ^ MH7:/PKHK4X15T9PDWN=I1117*:GSA^T9_P CUIO_ _P"C7KR-69&#*2I' M0@XKZK\??">R\?:S;ZC=:G<6C06X@"11JP(W%L\_[U ?:9_P#GO)_WV:C9BS98ECZDYKZ#_P"&;M*_Z&"]_P"_ M*5:L_P!G/P[$^;W5=1N1_=0I&#^AJ_;TQ>SD?/6GZ?=ZMJ$-CIMO)&O)EVR:E=XDO)5.1D=$'LN3]22:V/#O@S0/"D'EZ# MID-LQ&&EQND?ZN<&B0,6.TC'/UKA$_9PTM)%;^ MW[P[2#_J4KLI581A9F,H-NY[/113)E9X76-_+=E(5P,[3ZXKC-CY)^+>MC7? MB;JLT;;H;9Q:Q\Y&(QM./8MN/XUK? G0_P"UOB1'=R+F'3(6N#G^^?E7]6)_ MX#7=M^SAICN7?Q#>LS'+$PIR:[?X??#JQ^']M>QV=W+=R7CJSR2J%("@X Q] M2?QKLE5@H1ZS^S]I&K:W>Z@FKW5J+J9IO)CB4JA8Y('MDUT4:BA=2 M,YQ?+=DSUVL1FE-Q,1@S2$>[FOH#_AF[2O M^A@O?^_*4O\ PS=I7_0?O?\ ORE:^WI]R?9R/GJNL^'_ ("O_'>O+;6X:*PA M(:[NL<1KZ#U8]A^/05[AI7P \(V$J2WK7NI,IR4GE"H?P4 _K7I%AI]GI=FE MIIMK#:VZ?=BA0*H_ 5E/$*WNE1I]Q--T^UTG3+?3]/B$-M;1B.*,?PJ!C_)K MPO\ :3_Y"7A__KE-_-*]^KA_B#\,K3X@7%C+=ZC/9FS5U41(&W;B.N?I7/2D MHSNS22O&R/F[X>?\E*\._P#81A_]#%?9->3:%\ ]-T+Q!8:K%K=W,]E.DZQM M$H#%3G!KUFKK3C-JPH1<5J?.GQK^&DNEZC/XHT2 O87+%[R-.?(D)Y?_ '6/ MY'ZBO'J^ZI(UEC:.15='!5E89!!Z@BO+O%/P%\.ZY+?$<5C]CCU[4UML8\D7;A<>F,UD$EB2Q)). M23WKV1_V;]:$N(]=L#'G[S1N#^7_ ->NF\._L\:18W"3^(-1FU,J0?L\:>5& M3Z$Y+$?B*V=:FB.23/.?A#\/9/&'B)+[4(&_L:Q.WMXAM2*)0JJ/8"IZXJE1S=S>,>56"BBBLRCSGXB?%&; MP+K=M81:4EZ)[?SB[3%,?,5QC!]*Y+_AH>Z_Z%V'_P "C_\ $UG_ +0/_(Z: M=_V#Q_Z,>O*:X9U)J329]!AL+1G1C*4=3V;_ (:'NO\ H78?_ H__$T?\-#W M7_0NP_\ @4?_ (FO&:*CVL^YT?4L/_+^9[-_PT/=?]"[#_X%'_XFC_AH>Z_Z M%V'_ ,"C_P#$UXS11[6?,T4>UGW#ZEA_Y?S/9O^&A[K_H78?\ P*/_ ,31_P -#W7_ $+L M/_@4?_B:\9HH]K/N'U+#_P OYGLW_#0]U_T+L/\ X%'_ .)H_P"&A[K_ *%V M'_P*/_Q->,T4>UGW#ZEA_P"7\SV;_AH>Z_Z%V'_P*/\ \31_PT/=?]"[#_X% M'_XFO&:*/:S[A]2P_P#+^9[-_P -#W7_ $+L/_@4?_B:/^&A[K_H78?_ */ M_P 37C-%'M9]P^I8?^7\SV;_ (:'NO\ H78?_ H__$T?\-#W7_0NP_\ @4?_ M (FO&:*/:S[A]2P_\OYGLW_#0]U_T+L/_@4?_B:/^&A[K_H78?\ P*/_ ,37 MC-%'M9]P^I8?^7\SV;_AH>Z_Z%V'_P "C_\ $T?\-#W7_0NP_P#@4?\ XFO& M:*/:S[A]2P_\OYGLW_#0]U_T+L/_ (%'_P")H_X:'NO^A=A_\"C_ /$UXS11 M[6?S?\-#W7_0NP_P#@4?\ XFC_ (:'NO\ H78?_ H__$UXS11[ M6?,T4>UGW# MZEA_Y?S/HCP-\7Y_&'BJ'2)-'CM5DC=_-6; M_P!!KZ9KJHR7L26(1GMX&< ^8 MQP2!UY%>:?\ "%^*/^A=U7_P#D_PKZ^HI2H*3O .YK8_X0OQ1_P!"[JO_ (!R?X5'X3_Y'31?^O\ @_\ 1@K[ M"JZ5/GN88O%O#M)*]SY!_P"$+\4?]"[JO_@')_A1_P (7XH_Z%W5?_ .3_"O MKZBMOJZ[G%_:D_Y3Y!_X0OQ1_P!"[JO_ (!R?X5#=^%]>L+5[F^T74+:WC&7 MEEMG55YQR2,#FOL2N-^+7_)*]:_ZYQ_^C4J94$HMW+IYC*2_M!_\BII M?_7[_P"R-7@%>_\ [0?_ "*FE_\ 7[_[(U> 5Y];^(SZ7+_]W7S-?PG_ ,CI MHO\ U_P?^C!7V%7Q[X3_ .1TT7_K_@_]&"OL*ML/U.+-/BB%%%%=1XX5QOQ: M_P"25ZU_USC_ /1J5V5<;\6O^25ZU_USC_\ 1J5%3X&;8?\ C0]5^9\L4AZ& MEI#T->8?6GV3X>_Y%G2_^O.+_P! %:-9WA[_ )%G2_\ KSB_] %:->I'X4?' MS^)A1115$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 >2_M!_\ (J:7_P!?O_LC5X!7O_[0?_(J:7_U^_\ LC5X!7GUOXC/ MIM?]AI:0]#7F'UI]D^'O\ D6=+_P"O.+_T 5HUG>'O^19TO_KS MB_\ 0!6C7J1^%'Q\_B844451 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% 'DO[0?_(J:7_U^_\ LC5X!7O_ .T'_P BII?_ M %^_^R-7@%>?6_B,^ER__=U\S7\)_P#(Z:+_ -?\'_HP5]A5\>^$_P#D=-%_ MZ_X/_1@K["K;#]3BS3XHA11174>.%<;\6O\ DE>M?]M?]AI:0]#7F'UI]D^'O^19TO_KSB_\ M0!6C6=X>_P"19TO_ *\XO_0!6C7J1^%'Q\_B844451 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DO[0?_ "*FE_\ 7[_[ M(U> 5[_^T'_R*FE_]?O_ +(U> 5Y];^(SZ7+_P#=U\S7\)_\CIHO_7_!_P"C M!7V%7Q[X3_Y'31?^O^#_ -&"OL*ML/U.+-/BB%%%%=1XX5QOQ:_Y)7K7_7./ M_P!&I795QOQ:_P"25ZU_USC_ /1J5%3X&;8?^-#U7YGRQ2'H:6D/0UYA]:?9 M/A[_ )%G2_\ KSB_] %:-9WA[_D6=+_Z\XO_ $ 5HUZD?A1\?/XF%%%%40%% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y+^ MT'_R*FE_]?O_ +(U> 5[_P#M!_\ (J:7_P!?O_LC5X!7GUOXC/I'O\ D6=+_P"O.+_T 5HU MZD?A1\?/XF%%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110!Y+^T'_P BII?_ %^_^R-7@%>__M!_\BII?_7[_P"R-7@% M>?6_B,^ER_\ W=?,U_"?_(Z:+_U_P?\ HP5]A5\>^$_^1TT7_K_@_P#1@K[" MK;#]3BS3XHA11174>.%<;\6O^25ZU_USC_\ 1J5V5<;\6O\ DE>M?]8?6GV3X>_P"19TO_ *\XO_0!6C6=X>_Y M%G2_^O.+_P! %:->I'X4?'S^)A1115$!1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 >2_M!?\BII?_7[_P"R-7@%?5?Q#\#G MQWI-K9+?_8?L\_F[S%YF[Y2,8R/6O/O^&=G_ .AE7_P"_P#LZXJM.YRX^M3JRBX.X4445T'FA7&_%K_DE>M?]O>'O^19T MO_KSB_\ 0!6C5;3K3[!I=K:;]_V>%(MV,;MJ@9Q^%6:]".B1\U)WDV@HHHID MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 %44 ?_]D! end XML 12 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]    
Prepaid insurance $ 198,554 $ 173,890
Prepaid expenses - various 88,607 101,221
Prepaid taxes 1,334 2,888
Prepaid expenses and other current assets $ 288,495 $ 277,999
XML 13 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Cash, Cash Equivalent, and Investments (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents $ 4,696,831   $ 4,823,544
Short term investments, adjusted cost 26,587,752   29,399,146
Long term investments, adjusted cost 2,518,160   1,511,636
Cash and Investment, fair value 33,673,423   35,738,787
Investment, gross unrealized holding gain 24,812   22,452
Investment, gross unrealized holding losses (154,132)   (17,991)
Cash and Investment, adjusted cost 33,802,743   35,734,326
Cash      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents 523,626   1,010,510
Money Market Funds | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and Cash Equivalents 4,173,205   3,813,034
Corporate bonds      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Held-to-maturity, premium paid on purchase 196,385 $ 80,855 233,550
Corporate bonds | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Short term investments, fair value 26,439,982   29,387,053
Short term investments, gross unrealized holding gain     5,898
Short term investments, gross unrealized holding loss (147,770)   (17,991)
Short term investments, adjusted cost 26,587,752   29,399,146
Long term Investments, fair value 2,536,610   1,528,190
Long term Investments, gross unrealized holding gain 24,812   16,554
Long term Investments, gross unrealized holding loss (6,362)    
Long term investments, adjusted cost $ 2,518,160   $ 1,511,636
XML 14 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation - Assumptions (Details) - Stock Option
 3 Months Ended
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Risk-Free interest rate, minimum 0.25%
Risk-Free interest rate, maximum 1.72%
Expected dividend rate 0.00%
Expected stock price volatility, minimum 39.94%
Expected stock price volatility, maximum 51.22%
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected life of options 1 year 9 months
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected life of options 6 years 3 months
XML 15 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent Events
 3 Months Ended
Mar. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Management continues to actively monitor the COVID-19 pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce.
For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through May 14, 2020, the date the consolidated financial statements were available to be issued. Management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.
XML 16 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of valuation assumptions
The assumptions used in the Black-Scholes option pricing model for stock options granted during the three months ended March 31, 2020 are as follows:
Risk-Free interest rate
0.25% - 1.72%
Expected dividend yield— %
Expected stock price volatility
39.94% - 51.22%
Expected life of options
1.75 - 6.25 Years
Schedule of stock option activity
The following table summarizes the stock option activities during the three months ended March 31, 2020: 
SharesWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
Outstanding at December 31, 20193,860,390  $1.765.7$13,287,932
Granted (1)
913,000  5.24  
Exercised (2)
(110,000) 1.78  
Expired —  —  
Canceled —  —  
Outstanding at March 31, 20204,663,390  $2.446.4$13,017,190
Exercisable at March 31, 20203,167,983  $1.675.1$11,201,783
_________________
Notes:
(1) Represents the following stock options granted:
•Annual share-based compensation awards on January 2, 2020, including: (a) 525,000 stock options with an exercise price of $5.27 per share granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 325,000 stock options with an exercise price of $5.27 per share granted to the Board of Directors, vesting upon one year anniversary, (c) 23,000 stock options with an exercise price of $5.27 per share granted to employees, vesting annually in equal installments over four years, and (d) 15,000 stock options with an exercise price of $5.27 per share granted to a consultant, vesting upon one year anniversary.
•One-time awards on March 22, 2020, including 25,000 stock options to a contractor with an exercise price of $3.99 per share, vesting in six months from the date of grant.
(2) Represents the following stock options exercised:
•A total of 110,000 stock options exercised with a weighted average market price of $1.78, among which, 10,000 shares were issued in May 2020.
Schedule of non-cash stock option compensation expense
Total non-cash stock option compensation expense was allocated among the following expense categories: 
Three Months Ended March 31,
20202019
General and administrative$380,251  $233,214  
Research and development46,688  76,349  
Total $426,939  $309,563  
XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Shareholders' Equity - Changes in Shareholders’ Equity (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance $ 35,864,471 $ 42,451,169
Stock-based compensation 426,939 309,563
Exercise of stock options 175,000  
Net loss (2,214,139) (2,175,258)
Ending balance 34,252,271 40,585,474
Common Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance 39,613 38,967
Exercise of stock options 100  
Ending balance 39,713 38,967
Treasury Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance (18,929,915) (18,929,915)
Ending balance (18,929,915) (18,929,915)
Additional paid-in capital    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance 96,105,851 94,385,230
Stock-based compensation 426,939 309,563
Exercise of stock options 174,900  
Ending balance 96,707,690 94,694,793
Accumulated deficit    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance (41,351,078) (33,043,113)
Net loss (2,214,139) (2,175,258)
Ending balance $ (43,565,217) $ (35,218,371)
XML 19 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation - Stock Option Activity (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]    
Outstanding, beginning (in shares) 3,860,390  
Granted (in shares) 913,000  
Exercised (in shares) (110,000)  
Expired (in shares) 0  
Canceled (in shares) 0  
Outstanding, ending (in shares) 4,663,390 3,860,390
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]    
Weighted average exercise price, outstanding, beginning (USD per share) $ 1.76  
Weighted average exercise price, granted (USD per share) 5.24  
Weighted average exercise price, exercised (in USD per share) 1.78  
Weighted average exercise price, expired (USD per share) 0  
Weighted average exercise price, canceled (USD per share) 0  
Weighted average exercise price, outstanding, ending (USD per share) $ 2.44 $ 1.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]    
Exercisable (in shares) 3,167,983  
Weighted average exercise price, exercisable (USD per share) $ 1.67  
Weighted-average remaining contractual term, outstanding 6 years 4 months 24 days 5 years 8 months 12 days
Weighted-average remaining contractual term, exercisable 5 years 1 month 6 days  
Aggregate intrinsic value, outstanding $ 13,017,190 $ 13,287,932
Aggregate intrinsic value, exercisable $ 11,201,783  
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Research Collaboration and Sub-licensing Agreements
 3 Months Ended
Mar. 31, 2020
Research and Development [Abstract]  
Research Collaboration and Sub-licensing Agreements Research Collaboration and Sub-licensing Agreements
BDI Agreements
On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”).

The R&D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic’s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.
Upon closing of the BDI transaction, the Company paid EUR €1 million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR €936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR €1 million for a 50% share or EUR €8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR €1.5 million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million (the “SFA Commitment”) in contract research services specified by Dyadic over two years since the closing of the BDI transaction.

The Company has concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results.

The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1 million (EUR €1 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1 million paid by Dyadic were expensed as the related research services were performed by BDI. In June 2019, BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. As of December 31, 2019, Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA. However, the Company may in the future continue to provide funding to BDI for certain research and commercialization projects.

As of March 31, 2020 and December 31, 2019, there were no balances in the prepaid research and development collaboration related to BDI recorded on our consolidated balance sheets. For the three months ended March 31, 2020, and 2019, research and development expenses related to BDI recorded as research and development - related party in our consolidated statements of operations were none and approximately $0.4 million, respectively.

Novovet and Luina Bio Sub-License Agreement
On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.

In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic’s proprietary C1 gene expression platform.

The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet.

As of March 31, 2020, Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity
method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.

Alphazyme Sub-License Agreement
On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.

In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a 7.5% ownership interest in Alphazyme (“Alphazyme Up-Front Consideration”) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic’s proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of 18 months (“Exclusivity Period”) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period, Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional 2.5% ownership interest in Alphazyme.

The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme.

As of March 31, 2020, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded during the three months ended March 31, 2020.

Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.

Research and Commercialization Collaboration with Serum Institute of India
On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (“Serum”). Under the terms of this collaboration, Serum anticipates applying Dyadic’s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic’s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.
For the three months ended March 31, 2020, the Company recognized approximately $75,000 in research and research revenue from Serum. As of March 31, 2020, the Company recorded approximately $82,000 in deferred research and development obligations related to this agreement.
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
Total
Common Stock
Treasury Stock
Additional paid-in capital
Accumulated deficit
Beginning balance at Dec. 31, 2018 $ 42,451,169 $ 38,967 $ (18,929,915) $ 94,385,230 $ (33,043,113)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 309,563     309,563  
Net loss (2,175,258)       (2,175,258)
Ending balance at Mar. 31, 2019 $ 40,585,474 $ 38,967 $ (18,929,915) 94,694,793 (35,218,371)
Beginning balance (in shares) at Dec. 31, 2019 39,612,659 39,612,659 (12,253,502)    
Beginning balance at Dec. 31, 2019 $ 35,864,471 $ 39,613 $ (18,929,915) 96,105,851 (41,351,078)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation $ 426,939     426,939  
Exercise of stock options (in shares) 110,000 100,000      
Exercise of stock options $ 175,000 $ 100   174,900  
Net loss $ (2,214,139)       (2,214,139)
Ending balance (in shares) at Mar. 31, 2020 39,722,659 39,712,659 (12,253,502)    
Ending balance at Mar. 31, 2020 $ 34,252,271 $ 39,713 $ (18,929,915) $ 96,707,690 $ (43,565,217)
EXCEL 22 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2020
May 13, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2020  
Document Transition Report false  
Entity File Number 000-55264  
Entity Registrant Name DYADIC INTERNATIONAL, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 45-0486747  
Entity Address, Address Line One 140 Intracoastal Pointe Drive  
Entity Address, Address Line Two Suite 404  
Entity Address, City or Town Jupiter  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33477  
City Area Code 561  
Local Phone Number 743-8333  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol DYAI  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   27,469,157
Entity Central Index Key 0001213809  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Amendment Flag false  

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Shareholders' Equity
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Stockholders' Equity Shareholders’ Equity
Issuances of Common Stock
For the three months ended March 31, 2020, there were 100,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.78 per share. For the three months ended March 31, 2019, no shares were issued.
Three Months Ended March 31, 2020 (Unaudited)
Common StockTreasury StockAdditional Paid-In CapitalAccumulated DeficitTotal
January 1, 2020$39,613  $(18,929,915) $96,105,851  $(41,351,078) $35,864,471  
Stock-based compensation—  —  426,939  —  426,939  
Exercise of stock options100  —  174,900  —  175,000  
Net loss—  —  —  (2,214,139) (2,214,139) 
March 31, 2020$39,713  $(18,929,915) $96,707,690  $(43,565,217) $34,252,271  
Three Months Ended March 31, 2019 (Unaudited)
Common StockTreasury StockAdditional Paid-In CapitalAccumulated DeficitTotal
January 1, 2019$38,967  $(18,929,915) $94,385,230  $(33,043,113) $42,451,169  
Stock-based compensation—  —  309,563  —  309,563  
Net loss—  —  —  (2,175,258) (2,175,258) 
March 31, 2019$38,967  $(18,929,915) $94,694,793  $(35,218,371) $40,585,474  

Treasury Stock
As of March 31, 2020 and December 31, 2019, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Cash, Cash Equivalent, and Investments (Tables)
 3 Months Ended
Mar. 31, 2020
Cash and Cash Equivalents [Abstract]  
Schedule of Cash, Available-for-sale Securities, Short-term and Long-term Investment Securities The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of March 31, 2020 and December 31, 2019:
March 31, 2020 (Unaudited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$523,626  $—  $—  $523,626  
Money Market Funds14,173,205  —  —  4,173,205  
Subtotal4,696,831  —  —  4,696,831  
Short-Term Investment Securities (2)
Corporate Bonds (4)
226,439,982  —  (147,770) 26,587,752  
Long-Term Investment Securities (3)
Corporate Bonds (4)
22,536,610  24,812  (6,362) 2,518,160  
Total$33,673,423  $24,812  $(154,132) $33,802,743  
December 31, 2019 (Audited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$1,010,510  $—  $—  $1,010,510  
Money Market Funds13,813,034  —  —  3,813,034  
Subtotal4,823,544  —  —  4,823,544  
Short-Term Investment Securities (2)
Corporate Bonds (4)
229,387,053  5,898  (17,991) 29,399,146  
Long-Term Investment Securities (3)
Corporate Bonds (4)
21,528,190  16,554  —  1,511,636  
Total$35,738,787  $22,452  $(17,991) $35,734,326  
_________________
Notes:
(1) Definition of the three-level fair value hierarchy:
•Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
•Level 2 - Other inputs that are directly or indirectly observable in the markets
•Level 3 - Inputs that are generally unobservable
(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.
(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.
(4) The premium paid to purchase held-to-maturity investment securities was $196,385 and $80,855 for the three months ended March 31, 2020 and 2019, respectively. The premium paid to purchase held-to-maturity investment securities was $233,550 for the year ended December 31, 2019.
XML 26 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation - Stock Option Activity - Textual (Details) - $ / shares
 3 Months Ended
May 14, 2020
Mar. 22, 2020
Jan. 02, 2020
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options granted (in shares)       913,000
Weighted average exercise price, granted (USD per share)       $ 5.24
Exercise of stock options (in shares)       110,000
Weighted average exercise price, exercised (in USD per share)       $ 1.78
Subsequent Event        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 10,000      
Executives and Key Personnel        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Weighted average exercise price, granted (USD per share)     $ 5.27  
Award requisite service period     1 year  
Board of Directors        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options granted (in shares)     325,000  
Weighted average exercise price, granted (USD per share)     $ 5.27  
Employee        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options granted (in shares)     23,000  
Weighted average exercise price, granted (USD per share)     $ 5.27  
Consultant        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Weighted average exercise price, granted (USD per share)     $ 5.27  
Award requisite service period     1 year  
Contractor        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Weighted average exercise price, granted (USD per share)   $ 3.99    
Award requisite service period   6 months    
Stock Option | Executives and Key Personnel        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options granted (in shares)     525,000  
Award vesting period     4 years  
Stock Option | Employee        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period     4 years  
Stock Option | Consultant        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options granted (in shares)     15,000  
Stock Option | Contractor        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares available for grant (in shares)   25,000    
XML 27 R4.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenues:    
Research and development revenue $ 315,372 $ 402,527
Costs and expenses:    
Costs of research and development revenue 278,182 327,903
Research and development 755,453 692,370
Research and development - related party 0 389,473
General and administrative 1,653,392 1,428,067
Foreign currency exchange loss (gain), net 10,867 6,034
Total costs and expenses 2,697,894 2,843,847
Loss from operations (2,382,522) (2,441,320)
Interest income 168,383 266,962
Loss before income taxes (2,214,139) (2,174,358)
Provision for income taxes 0 900
Net loss $ (2,214,139) $ (2,175,258)
Basic and diluted net loss per common share (USD per share) $ (0.08) $ (0.08)
Basic and diluted weighted-average common shares outstanding (in shares) 27,452,490 26,713,486
XML 28 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Cash, Cash Equivalent, and Investments
 3 Months Ended
Mar. 31, 2020
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalent, and Investments Cash, Cash Equivalent, and Investments
The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of March 31, 2020 and December 31, 2019:
March 31, 2020 (Unaudited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$523,626  $—  $—  $523,626  
Money Market Funds14,173,205  —  —  4,173,205  
Subtotal4,696,831  —  —  4,696,831  
Short-Term Investment Securities (2)
Corporate Bonds (4)
226,439,982  —  (147,770) 26,587,752  
Long-Term Investment Securities (3)
Corporate Bonds (4)
22,536,610  24,812  (6,362) 2,518,160  
Total$33,673,423  $24,812  $(154,132) $33,802,743  
December 31, 2019 (Audited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$1,010,510  $—  $—  $1,010,510  
Money Market Funds13,813,034  —  —  3,813,034  
Subtotal4,823,544  —  —  4,823,544  
Short-Term Investment Securities (2)
Corporate Bonds (4)
229,387,053  5,898  (17,991) 29,399,146  
Long-Term Investment Securities (3)
Corporate Bonds (4)
21,528,190  16,554  —  1,511,636  
Total$35,738,787  $22,452  $(17,991) $35,734,326  
_________________
Notes:
(1) Definition of the three-level fair value hierarchy:
•Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
•Level 2 - Other inputs that are directly or indirectly observable in the markets
•Level 3 - Inputs that are generally unobservable
(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.
(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.
(4) The premium paid to purchase held-to-maturity investment securities was $196,385 and $80,855 for the three months ended March 31, 2020 and 2019, respectively. The premium paid to purchase held-to-maturity investment securities was $233,550 for the year ended December 31, 2019.
The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. As of March 31, 2020, the Company does not consider any of its investments to be other-than-temporarily impaired.
ZIP 30 0001213809-20-000024-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213809-20-000024-xbrl.zip M4$L#!!0 ( $>!KE!5#<@IP($! #&Q$ 1 9'EA:2TR,#(P,#,S,2YH M=&WLO6E7(TF2+OQ]?H5>>N[A/\AZW7\NX"6T M4/E_RW_^?TGR[T^;7RK5GAMU0G=86>T',PR^VWU[J]?<^9-UVU@UQ MN!^&?=,=I+U^QPQA.CX0A'F"2$+$PN0AT/+PYJ<0A.B'>-F:09@V/_VA_0G- M6V.M]8?\ZJ3I[8WB$!8NQI ,@KO2&+XO[?6.[QR&2BB>/F?0OYB+U QL_CKX M,395"<*7FIX.LIOZ!L/%'_Y=^[+E]D/')%EW,#1=%RXZ>MLL87JII]/F/ER\ M)&\['11,!LF>,4<_CGERX:9QP_.RG[WAVHCC M57]M%)/&XD-Q\;PWP_ZM#]8?X.KYM(S-U2[ #SYS2Z[7^1 %#-%)?S^V37?O MGPNAFVQO+0#7!^.7_^R$H:G$FY/PGU%V_,^%U5YW"+*<-,='T&U7?/OGPC"< M#C_D7/9A^;_^Z[_^'&;#=EB.[TZF+_GS0_'CGQ^*1]N>'R__Z;/CRF X;H=_ M+OAL<-0VXX_=7C= ![+3C[%AZ!\_'6Z&])\+&5=2 M(2*Q%$@QY;5.)2$I]LRG+ 44V*WF7<% HHN!=TTGOCID']>ZT+_Q*@RG;]H; M71]._S>,%RJ9AT=[^O?85GO'7\CF<8O61OY@[7CGLSYH'.RAG6:]W?A^;G?K9^N%.LW:RT]P\J!TKMUUF/US]MG.\W]@YUJ M#=>K>ZC57.&-[]#VP)WNP+7:YVW4.MO@M;9"7\C.N/7=B7JG?K#3;)W6JH[7 M/M=8O?IW9^?SQKAU=GBV\[W%ZLWU3HVL[]>^UX[]Y_7,?MX6.]"7.MG<;S2_ MH<;GG8-Z-=YW.*Y_7N.-Z@JOG^UT:F>'?.=@97+/W_ NWMUI'AU"&[H#[>K5 M;PQ:H=K9'FHT-Z"OAPS&1^N=UEFCV>[4UM79E^;:L+:%3K\T5W:UD0ACH1.K M:4@8-BK12 +^6NJ]P)YX!J1%0 2"J4+ZSP]7Z/GTY"T #.X^'7[TH'PZ\,1] M;\;C8/JA>YG\4RWU%=[<\VM=7X7F)?GO(C^]3'ZA<.H8 HW,-4H8*./$@KH% M]:-(",M6_[QRV#OXZ:$"_=P[V<.U[ MZZSU?>VTA=6X=K*;ZD!$ZG7B,65@,3F:6"Q=8H5@6"*=,G /EC%#E8UHF+J> M 9>A7?G:RX &F5 )H;8:Q%I%3XV^LW>2?=]D>BL]FV7(Q=2;!V '_8)\]HGB@20,H&, M(IAA1M.%Y;]&1T"C_DNZ(C'^\A'D>!B.^KWC2+FKOL@5"F[%=HW^5VB9Y;&" M=T7&^K==BJ6W* 6;Q"D--HG! )&*)SRE*?54 $2*A>7U=J^?>?/B9+2]7MN: M=KLWM+W3'XFXU8%KGT8# ,G!?!JCCZ;=:;VYMRNP%8$"3*H0)8\&DQ@&?J'W M3%(-1B:),O@__]"2B3]FC7AK\-Z]K+OWN=\[&>ZO]CI'ICN?(:''$[%1W=YU MG*% HG*+PL>H 0_?4)]XP1#!/&@27;ZG/543]? M66BD*WO]D/_TRF2KK>J.ZZQW&P?K[=K!'F]U:J>UL]:X?@:.6W2TFC5>(_'? M-JF?K5!H<_*%;K;#OS;'.]_]D25,U+YOCQO5=M8Z6SNK'VQ0<-QPH[D'SSD\ MR\G>A!%5';3YE-;/W.ENFJ9!2P)2A0DX:)B21!O.$LTM!;(12QU=6/Y*6@^A MF7%&>BY2AX-@J18ZQ9J ,V]T*AQ.PT_$:K*8\7%KW_1#7(;R$?9"=Y 3ZQ+] M/HTOFGPUX_C3RHGI^[73HZR@;!&%>66BUK,)43MK9*?YC=:;CC>:^QEXTB?U M#GC3U2A?[7UX7@?T%6Y\_VO_.E%;S9UVO>HPR")O?-Y ]>H*V:GN'S::GP[@ MO=#W%@:8!(993^O-;^#);\/W-03M47UOUWLMG7$XX5JAZ(.#_4+!()5"4JX% M"3Q-'TQBQZQU7'OC,6,4(26-!A%-K:".&XE*$K\4B4GCVV[07#A WL03%1+F MB$],"JX\XH"]U"@E991B6DKQG)#XK,7K!]L ^=].:F=[I_654HK?-HG'M97G MD6)E>: F&,]3(#%.+7::.)F2E%KO'9F0F!*23#_<2.)/=Y/XTW42Y_^S&5?N M!]DP;(7^<>9"0>W7#K6^,FBS&KBF)B"F%4F$(B9A-KA$(6\31)%E6%+IK 9R MB]H/Y/YP-2&A']( ?H@+@^4_8SK.QT&>T +TK^3I.1^'XR,@YR#K'+5CKD?^ MVWX_LL>5#(FETX%?@*=??4;QNLOOR+\.>J-^_BU/,ODXX;F"J(]QJZ8/"KGG M._V6^?@]S4*_DGK3CW)6G'X;#$U_&-VW?/$P M9M(@/+WOXMIY-_VEIC1W:JY>F7Z?ON3#E8F:/F?4S8I)&T0)&IQ/0R>8P:@? MEB>OSR].'S&]-OT>GW$C'52J95 4+'R %26PHAX%1#Q"VD5ELKN13S_'= :F MOTA&&DYFE">8GC]H#F:_.YF7^?-AL7N4GC)$U%#E) R.$*"VP56 D*@YZ1=(X M UAC,F,S@/4T[/"K_ 2Z*]=TY\/SV3%TZW+3'*3-L-=_).O]<'_\L1JZO4[6 MO>FQ]P6(*X_X<+7W=^((H4H#EA#A#,/$:RH9#9APR>QZ>/Q_,J\D6"E58P[8S!+F;&!.Z=#C%UY:WAX.7F9C#KL1=NL M^.KA9:='[ZJ.2*L9]]Z E8J,X0QA+YQRWBO.W"NX86]%GE[%5[Q"7.\4\5)I M"<9_5R'A]@F+,=1I2A0WE3.*@).4*$9!>*81@ M[.T1]/EA]?6IBJ3T*;C*J:.&*6TL0\Y0ACW62F-+7RYH,,_2^2S1#&0U]RSE MW"+-1"2.%%Z!BG2&*&WYFR'-B[D 3T@<,"TE8B)'0 :N,O@"DB(J !H#HO@% M@VUOQ61Y%C)QP9 6)BBF-5." IFLL<@R)T/@XNW VTNZ $\I1LRD02#,B5#, M>:Q4Z@E'G#LDD?0V=]'4[$5LU=,Y04%Y#AH86! Q:9VFV*8B38W4" G$"R=U M1D*65]S )Y-1ZH'Z<;, %O>61!Y+IAUD3UD%_" ;& M" ;5/P*K;5PWG5#(9Y[C5QU]A0%733<;N-X=DGEO8-CHNEXGG,/#)]..6^6W M]D,8KG3]!6Q7X:7M7HRW#SZ-X>8"+V 9ZF'5'P3>. M0I'V,+@T@HVN'PV&_1\6M-'[O26?3T MA[6Y?"(F%^^S.'?^0 =3!Z3JW_S$Z=4'K_>YN,$&K':>IIY)@3327* T335. MI9'I'#EDJSU@W;A_*_+=9C8X_#3^%+INOV/ZAU?UW)9IA\%F. [ JO4P?"IA MNJ$#L8+#-1=B0JD?&K]%QQ!\0$TY.!O2$F9)4!2GF,E\D2CXP%]A3:WDKN? MU]=9>:2(!/"7@D6420IVN9 2RZ"5<,0P/ ?8%77^N?;]''I[?7.TGSG3ODK6 M>J^[?9>*? 9.7G$NVB/ S"YDQ\:VPWM@YM>!2N53HZ0-*0*$9)RIR&18(,E] M")*;:U YBP9LR6#/@9:_8(U>14M.-3$I\0$91H0P%KC+LC00AA6RID3+4N_/ M+%2>NT'=4>SX+1FD1_#QP1X0,=1*:1@UF#"&J&;4(V:DQU)Z;_TR%PM0IH[V3#$MA'14>_'ON#!& ]K,;IYYM!GX_5LJSA.=ERE*-.+74 M.J8%T5;$[$/B::I22L,<6+8E?\X&?[Z^%1U8ZG3<(LHT8S@0ZQW60ELPH@WC M2,YN.F#)P[/!P\^2!6FH ,TO%.%,,A>X8B0@S%&L)4%0RN?$N?O)\E>LB=PW M;K@9!B'6-FWT]TPW.RL6F=XJK[Q^6"H5A*(@;3#(,E#@2@5M"-+,TL"XG(<( M?LE8L^BL,($YL)!"\'_,ZJ#!!?<.X=0RA!5BL^VLO&E^>D;U_M6,[Z';9\5S MH:D6% FKC*2@2>,R.1),ILX(@KBGI58MF74^U3HBD@H2O!.> ^Q:I7U,0+6. M^,C?,[PSL&3H&63H9_%I@F(<>X93I!%#0BJ9:JKC9F/NL QH3N)&);/.&+.^ M?A")&RPXIXKK5##EM+&* +RGUB+LF,&S:_M>)U*]-PR#+SW3':QT_7K6-5V7 M=??%R\)/EH7G).">&4:I!3QHA&,%"2R>8)H)Q M9;W0,ZP^YYF 3ZA;9*!$:FICV8JX>T!YB1T-G*5!IRF3[TD"M[MV'F70<0FX MJ<%@%9H%Q&(Q+HEDRK6S<&D.-N;/)PF?TL+3*4::Z^"88Y)BXX,)7C$/OC6C M:!ZBUN?;#\UI4?/OVJY$24.02A6RGE@S M^P19-UG_;],>A4_C\X__@B=&_VC\!?#MVGKE>:.-[M%H.,A;X"?S6N[!';5> M-XQKX,:$X?JHZ^=%?6H2#!< M*>WFJ>+6,['-7#IJ:40 "AX!. :,!*$<9E8X1G(P0'@.TGAFFZRODT0CP?\F MFJ>IMI)):;0*2'K!4_B$>+%[?\:7R-X269]J?>@QQX$],UD?.F\R02*AZ#[S M=JWI(S>&A=&/N\*FUGM]^_$#[!P2D/FL_%Z"2/)PO$_;C8,4R-#:] M@\>[/GFUK>PLGFTR& X:Z78WGHD:_-=^#Z8WBM':::SB$OQZO]=9Z?3@MV(9 M^M-XTF:6RI?BKFMEII )()06G"[&L8RI MBS8U-BX#.AYTR1&_P!%W=CVF4C1.NJ$_V,^.+KWP4W7C7[VV?_[2FJ_#="EA M-( J$,!H3&@$CIM/B68VY?%<'3D'3'<;Y?[^\M5F3U;):O98>B[YC0.42>N1 M%H$R;S3\-1Y^217V(A5%M$#.LB$Y>XSP*]CVK&$#^73[CY 5S#B<8@ LJ7S, MYJ>2&XT KH(I=>/;X9_7QR@;4D>%-2+@E'E.K.3!QGPL)F,\7,T!LT6*;<:3 M!0MJQ:^UK)MU1IU2'\X4KW%N>2I21BW%C.F@,,5:>DFID(Y8.Z>\9DY+7ILY M7I,2:4\U=MY0EF*B.?'H>L^TG=!TO6\ZX:37/YPWVEKLI B. M*J<82X&8T@L:@C-@O2.,RU#$"Q/Y]9&<*H!MESH=6&!IFEKK4#RJ*@6WSBDY M.6D3,2)FC1'RFDWP1C]JAT9:'-Y2"\/]GM_H'H?!,#[FQU]#N+;/M-X[!J9Y M7@'6"6()$4\@P $%1C@'M\=S)C4RB"DC"3*<6..IF)"+(_Y&R;72/MHW9^/. M8$'.$4C.&A\_+]_< M2XQ^4N\ K(X[/>BG #7Y.% [9S>PL88AZ][,89.+#V8J;Y6@VFD"[,1\( 9T M&E->.G K:6K$.4K*I.2N&>*N&Y!/WA_YY..0[UKE?H^P]]9ZQL%7U@ 4]T0JYJU@2&C+@R#(F53HU 07W@YQZ^!H MAWX;_+A!(TTS%]XL32GBG!!A05@-P\*9@%///$@K,8KH:7Q2$#5KI+Q#3?[= M;.8GO<8J\],EHU5XB?VR$4"5%/ *M2H=1[;GS<$Y)R9:FV M&'OA&$IM7#.J3JF4E.3Z)0_K,L'N\+ N-_V5M5XCO"(LM0$KAD*(,4Q)P5=' MEJ3J?#<](C,9N)Q!DE[=FXP2\A1Q9NL0"!HF/$68J316_](JQ3Q(9:7AI)# M2*6D)->O2. 5@MVQY?%RTU_9YV(-BT<#(2D80RPHQ04E+E"!D<0D3'T+0DN2 M/LJU(/0IEN:$$II0YT603 FK4LY2AZ5RL3*ZGA9L RHE);E^R0J]3+ [K="+ MIK]2$EQ+):V*8&K!I$EU" )YXT +IMC9.?#NOP)UKB_(08]%_'U.?'=,7:H= M]P)[%\].-SAPY%(,M$@-4W-0O^UF(F \1T1@&*G #<$NI##M*;9 T>-!+ M=K+1]U*Q#/A04N,F0_X!!3$N-_VE(S!9H$:I@*QGV'I%J634I_$<3(\*)^UR M>*0DW:]'09Z(= (K33C&J=>.6?">,58@;33J)>?Q'-2I>BWH>\IB82@8C46* M&$\9\<0*%[ST&DQPI#B9AQ-OGH :]W['RHGI^Q_+,:]UCMJ]<0A;PYX[;!S% M=,R9DM@GBELZBHW#VCKK*)-:VB ,MRX@ZK0'O[QDEBOO^#L,AEEW[]KAV/NF M'SZ90/%F-A"=CUWN_L9D-8T+=1M=GQYD?73]L M='4_"^G::7"CN'Y;A/G[;U%4C#/25JP+O7( MB^J1]R 5@&$$"8^(UN%:IM*FS M5" 1+"7*.CT'A'S^W?WOFT4<"X'P- 1E*<.4Q5.1E6.$&^($27^(7LT)BSSM MSOGWS2($QT4URH@F@>%X*"8.U()J"%A*S*^?Q_X2X;)G#0P_54E=:X-CV'B6 M*L^$P0QS1,(94]%OF&GBZ9/, M:<\P<4QR8:CT@@D$!.4AO>0RE4SSX*C:8-2.Z\AOD6T4\0'8 SG&,6,"&Z5B MGH\BX$*EF*,Y8IOW2T1",#AQ",6B/@PCIU+*E(D%S)TF[.((2S*SM)LYD7^V M0/H/ZTN#YR346H8Y_.PS#&E MUD;7]3H PC 3\?0#7T0UZY?\9VLFPV&13&"M=.X"OLF]ZL2 MHY52<9,.V-Q.!94Z%RA6J9"::C]/APG./HE?YV!!8A2WU%F,B0 Z"\5,JBP* MU'DBC9JG?*5[D7BZU0=H7(W'M?:.8MLW+,- 3LV-#@IYR[!QVGH53YK2&-F4 M:/369/@5"?Q*1X-B[%*4$D2%8R:>7>B]0#0$0RB2Q.;I]&J6T^G/*5H47HQY M3;UN^/'0]EZGT^OFKM*S)MFK)TNR#R)%3@<: #<9(DYI:E,G72")^+PP!EQ0@3M/'/"ZU0I8KB25&%G9'@SQ%GQ/HLX:=I?3>8WNI-B MTW-")H),FB+$)&.*R0#T4=PX&JPFE(84OQDR;8:AR;K!KYE^]WD.N7P6^E!) M<."$>Z_CL>-&":XH(ZD&JR.--;?GQ[Z8-7EZ?=M">9[RF'*D/&5*"$5M$,Q8 MY6*!4SQ/QN/,2.'K4]4J;%)F&'+",,RHQ=J+(*PQ@2E+T:0,U?P3\Z4L1OUD M.](#H"9W1H%,R7QIG""-/:=,:\^"]F^&-"]G,3X=<7QJ*.5<$1GM$1+ 7+1 M+(-9W,+,Q9LASFM8C$]')BFE(=B; -+#M.$6<85%2L" 5!BE;X=,+VHQ/I(^ M'[+3C_TPZ(WZ+@R*K_O!^+P_/CM>_A/^9V)K,'"4E?.4@Z%OD-;&IQ+[0&.! M?J+);B37Q3V#X;@="1.RO?WA1T:6)#\:_G&2^>'^1XS0__ECX4J[V)LDZT;B M?*0"6N8_F':VU_UX,!H Q<9_=$Q_+^LFMC<<]CH?,8%6\)#!D>DN_VG['^#M MQ>>B$S]TY=(378AEAZ9W3QM8XP[W^KU1UR>NU^[U/_;W[&^$\\7IOPI:0K__ M45S[!\K_^R.%F4Q2T\G:XX__MPF\,JC4PTEEL]?STI9@?PZH\V<$HRF2U,\OG9KF\TUZJ5K>9*5A;:ZO; MFQO-C;6MRDJ]6EG[]^J_5NJ?URJKC5IM8VMKHU&?@[&2^XWUNQGL@^@/>]W% M2G5I=:E"XDEG#Q_?30P^D_.B[C IKC+!I,V0YJN7 M4B$BL11(,>6U3B4A*?;,IRP-3MRT[E'IFJ@+?,@^5GMNU)FL_"Y,K /Z]]A6 M>\=?R.9QB]9&_F#M>.>S/F@<[*&=9KW=^%P_K)UMHT9U<[]6/>2M[YN=^MGZ MX4ZS=K+3W#RH'1R.O]!ZNW768_7/VV<[S?V#G6H-UZM[J-5[ MM=KG;=0ZV^"UMCK]0G;&K>].U+^OG36:F^W:F3MI5-U)_?-ZN_Y]_:!VMM^I MD1JMD(>UC>]##K6:-QW?6SU88_$.M[]NX];UV MUOC<.FN=N;.=S^N=UL$W5EM7K':R:P7%(;4Z\=K9A"&!$F.Q2QR7'L=3X5&@ M"\L8)=]RP+^@P8\<]CILI._'1;_53/^PTNB&WV^5C*LZ0Q0J8VAL.UQKT0[I M\*,9#7M3-=//WY3_8GM]T(AQR&US- @?IQ\N*ZEX_Q^7M1B"=_EL<-0V8]#& M>>_S]TYTH-9+BM-<#0Y!V0[]M#_%9;2$\VL?AO['BZ!,B;K]\D_OQ4OH]HN: M+R%)[GGSA[S?1=]A1B(!_KE %Z9W'!FP4KM[R;!W])$PX%>/#7PI;U^QPSA;I@HL']A2GIM:]KMWM#V3F_"Q6]%>?;V>#,< M]?K#N83(]Q;L[S:.#G8._LGIUYV#G\U\']8,55*MNTT;UKWWXE]6JGPYVFMOC M5F?CM/&W.OG27!G6MM I_-T-<3<#TB&1F-&$,>Z2F'J16&FMT(P)Q/7"\O_\ M0TLF_K@58B<"-N>B-L&&K&!::6Q6,/_-_UYIK%>:_UJK7+(\SZW.E=5FO(PU957Q.*^-^-Q,/W0O4E%?LVG;*T(XY<* M\BX%"8IQ;:H@K_LO)W6RANH'>ZQ>7<]JX+_L--L=K!_ M6&OZ@\:Z.JOO[0J%TWB:0V*Y1@FH5Y58T+()(LHB;+U,!5Y8KL4TH@)D*%ZL M1%K_W)VY#ZY/^# Z"J^ .3\!R1GH6&GPSZ_!'VM/#?)%@]+BOQ^@G5VV^%.# M"?C<-I%!VX0Y3!-KC4R49=P:AE$:IA8_*RW^I[ Y]4S,X[?/M2U8M'Y&_2=#?$4F,N1C:(ZYR5]:P=*@!>-O0_5E[36_BA[[?$@9]Q(6$M M7WV-,U),R%SJS4.CC:6ZB8]O"V2]=6H#D@ M8A'%YA(^+GR8;9Y^7<&[YS+>LPO>9MC+=WEUA[&8Z[L3OKW=N)O>!2039BU. M6&I(8@D%5]@PGLI48YC2A>5J:Z6ZL5K9J#?7-NLKT19:^;((7U>7'B:-LQ#C MNJ_"^FWMU+AA)?)%I9=6+CBE8@:5K:/@8I*/KV3=2C8<5%;W\U#8[0N%=^GP MV5HZE$C>NG3XTQ4^)I:0IH]<'KSCHA#\.1X,729LEABTP/VXC[!_E1\G'Y&!HG1\3UQ^O]OQ\JH B;E'K?$.-YK>S M>G-SOWZV=UJOKIRUR%^=>O.O&(\XA'Z<-JH[;7C>M;A%;[Q3_<;KL7^?UVBC MNH9JU?I!J]/"M4[]L 7/W6FNL7IGF]7QU95*YBFW*7.)DPXE3&*1V,!($J2C MF"$:B'"@/D+;G)A^* ,7;VP1K$2FAQB;37.Z,+%:L>&*XY$D:28)#FGJI%I;C:@Y30C+Y4]"9.74^L>?B"T% *H-> M._.5*2O/6X0L5ZZ57K_2&.Z'?N6O43\;^,SEH3(PJ:\HXKQ9?\]TL[/\^QO7 M#6\_0>+]L/G&TN;2UE)E4LRM7[D*\I5Z;^DAF#/Q0M6LKA"7'7LK2]?WB4[$ M'M/76UVX9Z+VLYMN*][WPV P^?,%>H!+L^TNL^WR"O?U0"6I?=YLMPZV4>W@ MTW[C&0Q-N_*UEP$C5*K][/@'WW/Q.;>'W,8T MI&2:EV(:OILJ*XR1:2*]D0DC!B6*6Y0P0V.M>$(QMV"CCC)@$88>N*XTOU@Y ML0I?B/E7X6.CW^R==$O6?RG6/ZV=['+D0HJM2XC#/F%>^T21 -@ID%$$Q[(/ MZ<+R7Z,CX/[^"V#C@Z.T$_[)7W",WMLQ[>@MQTI=5(%][T93;R8[*U9E[ MBO]%J-32H(SU8"R3U(#=HTVBJ(N+^]RX5'ENP")=II3),DKZ>N&C":/'B.C7 M/BBY[ AF#>X3QWCN0OBFN ,2K1,A[:-[H/%=WN.^V_&?4/=%? M6>D',[?:YO'I8 W0,KL:,^^HD(DW*"[H!YY8T!:)5YI99*7$%B\L$DL]M[_N][KO,TNV4=T^V94^:.Z %-@2 92Q.K'>J@0I0AT2V!'&%I8E MHZ#C*7T#>7EW):[.=8J=7"*$/"[%#JLEA!Z?15<^^3F>/ =[>_0;\7%?POJZ MR/;]GW\H@N4?@THSM,-15$&3K2N+,7^A/8JCJ$2+X4=K[696F*("@'.XPX1^ M0-,97?B+5Y7TA_N> MK^U#WE["! SC?'?'8F7R91J(,5T__6D]&\"<55K! -YG:=SFT=T+OK(5%R,J M7\Q@6"GVN]]K%QH5/R\I>LMM^6ZI&^J5OM(,7]^[=R7[(DP'CSMG^Q9Z:W_#OE7TSJ*19&Z;7M-MP,<[K /[^9Y3UX<=A MKV+#I $\=&60>4W>%X*_P8CMU\9[/?BQI[IUM[AOAE>[_N)N=K+ MV,7BYLD8?E_,>>HW4HS1A@!$&]D#&$%LGS>%FV(O)L^))14&>2?R3D8^TZCB MS7BP5(3?*\6?%XK%KX[Z?>A1P>K0S;@J-QJ\+R^I_/]-VRYNKB#Q\L]NDEMRK;@J])ZY4ZKUY MF$SVQP_87@+_#< ? 1&PL),-AX">X&.Y8;_7C99*>[Q8"6"VC&-25XCGXL;E MD*H9FJ*"P#7%HGI):;?%],!14VE;?I@=AOG -/[)N)R M1+E^-(5O_+4"DI7<>&'0 64 ;^E/S4] PP[,U3@:_O TL)9CS'ZO A-V,MR? M7ET"/R#D7?,AS;IYA9Y\E3V&] @,\Y8.YI?Q']-F=S:XM7OG#:/Q/VE\2U^G M+;-NH;$PL0F9NC.7?9BEVY<_9G:Q USN\TCZ@U<["%XB^+'UQG]^D2PAS,HG M3R[R)7KOTNP/?_)]*S?,^T::V2G,=4]D_W(S"LY67:Z'*.4?0J?BU4.G<[NZ M<_,TED+XU$*X\H;%[PZ&+P'_A7GMV;=V% ?*Y6P<78:]7G]\TP:/&,/IKTX: MS&7889+8_7TGOI?7.MNGM3-_$,O_Q@3O%H'OW]=XK?E7NWY08ZVS'Q*[3W3C>::Z=U4D-U3LUVJBN'\#WTU;S\!2>2>#=!W4^UTUIU&]4/=@X:U4-<^PSO;6Z?U3L[[9V#S0R>@W>9$5XBGB8,&9TP M(65B%4V38)0T/G4(!;^P7+_)&WNA",@SP)2X"Z:>.3OF)LB!%_S2DOI- C\S M-26>,LVE-#V>3QULW1IG];,6J5?7VS#6L]JW78&M"%2F MB0IQ7RL-)C',J<1[)JF609"XP_6N0[*>PV:=!6^M[,V\]*94;L^GW-9NCK:7 MJNT>JFTZ=Y_SJ5LM9JY4<7>IN/%/5-Q^ZV#EM/&]=1;[5H.QUCK?>*NS?=)H M^OUZ],\^;^-&LW76^EN-&]]V'6ONZ;K,M..L?A8CS@V'@Q- MUYN^'U1BJ8S,7TMNN4B!_,W\?O-JX;M:5I]Q+GSX&OI@/[3;YUKK-V"_?"F[ M*#O_XT(Q4/QW('FE!9V>;;J_MG+;BA,[SSKM\9M)XSF)NXPJ(P7E"5%.)TP* ME6B1FL0*F&V/+4U_HEG*C*(G3,^Z%=VN6N=QV)?*C(F+KU?S/6:8))>R\@N< M"_W;]!GYS?Y^"=0^OH4MO[^4!4/YDF3/1][G6<[[>'PQD,\YZ5&FMFPG9]Q$XP#L[AM!O>I-E.2Y#E)TC=YNOG6N&-[[=\&O[]Y@DR: MG]/CEO8S2J_I*5&Y!(6I!P:J[&0_R_>!3?7='-?5NFMGZ]N2P&?#U[ZOT=;W^B&\"^[YZZ#>6=^O5[_Q6G,S V?D%-YSUNIL M7 ^JL9V#P]-6T^^WR.9A/+2]!6]I?5]#^5K/YPU:J\*[8T'*]I7DAUUFA;&> MV<1I'!*&J4D,DB$1#.M4"0=4$,5YHW&CS[#G#A**8)-Q; MP213^3F2&Z7 O2G+Y_G3"<&:^K%(]%2'3J/=KXW%^X8=;-"G(K7+EP5,95J&11-@W:"*8$5]2@@XA'2 M3CKC=C=RR>(8T-0'EW5,>_#/A8WZ^A5!^PB#\[WAI,$-]1_RSN=]W\I[T;@8 M.Z TP"4I>9>7;@\ ]XIUQ(_]$'>M'U\*)/Z?/Z:GCI,ER7_(TSB_TUC0):-A M^&.BJ]#E1RSF]^SW M+_3W7DAL/YC#Q*2@=#^:]HD9#^(1Z9=Z?6U(/_3T5NRX83?M[9DJMX_TYK#R MXY[XD&?-4(Q:ZR7%Z>-"U'))(?T<<62%EY1^ECV/;(EH^2L!ZGDMJ9BS[\N> M&Y /"Q3,Y+C'CZ#7@'TC!T;]NO+IRUJEL5Y9;=2;:_7FU@LDF,_EQJ,9JJWW MNJ=+EC,Y^R!S4T'GYY[+KV!JW!UC_[6>"_9V(_>PFO/H14> M:5+-DU8@SZ852GOTO8@EYPO+-=,%)RL]KJ^V)@2VVR&P:@]S)LTCD+1J1=0+L_ JJ5RF8U./XR+"7E![?(. M? Y:^ARE7/ZB7$JTL/PM;L;(AOF"8ZXHX(?V]'O4,^W>8!27OXWMC8;3;(#- M;'!8>B:S0>]WP*1$EZ[)4RH/5KHFI5S^JES2F'3='?:!1,A^K.'Q5%6)RKZ4B[8E#OP"#IPOVFY4&LU_K6V^Q(KM MK/!DJ;9FH],/8]<7=6C>032L7($OY?*7Y5(O+'\)>Z9=>#+Y^6_E\ON,D/$= M\%X9Y'IBG;!21KE*P?Q%P51D83DN=E36C1OV^F5H:T8H^ [8CJ+21YB/?*S2 M1W@W[E\H9;IEVR).JUOXSRH;CRJ6BAW%-9'N0EXF:.!2E-S$C!'\' M7/JBVN,=>!//EV]5.A/O1BYC2:20FCP1=_LHE@<)W:S7OZ0U2O]B-HCZ#CBQ M]"_F):FJ]"_>BUQJO+!<@WO KT@#N!.7$G!+WV$VB/D..)#BTG=X2LW 7]EW M>.CY;Z5HSJ9HLH7E1GYVT$:W*.8'SRH=AMD@XSO@O1=5"^_ 81"EPU#*Y:_* MI5Q87CO=SVQ6E@J9%>J] Y9[F"HH,_E+UKI?%1J$%I:W@)IF^."01YF[/PNT M?@\,^G/PNW\-_*>L.CV?Q<,Q>F/5PV\\E/+R Q\O'(\[\.#&HJPWG'BPNK(= M=TNM;+8J]49SK;*Y]GEEL[I1_UQ9;VQ^AX_)ET;C?^/WK>9*PO58 M5*,/C-$>5S;#$5S)#W4P67<0VYV8OD_:O=YA5AP!/JG\EQ\=GC\@5#K!=+/B MW(GX=3T =L'[!A?91FUS,EB<'#^7=8][[6.X*YXBW<\&AT4RTJCK0%G!6_,; MH.^Q&Z,VJ$@3CS7OC?H5Z/\(GMN?%(L:]BH^2U,8*8P;ILVT801IO]>!NWN# M>.Y%.CD>?=+/VT>S5%F_?:1[H1O' P]W,*$V 'S [UF:P9/M.#]T?3+RDUX\ M'3T6PB+HCW!Z!&]?S+_A/Z:_#O;CH*[_"J,.W1]^C;5/7'8$';E^Y21KMZ__ M=M3O'=SPPHX9__!39)P?;N\-XZC,Q7-[_>FUR ]9=Q2F5R*]"AX;9,#,!G@M M]#N#>,>Q 4+DY;LFD]*)OUYNEG5!)O;&2Y6M$7##3SC,]&&JNZX]BB?-YPJQ M4J1*3KMU_]ICDXXO5:ICXS-7V8A V,W["0.&KVYI,;\!'-7*8&0'F<]@(,"( MP'W%: #RH0<3SHRL>[WGV24)!*'J]J!990]$"\@8]Y2V!X?-W M%D^\RML%Z_^4O2=">CM[7^K09+(O3>Y$./(;04S[\&/E. LG.=FBL'7.)S<7 M]=BSH_R&7GZY=UZF;?&\T_'.\Y_SH4U&G)Z7?;LT]I_*W(\@L7@-(8"K"A9, MB]SW*2#!:S_ -1O&/>A 0>]S]HASUN^UERK-_0!3.+UUPF6+%3L:YFP7B=<& MGHW@ 0/^#?\^18$*&&G=7B=SBY6C7CO+K>M\J)VB]I";UK4;_%'YC?Q>X);- MVC']$IY4/&48)@?S_&>4Y<=.]WM^Y, P@E:+<1J*&Q;C>=3%WXMI6X17#(;0 MJEB#O1!%;X:FT@TN# :FG[_,F3Y\B(61L8^V:QWM&_@D2Z,BD$ M%8/I Y?$QG8T -8:#"K@M4QH&8\0&H8]D)ZL"R/,[;@X2/K#(/LA4BF_R0R' M\6R92H"7]\8A#&+WNY%=0"K@BX?Q%S3(6_OC; !?X*GLAZ=>]#_OSG [U&[T*\LKZ/9RY&MIE4/QN\*-" L0?\AQ[T;#ZN+JCL M=@;&U*"0WXMG[?5#P;]PN_CA]DYDW?B ^'LX!<4?P_4[]E$ZN+C8[GMJ_2/;SR_8:(HKPP"2-H-.X!F3>EOYN-M9#F*]8DB' ;H'!E2O$R;T=/$4&!N=FH*H MZO><[Z\Q7LYO&:B?W#CP\(0^L/Q>#YS7;IS-G#?W1NWXE,L,#_ $H')!TZ@4 M84:[DUDSOG<$<@(O:8,A5?#7$8S]N!"^2VI[%>=R&2<^#C ".+#],$H<=%H7 MG8X@-+DAA<=VLD'^M*.)NJL4A,OZDV\ A2<1F^'G":_D8@[-03@FPXA:OQU1 M.")_O CP%D<.?8&9F")2FD46 ^ J5,9UO7]A6Q?V2JY= MS5%^;=+]R_NUID.8&N*@$#L5C))OQ2!@5--?_C>^&3J9J^+XU&NI_-.3!_.3 MW;*"AW^;O'%K;77RHM_C9-4B$Q2G?%!4'/6V5/D>II9.9=P;%2;)Q*8(>[TX MS#;@5:04T P&".A]H3T+8R>.D<7 M]D-A0U_8DS]:4(OG[!9?DC/5)7I,+)LK) 1H& VF%L"U7O6ZT!1 +B@>&?1 MS='1I*-32^E*OV)')YA:?,]K$4ZZ"JHE]R_@=5&6^N&&";R'L[-8:4? MG!L*EPW)7KQC/X-&Q6A^YAR%1S]U@I %KD6%//&![O*N:L!&$<_!!PP3X8R$ M @-Y'WP1Z-D$X(-?O*)P/2[GG7[B_,$M] M$-V".EDG9]'\;^&13 7LJ =RG8-0H;,++#W3: MKW@U-[E9ET,0(7]/)-%2Y5.(6!4=AU 85A-#RQ5'70Z*H[>+RW&\A2,>;:10 M&)'1P?L!0)X4T$-[$$YR')CT[79T7UN]!:HG9"C0(F=VK2W'YDU5W.Y^3G1KE?4R /"5;D> 7X=@*4$@)"C*LAY[/5%P.%"AQ<]NHKY M@]M!/V?5X^(]T8C/^F[4B0>LNO"P7D:#/,;+)BHD5QH]!SIT*=HKX6@8I^_< M"08UTC8G^5AR61N"6 ,AP.L"OBJD,:+0@AGZQ*'K+/ MNYW?G!N>-P5 H_/4RV$@-KYJ)T37XBJF%5A?&&"#RKF#=T';)Q6E5SR@^+Z2 M!-;D?V*AYG2738>-H!NOL"DQ1]B47<_OY".MLD* MTP1%WS,N[.HZ7DB4Z.5/WP^?AW%+5BB^@?U?IFS130W++*^;6-JBV5JH;JY6->G-MLYY7XUWY ML@A?5\%IJU7+2GUU MK;+UK[6UNW)H?C+N&3);0&*6T$1J'FRW<+4D)'D.NP7+)2AR K%113R'D9@2>$YHW UN-"QH3\A M,M9WGUQ?4OL)SSB?H0V OVUWS_[!%1[^?],P;)>(G,0VV# M53,HDGY=_!#7GH]-^X<0[(5K^PJ:;;8F[+^?=V)R/KEC9@I>*H(+,S0S?V:G M<3_O>DS'CJN]HVXVW(Q;-4<#OY O%<,P\Q^R("2B(=5.,L529RU!P:O -):* M&*1V-Z)7C2C%"Q4?7-8Q[<$_%]!"I<#C]V1QW?&TXN+U2ZIA/BNY(] M8XX^1KY>Z?KX9^V"J5>&JS$''";Q;],>!0 'F.20/SF/7WOZ]]A6>\=?R.9Q MB]9&_F#M>.>S/F@<[*&=9KW=^%P_K)UMHT9U<[]6/>2M[YN=^MGZX4ZS=K+3 MW#RH'1R.O]!ZNW768_7/VV<[S?V#G6H-UZM[J-5[ M=KG;=0Z MV^"UMCIM;.F.ZZQW&YWU3J-:@W8MU&BND5;S&]NI?F,U4J.U:HO5R7JGUOR& MZ\V_]K_0S?U6Y[0-?3NIG[6S%FF=-KZO(6@_KC776.OL&]^I[IVTR!IK?-[, MZI];9]-[X%VC';(M&M45VOC^U\'.P1IO-36"Z2N&9%E&8/96Z>G]>V5DL=4.J )],!"F-D#45.TL ((4H+ M;)7T7/$4H(5&'8 U)J4.F"D=<':N PBSGIC@$IP:!SK VL385"=>*5#F0%;/ M>=0!BM!%SEBI WY=!\R8QSXG/L[6?J\_3.)>ZTF^>[Y%8'"IC/LM:I8\] MAQUO4<7S#/7/;^[_*[1]LU>+._2RX?@B^W02L"E!_B$@OW7)T _(Y4(+%CJ@:3(JG@@["+5>A$S44+@;!JZ M;S^8GY?Q ?MV4GX@9OT]EVW[.%?K#0+[\]NV4ZINGA.UA/1'0'IVR:H53G.4 MIB3Q6+.$(>P238U.TD! 03,9L/$ Z42^$)Z_^<#%# 2O2^2;.Y.V1+XG0KX+ M8U8"T018K ES'HQ9ZGFB.!*)#UA988&W<5A8IF#-0LL2^6;3DGW[(=L5YZ#5 MF/@/3QY5P,G'HBA$N\!8N6>?BDTX 38IAE M2 L)=V1=;1FKGWJZ=T'JM(/5*U^='V1=[ M^,N8QW'@MP:6=QC+TZ+Q,7+[VD7VGK O3U"\]64Z.DM]>:I)*_VSA\IMO==-W!,4 MY7RK)5YOMKC>W>+YS4KQK:]\EFN>OSR%7WIQ3LK*06\WVG-;V0S0+*[T:A[A MU7R[' )2QB#B#4ZPCPE]/*A$QPTJ05L?B$>84[:P3!;C[A2PP,L@?[G46<+@ M+%4/*F'P\3!X$=PQCA.G TTX#21A3JE$(6T2E3)IA5+:$+&PC $&\:*@906A MM[?6.8?V;KEC94[MW;/0[WDSV+]7VG8)\(\$^.TK"7TX]8X9E"@+UBW#%"?6 M*9YHHM.4\"_%YIXTJ)@(]'P L3%Z64>*EU MXK "$U<0DEBE5>(H$4SK()PM-[',NH'[]@.Z>09ON4]ECJS9GP+ZI83L$L8? M">.M*X8L1<:8U"9">1YWIK#$!A[KO2OM K+6IRSNP%YDJDS)+J.U)>R]BAU; MPMZ3P-Z%]:JL9ZD&Q#.&HX2IE"0J.)UP 8Z]4,XC&PM/X$6*7^(@HSS,6 MG?U%P_4ESL\N=J+<;+B^V*P]+-%MMKCP%0_M>T!J[#SKO9?:FE,JN@N\=3X/E(4\SITHM(OT2&1GO.\U\!@+9I?HH MU<<,J(^7VJQ4JH^'JH\+/TE0*8*@)"$>\819#AY3/$W &H14D")U- 7U(1<9 M)XM,SUZ-OK>F/NZW2TF_U'Z;&9JLF>K+E&1W*OZG(]@E3J? Z;XWLNWPY%NY M7HRSYFO.ROC&@S//,F.S=IYSFA>6&PQ[[G"_UP9Z#/*\&?E')?QGE W'LV8^ MO^OWS]@J]!SHI^4K[@N$?MV?Q94'VM9>DWMUZTWWW++ZMM8)97B68DQ27 M\[.SCLSXIJ3MU[-!9FN>7C&B,^O8,U,Q_PD[?RVXN2PU\X@@SL&5NEQC_&NA?1.Y3[U+&J$R,PS9AS #\,VX3;WS*4J.0,V1A6;,(^F5^_HRF.+W] M_'P0_/XH7!PR4>;HOP4#/I+T4H"WA//'P/G&U0VG/B6.Z80K21*6*I(8[$R" M)7)>>XJ43A>6"4.+0+LR8_7E;/@R47]^L.]%[-@2^YX&^RY,62H83H44"8[U M_9<']U-(#Y#/TI\(]+V'\, M[-= \/WZJ%IE_+<9B.8^UX/ WI^"[@,<_PBT%^IG2T#(97MN+6=S-ZYZF\-,']E;^++[I=YNJZ\ MR/EIY9256Y&>9"M2K]/)\C.-BCUW4?M!?T/7Q5UXO]5[PU!AO]_#:WO>B9L] M&^)][\UY'I?S=)!][&;M?RX,^Z/P8U#QG%-7NG[U,I^6%M.#+*8KU3ZI#JD1 M+"2!2G QM6>)"@8EP5%FC>8I4C+2_9JA-,O^4 E%)13]JC-70M%+0=&%\\:9 M$Y0&FVAI?<*\P(G6E"1I:H),B5'"L%NAZ#UZ&F57RM(%+XRZ6[?6Y"@K&,S2 M^V[+I5=Z^MTC<(5KMK!N2Z9'Q*#<#O_:G"7YY MK9K%RG__S!SY&OI;^Z8?GF11;J.^?MTL.>]-+J1?3;_1WQJ:8?!_F_8H7+R] MM% >8*$<#FNK$PME5:.=?^\CU_F[:[[K4>.@QNNDAEJ=]?9.9P-!'U'K^QJK M5_]NUSJQ[X>\WJR1%MD@_S[;&.]BA)'7CB;">)HPL&H22XU,K"",I!@;J]7/ M5R=NX:#'K5*4'#1W'"0T!C[!8"'[>(@HQB11<4.GIV ?JV E"W1A>0E0#]]@ M)E_[H7)D^I7C2-@+U0UX/(.9?^_Q_7-BFLZY E\9#?=[?;@#-'B$MD$EJ=P* MP$6+I\/>>Z\17X7E'(,'%STOX?@A<'RV\A,XWCZK5__*X%F=QO=O)_"L3NT, M[JW^G0$Q_>3UN=-0YPC'8=-EZF(BXO4YPPEK)$"9PFCNO@X8/!WOQ$ MH=_(3[]@#9;\-.?\Y)$&)+$L"53I!'0Y3A1G+@E6,9,B,!8=\!-?!%",_^Y6 M\7\\$,R>AOD C5UDP)->WP]"]S[FW1Z\#9(SAJ8S 8E5CV>LPD/*8I$BPAGH"KXAP'IP6# MEM2("$8\)?C!NO%I;*T2GN:3HSSGBD@F$J2921AB/%'4F80S*[%+!<-J?CBJ MA*?79:94 ;^05"221'A*B4LTTB(A+.4RN)1)91>6@9'"W5;6/4(M64[N/,.J M=X$E=X1=RAH?,[3KY2ST>]X,]G\NW'F]U?28MXLD7M MHBOEBO;3 =C:SU:TH0_?2/W[-FV=[<"XIW.W^U6#7K?K09OJR3, M')3$*AGQW3%BF2$T'QE"+Y'1<7I'(1+)5EJ$N0(2U@*QHERVB98@JN/4Z_@ ME]=9L"J9:>Z8R5)+G3 T\=KQA"&G$TL%6+K*!L=\0$;BA65<9 ;=-SMHLBPU M3\!6+IR^(A]^0[M.(TN94 GS#!QVK55BI96)LDAK1U-M@EE8IGI1$K(H^(\U MR?)%T#D O9+17I'1UDX:S4,,?22U \<:U6^[J0+Z^R 3K2/?,:838RE*+$9* M >FU%3;G.X%OYKO%RROOMD2!L2;QD* M01FG@UA8)G*1";V(N9Q;W"NY[;6Y[3KXN5U#@Q',A"0 !\2=@V#\Q7T'DH!9 MB!2FCJ*<^2B_C?D&E5Y:J<4S*(HU,8H7*Q&KA/2Z3E>8G6>F^$E^NWC]*RB_2E5+)L #L3ZA3X.('31*E"4ZX]P9%-U\% M75C#N#R&J,Q6*A'OEUH&R)Z@]"]2L'JWD%!BI3.@E O(19I\".Y2)1BNF4F]0P+!>6M5B42"X* M_>/B0GFJT+/9LN79:O,#?B]PG' )?D\#?I=,6L(IXTK$LW70_\_>FS?%D2OO MPE^E@_N[;\Q$M)C25I(\YR6" 3R'

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htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation - Textual (Details) - shares
 3 Months Ended
Jan. 01, 2020
Jan. 01, 2019
Mar. 31, 2020
Mar. 22, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Outstanding (in shares)     4,663,390   3,860,390
Stock Option | Contractor          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)       25,000  
2006 Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)     0    
2011 Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)     2,134,211   1,547,211
Common stock reserved for future issuance (in shares)     3,000,000    
Approved (in shares) 1,500,000 1,500,000      
2011 Plan | Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period     10 years    
2011 Plan | Stock Option | Chief Executive Officer | Period two          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period     5 years    
2011 Plan | Stock Option | Contractor | Period one          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period     2 years    
2011 Plan | Stock Option | Contractor | Period two          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period     3 years    

XML 33 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Accounts receivable $ 518,601 $ 558,530
Billed receivable    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Accounts receivable 405,101 432,546
Unbilled receivable    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Accounts receivable $ 113,500 $ 125,984
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Accounting Policies [Abstract]    
Outside contracted services $ 613,790 $ 585,487
Contracted services - related party 0 389,473
Personnel related costs 123,638 94,762
Facilities, overhead and other 18,025 12,121
Research and development expense, related party, net $ 755,453 $ 1,081,843
XML 35 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Shareholders' Equity - Textual (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Equity [Abstract]      
Exercise of stock options, common stock issued (in shares) 100,000 0  
Weighted average exercise price, exercised (in USD per share) $ 1.78    
Treasury stock (in shares) 12,253,502   12,253,502
Treasury stock, shares held at cost $ 18,929,915   $ 18,929,915
XML 36 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Leases
Jupiter, Florida Headquarters
The Company’s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700 in total. The lease expires on June 30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.
The Netherlands Office
The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies a flexible office space for an annual rental rate of approximately $4,000. The lease expires on January 31, 2021, and thereafter, the Company will reconsider the leased space to align with the future operations of the Company.
VTT Research Contract Extension
On June 28, 2019, the Company extended its research contract (“Contract”) through June 2022 with VTT Technical Research Centre of Finland Ltd. (“VTT”). Under the terms of this Contract, Dyadic will pay VTT a total of EUR €2.52 million over the next three years to continue developing Dyadic’s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR €450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR €690,000 over the next 1.5 years to reinforce the glycoengineering work. On March 23, 2020, the Company further expanded the Contract to pay an additional EUR €700,000 over the next 19 months to accelerate the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days’ notice.
Legal Proceedings
We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.
XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 114 294 1 false 48 0 false 10 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.dyadic.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Sheet http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101101 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 2110102 - Disclosure - Cash, Cash Equivalent, and Investments Sheet http://www.dyadic.com/role/CashCashEquivalentandInvestments Cash, Cash Equivalent, and Investments Notes 8 false false R9.htm 2113103 - Disclosure - Research Collaboration and Sub-licensing Agreements Sheet http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreements Research Collaboration and Sub-licensing Agreements Notes 9 false false R10.htm 2115104 - Disclosure - Commitments and Contingencies Sheet http://www.dyadic.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 10 false false R11.htm 2117105 - Disclosure - Share-Based Compensation Sheet http://www.dyadic.com/role/ShareBasedCompensation Share-Based Compensation Notes 11 false false R12.htm 2124106 - Disclosure - Shareholders' Equity Sheet http://www.dyadic.com/role/ShareholdersEquity Shareholders' Equity Notes 12 false false R13.htm 2128107 - Disclosure - Subsequent Events Sheet http://www.dyadic.com/role/SubsequentEvents Subsequent Events Notes 13 false false R14.htm 2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies 14 false false R15.htm 2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies 15 false false R16.htm 2311302 - Disclosure - Cash, Cash Equivalent, and Investments (Tables) Sheet http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables Cash, Cash Equivalent, and Investments (Tables) Tables http://www.dyadic.com/role/CashCashEquivalentandInvestments 16 false false R17.htm 2318303 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.dyadic.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.dyadic.com/role/ShareBasedCompensation 17 false false R18.htm 2325304 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.dyadic.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.dyadic.com/role/ShareholdersEquity 18 false false R19.htm 2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Textual (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails Organization and Summary of Significant Accounting Policies - Textual (Details) Details http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 19 false false R20.htm 2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) Details 20 false false R21.htm 2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) Details 21 false false R22.htm 2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) Details 22 false false R23.htm 2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) Details 23 false false R24.htm 2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) Details 24 false false R25.htm 2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details) Sheet http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails Cash, Cash Equivalent, and Investments (Details) Details http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables 25 false false R26.htm 2414408 - Disclosure - Research Collaboration and Sub-licensing Agreements (Details) Sheet http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails Research Collaboration and Sub-licensing Agreements (Details) Details http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreements 26 false false R27.htm 2416409 - Disclosure - Commitments and Contingencies - Textual (Details) Sheet http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails Commitments and Contingencies - Textual (Details) Details 27 false false R28.htm 2419410 - Disclosure - Share-Based Compensation - Textual (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationTextualDetails Share-Based Compensation - Textual (Details) Details 28 false false R29.htm 2420411 - Disclosure - Share-Based Compensation - Assumptions (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails Share-Based Compensation - Assumptions (Details) Details 29 false false R30.htm 2421412 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails Share-Based Compensation - Stock Option Activity (Details) Details 30 false false R31.htm 2422413 - Disclosure - Share-Based Compensation - Stock Option Activity - Textual (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails Share-Based Compensation - Stock Option Activity - Textual (Details) Details 31 false false R32.htm 2423414 - Disclosure - Share-Based Compensation - Compensation Expense (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails Share-Based Compensation - Compensation Expense (Details) Details 32 false false R33.htm 2426415 - Disclosure - Shareholders' Equity - Textual (Details) Sheet http://www.dyadic.com/role/ShareholdersEquityTextualDetails Shareholders' Equity - Textual (Details) Details 33 false false R34.htm 2427416 - Disclosure - Shareholders' Equity - Changes in Shareholders??? Equity (Details) Sheet http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails Shareholders' Equity - Changes in Shareholders??? Equity (Details) Details 34 false false All Reports Book All Reports dyai-20200331.htm dyai-20200331.xsd dyai-20200331_cal.xml dyai-20200331_def.xml dyai-20200331_lab.xml dyai-20200331_pre.xml exhibit311certificatio.htm exhibit312certificatio.htm exhibit321sec1350certi.htm exhibit322sec1350certi.htm dyai-20200331_g1.jpg http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2018-01-31 true true XML 38 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2019, included in our Form 10-K which was filed with the SEC on March 30, 2020.
In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.
Use of Estimates
Use of Estimates
The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
Concentrations and Credit Risk Concentrations and Credit RiskThe Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.
Cash and Cash Equivalents Cash and Cash EquivalentsWe treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.
Investment Securities
Investment Securities
The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).
The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets.
Accounts Receivable
Accounts Receivable
Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.
Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months.
Revenue Recognition Revenue Recognition
The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to grants and fundings: The Company may receive grants and fundings from governments, agencies, and other private and not-for-profit organizations. These grants and fundings are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred
research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.
Research and Development Costs Research and Development Costs Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.
Foreign Currency Transaction Gain or Loss Foreign Currency Transaction Gain or LossThe Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.
Fair Value Measurements
Fair Value Measurements
The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 – Quoted prices in active markets for identical assets or liabilities.
•Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.
The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
Income Taxes Income TaxesThe Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from 35% to 21% and repeal of the corporate alternative minimum tax (“AMT”).
Comprehensive Income (Loss)
Comprehensive Income (Loss)
Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.
Stock-Based Compensation
Stock-Based Compensation

We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Net Loss Per Share
Net Loss Per Share
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average
number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method.
Recent Accounting Pronouncements Not Adopted and Recently Adopted Accounting Pronouncements
Recent Accounting Pronouncements Not Adopted as of March 31, 2020
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2023. The Company does not expect ASU 2016-13 to have material impact on our consolidated financial statements.
Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.
Recently Adopted Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The ASU was effective for the Company beginning in the first quarter of 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
XML 39 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Shareholders' Equity (Tables)
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Schedule of stockholders equity
Three Months Ended March 31, 2020 (Unaudited)
Common StockTreasury StockAdditional Paid-In CapitalAccumulated DeficitTotal
January 1, 2020$39,613  $(18,929,915) $96,105,851  $(41,351,078) $35,864,471  
Stock-based compensation—  —  426,939  —  426,939  
Exercise of stock options100  —  174,900  —  175,000  
Net loss—  —  —  (2,214,139) (2,214,139) 
March 31, 2020$39,713  $(18,929,915) $96,707,690  $(43,565,217) $34,252,271  
Three Months Ended March 31, 2019 (Unaudited)
Common StockTreasury StockAdditional Paid-In CapitalAccumulated DeficitTotal
January 1, 2019$38,967  $(18,929,915) $94,385,230  $(33,043,113) $42,451,169  
Stock-based compensation—  —  309,563  —  309,563  
Net loss—  —  —  (2,175,258) (2,175,258) 
March 31, 2019$38,967  $(18,929,915) $94,694,793  $(35,218,371) $40,585,474  
XML 40 R6.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities    
Net loss $ (2,214,139) $ (2,175,258)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 426,939 309,563
Amortization of held-to-maturity securities, net 107,256 32,201
Foreign currency exchange loss (gain), net 10,867 5,148
Changes in operating assets and liabilities:    
Interest receivable 102,565 3,981
Accounts receivable 35,258 (106,781)
Income tax receivable 0 6,249
Prepaid research and development 0 83,112
Prepaid expenses and other current assets (10,529) 5,049
Accounts payable (292,361) 641,799
Accrued expenses (326,000) (96,606)
Deferred research and development obligation 163,799 (117,978)
Net cash used in operating activities (1,996,345) (1,409,521)
Cash flows from investing activities    
Purchases of held-to-maturity investment securities (11,652,385) (13,190,855)
Proceeds from maturities of investment securities 13,350,000 16,197,000
Net cash provided by investing activities 1,697,615 3,006,145
Cash flows from financing activities    
Proceeds from exercise of options 175,000 0
Net cash provided by financing activities 175,000 0
Effect of exchange rate changes on cash (2,983) (7,177)
Net (decrease) increase in cash and cash equivalents (126,713) 1,589,447
Cash and cash equivalents at beginning of period 4,823,544 2,386,314
Cash and cash equivalents at end of period 4,696,831 3,975,761
Supplemental cash flow information    
Cash received from income tax refund $ 0 $ 6,249
XML 41 R2.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 4,696,831 $ 4,823,544
Short-term investment securities 26,587,752 29,399,146
Interest receivable 227,146 329,711
Accounts receivable 518,601 558,530
Income tax receivable 500,616 250,308
Prepaid expenses and other current assets 288,495 277,999
Total current assets 32,819,441 35,639,238
Non-current assets:    
Long-term investment securities 2,518,160 1,511,636
Long-term income tax receivable 0 250,308
Other assets 50,489 51,314
Total assets 35,388,090 37,452,496
Current liabilities:    
Accounts payable 653,373 943,378
Accrued expenses 240,003 566,003
Deferred research and development obligations 242,443 78,644
Total current liabilities 1,135,819 1,588,025
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock 0 0
Common stock 39,713 39,613
Additional paid-in capital 96,707,690 96,105,851
Treasury stock, shares held at cost (18,929,915) (18,929,915)
Accumulated deficit (43,565,217) (41,351,078)
Total stockholders’ equity 34,252,271 35,864,471
Total liabilities and stockholders’ equity $ 35,388,090 $ 37,452,496
XML 42 dyai-20200331_htm.xml IDEA: XBRL DOCUMENT 0001213809 2020-01-01 2020-03-31 0001213809 2020-05-13 0001213809 2020-03-31 0001213809 2019-12-31 0001213809 2019-01-01 2019-03-31 0001213809 us-gaap:CommonStockMember 2019-12-31 0001213809 us-gaap:TreasuryStockMember 2019-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001213809 us-gaap:RetainedEarningsMember 2019-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001213809 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001213809 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001213809 us-gaap:CommonStockMember 2020-03-31 0001213809 us-gaap:TreasuryStockMember 2020-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001213809 us-gaap:RetainedEarningsMember 2020-03-31 0001213809 2018-12-31 0001213809 2019-03-31 0001213809 dyai:DuPontDaniscoMember dyai:IndustrialTechnologyBusinessMember 2015-12-31 2015-12-31 0001213809 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001213809 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001213809 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001213809 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001213809 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-03-31 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-12-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember 2020-03-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember 2019-12-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001213809 us-gaap:BilledRevenuesMember 2020-03-31 0001213809 us-gaap:BilledRevenuesMember 2019-12-31 0001213809 us-gaap:UnbilledRevenuesMember 2020-03-31 0001213809 us-gaap:UnbilledRevenuesMember 2019-12-31 0001213809 us-gaap:TaxYear2018Member 2020-01-01 2020-03-31 0001213809 us-gaap:CashMember 2020-03-31 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0001213809 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0001213809 us-gaap:CashMember 2019-12-31 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001213809 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001213809 us-gaap:CorporateDebtSecuritiesMember 2020-01-01 2020-03-31 0001213809 us-gaap:CorporateDebtSecuritiesMember 2019-01-01 2019-03-31 0001213809 us-gaap:CorporateDebtSecuritiesMember 2019-01-01 2019-12-31 0001213809 2017-06-30 2017-06-30 0001213809 dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIHoldingsMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:VLPbioMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIMember dyai:ResearchServicesAgreementMember 2017-12-31 0001213809 dyai:BDIMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 srt:MinimumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 srt:MaximumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIMember srt:MinimumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIMember srt:MaximumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:ResearchServicesAgreementMember 2017-12-31 0001213809 dyai:ServiceFrameworkAgreementMember 2017-12-31 0001213809 dyai:ServiceFrameworkAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:NovovetMember 2019-04-26 0001213809 dyai:AlphazymeMember 2019-05-05 0001213809 dyai:AlphazymeMember us-gaap:CollaborativeArrangementMember 2019-05-05 2019-05-05 0001213809 dyai:SerumMember us-gaap:CollaborativeArrangementMember 2019-05-07 0001213809 dyai:SerumMember us-gaap:CollaborativeArrangementMember 2019-05-07 2019-05-07 0001213809 dyai:SerumMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0001213809 dyai:SerumMember us-gaap:CollaborativeArrangementMember 2020-03-31 0001213809 dyai:JupiterFloridaHeadquartersLeaseMember 2020-03-31 0001213809 dyai:JupiterFloridaHeadquartersLeaseMember 2020-01-01 2020-03-31 0001213809 dyai:NetherlandsOfficeLeaseMember 2020-01-01 2020-03-31 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-06-28 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-06-28 2019-06-28 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-10-25 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-10-25 2019-10-25 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2020-03-23 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2020-03-23 2020-03-23 0001213809 dyai:A2006PlanMember 2020-03-31 0001213809 dyai:A2011PlanMember 2020-03-31 0001213809 dyai:A2011PlanMember 2019-01-01 2019-01-01 0001213809 dyai:A2011PlanMember 2020-01-01 2020-01-01 0001213809 dyai:A2011PlanMember 2019-12-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:A2011PlanMember 2020-01-01 2020-03-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:A2011PlanMember us-gaap:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-01-01 2020-03-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:A2011PlanMember dyai:ContractorMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-03-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:A2011PlanMember dyai:ContractorMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-01-01 2020-03-31 0001213809 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001213809 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001213809 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001213809 2019-01-01 2019-12-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:ExecutivesandKeyPersonnelMember 2020-01-02 2020-01-02 0001213809 dyai:ExecutivesandKeyPersonnelMember 2020-01-02 2020-01-02 0001213809 us-gaap:DirectorMember 2020-01-02 2020-01-02 0001213809 dyai:EmployeeMember 2020-01-02 2020-01-02 0001213809 us-gaap:EmployeeStockOptionMember dyai:EmployeeMember 2020-01-02 2020-01-02 0001213809 us-gaap:EmployeeStockOptionMember dyai:ConsultantMember 2020-01-02 2020-01-02 0001213809 dyai:ConsultantMember 2020-01-02 2020-01-02 0001213809 us-gaap:EmployeeStockOptionMember dyai:ContractorMember 2020-03-22 0001213809 dyai:ContractorMember 2020-03-22 2020-03-22 0001213809 us-gaap:SubsequentEventMember 2020-05-01 2020-05-14 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001213809 us-gaap:CommonStockMember 2018-12-31 0001213809 us-gaap:TreasuryStockMember 2018-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001213809 us-gaap:RetainedEarningsMember 2018-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001213809 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001213809 us-gaap:CommonStockMember 2019-03-31 0001213809 us-gaap:TreasuryStockMember 2019-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001213809 us-gaap:RetainedEarningsMember 2019-03-31 shares iso4217:USD iso4217:USD shares dyai:segment dyai:customer pure iso4217:EUR dyai:antibody_and_vaccine dyai:protein utr:sqft 0001213809 2020-03-31 2020 Q1 false 140 Intracoastal Pointe Drive Suite 404 Jupiter FL true false --12-31 P2Y P2Y P3Y P2Y P3Y P6M 10-Q true 2020-03-31 false 000-55264 DYADIC INTERNATIONAL, INC. DE 45-0486747 140 Intracoastal Pointe Drive Suite 404 Jupiter FL 33477 561 743-8333 Yes Yes Non-accelerated Filer true false false Common Stock, par value $0.001 per share DYAI NASDAQ 27469157 4696831 4823544 26587752 29399146 227146 329711 518601 558530 500616 250308 288495 277999 32819441 35639238 2518160 1511636 0 250308 50489 51314 35388090 37452496 653373 943378 240003 566003 242443 78644 1135819 1588025 0.0001 0.0001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 100000000 100000000 39722659 39612659 27469157 27359157 39713 39613 96707690 96105851 12253502 12253502 18929915 18929915 -43565217 -41351078 34252271 35864471 35388090 37452496 315372 402527 278182 327903 755453 692370 0 389473 1653392 1428067 -10867 -6034 2697894 2843847 -2382522 -2441320 168383 266962 -2214139 -2174358 0 900 -2214139 -2175258 -0.08 -0.08 27452490 26713486 39612659 39613 -12253502 -18929915 96105851 -41351078 35864471 426939 426939 100000 100 174900 175000 -2214139 -2214139 39712659 39713 -12253502 -18929915 96707690 -43565217 34252271 -2214139 -2175258 426939 309563 107256 32201 -10867 -5148 -102565 -3981 -35258 106781 0 -6249 0 -83112 10529 -5049 -292361 641799 -326000 -96606 163799 -117978 -1996345 -1409521 11652385 13190855 13350000 16197000 1697615 3006145 175000 0 175000 0 -2983 -7177 -126713 1589447 4823544 2386314 4696831 3975761 0 6249 Organization and Summary of Significant Accounting Policies<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Thermothelomyces heterothallica </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(formerly </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Myceliophthora thermophila</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (“DuPont”), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is aiming to develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”. Prior to the Company’s uplisting to the NASDAQ, the Company’s common stock traded on the OTCQX market.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Impact of COVID-19</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The recent outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company’s employees, operations, and research projects.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, as a direct result of COVID-19, most of our employees are working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the response to curb its spread, currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is currently working on several COVID-19 related vaccine and antibody opportunities. For example, the Israel Institute for Biologic Research (“IIBR”) is exploring the potential of Dyadic’s industrially proven C1 gene expression platform to express certain gene sequences and targets developed by IIBR into both an rVaccine candidate and mAbs that may potentially help combat the outbreak of the COVID-19 virus. The Company is also working with three scientists who are a part of the EU ZAPI initiative: Dr. Bosch at Utrecht University, Dr. Haagmans at Erasmus Medical Center, and Prof. Osterhaus at University of Veterinary Medicine Hannover, as well as with Dr. Erroba and Mr. Es-Sbai at clinical contract research organizations to develop and submit a proposal for funding to pharmaceutical organizations and governmental agencies. The objective of this proposal is to develop, and pre-clinically and clinically evaluate (in Phase I/II trials), a multimeric self-assembling SARS-CoV-2 Receptor Binding Domain vaccine candidate to rapidly respond to the COVID-19 pandemic. Another proposal was developed in conjunction with Ufovax, a spin-off vaccine company of Scripps Research, which was submitted to many of the same parties. In addition, the Company is pursuing other opportunities where it may be able to apply its C1gene expression platform to help combat the COVID-19 pandemic; however, there is no assurance that any of these opportunities will materialize or that the C1 technology or any product expressed from C1 or any of the various other steps in a vaccine or drug development process will perform, provide benefits, obtain governmental safety and regulatory approvals, be registered or gain market acceptance. In addition, our C1 technology has yet to be used to produce a vaccine, antibody or other biologic product that has entered the clinical trial phase, and we are competing with more experienced companies for grants or funding of this type. As a result, there is no assurance that we will receive these grants or funding resulting from these proposals.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs of our operations. We believe that we have sufficient cash, cash equivalents and investments to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing balances of cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2019, included in our Form 10-K which was filed with the SEC on March 30, 2020.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations and Credit Risk</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020 and 2019, the Company’s revenue was generated from five and six customers, respectively. As of March 31, 2020 and December 31, 2019, the Company’s accounts receivable was from eight and five customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company generates a portion of its revenues from customers that are located outside of the United States. For the three months ended March 31, 2020, the Company had three customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 58.0% or $183,000 of total revenue. For the three months ended March 31, 2019, the Company had one customer outside of the United States (i.e. European customer) that accounted for approximately 69.7% or $281,000 of total revenue.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, the Company had eight customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 72.9% or $378,000 of accounts receivable. As of December 31, 2019, the Company had four customers outside of the United States that accounted for approximately 69.5% or $388,000 of accounts receivable. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses a few contract research organizations (“CROs”) to conduct its research projects. For the three months ended March 31, 2020 and 2019, one CRO accounted for approximately 100% and 68.1% of total research services we purchased, respectively. As of March 31, 2020, approximately $596,000 or 91.2% of accounts payable was related to this CRO. At December 31, 2019, approximately $706,000 or 74.9% of accounts payable was to this CRO. The loss of business from this CRO or a combination of the Company’s CROs could adversely affect its operations. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash and Cash Equivalents</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investment Securities</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of March 31, 2020 and December 31, 2019, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of March 31, 2020 or December 31, 2019.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. There was no allowance for doubtful accounts as of March 31, 2020 and December 31, 2019.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:61.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Billed receivable </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">405,101 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">432,546 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unbilled receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,500 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,984 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">518,601 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">558,530 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:61.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198,554 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173,890 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses - various</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,607 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,221 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,334 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,888 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">288,495 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277,999 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Payable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:61.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">590,452 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">766,001 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,782 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,994 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,139 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,383 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">653,373 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">943,378 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:61.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee wages and benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162,310 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">474,388 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,035 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,795 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,658 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,820 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240,003 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">566,003 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to research collaborations and agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue related to grants and fundings: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company may receive grants and fundings from governments, agencies, and other private and not-for-profit organizations. These grants and fundings are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue related to sublicensing agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone payments: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalties: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to licenses deemed to be the predominant item to which the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Costs </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development (“R&amp;D”) costs are expensed as incurred. R&amp;D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three months ended March 31, 2020 and 2019 were as follows: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:65.690%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.644%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outside contracted services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">613,790 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">585,487 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contracted services - related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">389,473 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personnel related costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,638 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,762 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities, overhead and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,025 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,121 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">755,453 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,081,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Transaction Gain or Loss</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> – Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from 35% to 21% and repeal of the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended December 31, 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The TCJA repealed the corporate AMT but permitted unused AMT credit carryforwards to be used to reduce the regular tax obligation in future years. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Subsequently, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), which was signed into law in March 2020, accelerated the full refund of any unused AMT credits from 2021 (as provided for in the TCJA) to 2018 or 2019, at the taxpayer’s election. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of March 31, 2020, we have received 50% or approximately a $0.5 million refund for tax year 2018 and we expect to receive the remaining portion in 2020 pursuant to the CARES Act.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For the three months ended March 31, 2020, there were no provision for income taxes and unrecognized tax benefits recorded.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets as of March 31, 2020 and December 31, 2019 were approximately $9.6 million and $7.2 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of March 31, 2020 and December 31, 2019.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 20, 2019, the Company received a letter from the United States Internal Revenue Service (the “IRS”) informing the Company that its 2016 federal tax return was selected for examination. In August 2019, the Company had a meeting with the IRS agent and provided the IRS with all requested information. Thus far, the Company has not been informed of any assessment and we are unable to predict when the audit will be concluded or whether any assessment will be proposed. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020 and 2019, the effect of the potential exercise of options to purchase 4,663,390 and 4,541,890 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Adopted as of March 31, 2020 </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2023. The Company does not expect ASU 2016-13 to have material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The ASU was effective for the Company beginning in the first quarter of 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div> 75000000 <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2019, included in our Form 10-K which was filed with the SEC on March 30, 2020.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</span></div> 1 <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</span></div> Concentrations and Credit RiskThe Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts. 5 6 8 5 3 3 0.580 183000 0.697 281000 8 0.729 378000 4 0.695 388000 1 0.681 596000 0.912 706000 0.749 Cash and Cash EquivalentsWe treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use. <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investment Securities</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</span></div>The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. </span></div>Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. 0 0 <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:61.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Billed receivable </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">405,101 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">432,546 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unbilled receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113,500 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,984 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">518,601 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">558,530 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 405101 432546 113500 125984 518601 558530 <div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:61.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198,554 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173,890 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses - various</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,607 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,221 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,334 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,888 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">288,495 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277,999 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 198554 173890 88607 101221 1334 2888 288495 277999 <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:61.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">590,452 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">766,001 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,782 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,994 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,139 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,383 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">653,373 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">943,378 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 590452 766001 9782 26994 53139 150383 653373 943378 <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:61.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee wages and benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162,310 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">474,388 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,035 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,795 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,658 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,820 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240,003 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">566,003 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 162310 474388 20035 69795 57658 21820 240003 566003 Revenue Recognition <div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to research collaborations and agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue related to grants and fundings: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company may receive grants and fundings from governments, agencies, and other private and not-for-profit organizations. These grants and fundings are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue related to sublicensing agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone payments: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalties: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to licenses deemed to be the predominant item to which the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</span></div> Research and Development Costs Research and development (“R&amp;D”) costs are expensed as incurred. R&amp;D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects. Research and development costs, including related party, during the three months ended March 31, 2020 and 2019 were as follows: <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:65.690%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.644%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outside contracted services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">613,790 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">585,487 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contracted services - related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">389,473 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personnel related costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,638 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,762 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities, overhead and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,025 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,121 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">755,453 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,081,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 613790 585487 0 389473 123638 94762 18025 12121 755453 1081843 Foreign Currency Transaction Gain or LossThe Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates. <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> – Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. </span></div>The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches. Income TaxesThe Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from 35% to 21% and repeal of the corporate alternative minimum tax (“AMT”). 1001233 500000 0 0 9600000 7200000 1 1 <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.</span></div> <div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</span></div> <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average </span></div>number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method. 4663390 4541890 <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Adopted as of March 31, 2020 </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2023. The Company does not expect ASU 2016-13 to have material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The ASU was effective for the Company beginning in the first quarter of 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div> Cash, Cash Equivalent, and Investments <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of March 31, 2020 and December 31, 2019:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:33.871%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.442%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.884%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.055%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.475%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020 (Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">523,626 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">523,626 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,173,205 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,173,205 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,696,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,696,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,439,982 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(147,770)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,587,752 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Long-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,536,610 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,812 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,362)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,518,160 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,673,423 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,812 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(154,132)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,802,743 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.818%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.432%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.450%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019 (Audited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,010,510 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,010,510 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,813,034 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,813,034 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,823,544 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,823,544 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,387,053 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,898 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,991)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,399,146 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Long-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,528,190 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,554 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,511,636 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,738,787 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,452 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,991)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,734,326 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Definition of the three-level fair value hierarchy:</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 2 - Other inputs that are directly or indirectly observable in the markets</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 3 - Inputs that are generally unobservable </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4) The premium paid to purchase held-to-maturity investment securities was $196,385 and $80,855 for the three months ended March 31, 2020 and 2019, respectively. The premium paid to purchase held-to-maturity investment securities was $233,550 for the year ended December 31, 2019.</span></div>The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. As of March 31, 2020, the Company does not consider any of its investments to be other-than-temporarily impaired. The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of March 31, 2020 and December 31, 2019:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:33.871%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.442%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.884%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.055%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.475%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020 (Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">523,626 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">523,626 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,173,205 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,173,205 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,696,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,696,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,439,982 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(147,770)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,587,752 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Long-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,536,610 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,812 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,362)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,518,160 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,673,423 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,812 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(154,132)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,802,743 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.818%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.432%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.450%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019 (Audited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,010,510 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,010,510 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,813,034 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,813,034 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,823,544 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,823,544 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,387,053 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,898 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,991)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,399,146 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Long-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,528,190 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,554 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,511,636 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,738,787 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,452 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,991)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,734,326 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Definition of the three-level fair value hierarchy:</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 2 - Other inputs that are directly or indirectly observable in the markets</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 3 - Inputs that are generally unobservable </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4) The premium paid to purchase held-to-maturity investment securities was $196,385 and $80,855 for the three months ended March 31, 2020 and 2019, respectively. The premium paid to purchase held-to-maturity investment securities was $233,550 for the year ended December 31, 2019.</span></div> 523626 523626 4173205 4173205 4696831 4696831 26439982 147770 26587752 2536610 24812 6362 2518160 33673423 24812 154132 33802743 1010510 1010510 3813034 3813034 4823544 4823544 29387053 5898 17991 29399146 1528190 16554 1511636 35738787 22452 17991 35734326 196385 80855 233550 Research Collaboration and Sub-licensing Agreements<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">BDI Agreements</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&amp;D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”). </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZTNlOGNkMzU0ODRhMDk5YWRmNzFkZTMwZTRjMjkyL3NlYzo4NGUzZThjZDM1NDg0YTA5OWFkZjcxZGUzMGU0YzI5Ml80MC9mcmFnOjFlMjg5YmMxMzYyNzRhNTk4MTM5M2M5M2U2NzA3MjgwL3RleHRyZWdpb246MWUyODliYzEzNjI3NGE1OTgxMzkzYzkzZTY3MDcyODBfNzcx_fffe9721-4126-4132-9a54-95b3b502b3c3">two</span>-year period, with a focus on advancing Dyadic’s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon closing of the BDI transaction, the Company paid EUR €1 million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR €936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR €1 million for a 50% share or EUR €8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR €1.5 million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million (the “SFA Commitment”) in contract research services specified by Dyadic over two years since the closing of the BDI transaction. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1 million (EUR €1 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1 million paid by Dyadic were expensed as the related research services were performed by BDI. In June 2019, BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. As of December 31, 2019, Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA. However, the Company may in the future continue to provide funding to BDI for certain research and commercialization projects.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020 and December 31, 2019, there were no balances in the prepaid research and development collaboration related to BDI recorded on our consolidated balance sheets. For the three months ended March 31, 2020, and 2019, research and development expenses related to BDI recorded as research and development - related party in our consolidated statements of operations were none and approximately $0.4 million, respectively. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novovet and Luina Bio Sub-License Agreement</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic’s proprietary C1 gene expression platform. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Alphazyme Sub-License Agreement</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a 7.5% ownership interest in Alphazyme (“Alphazyme Up-Front Consideration”) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic’s proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of 18 months (“Exclusivity Period”) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period, Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional 2.5% ownership interest in Alphazyme.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded during the three months ended March 31, 2020.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Commercialization Collaboration with Serum Institute of India</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (“Serum”). Under the terms of this collaboration, Serum anticipates applying Dyadic’s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic’s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.</span></div>For the three months ended March 31, 2020, the Company recognized approximately $75,000 in research and research revenue from Serum. As of March 31, 2020, the Company recorded approximately $82,000 in deferred research and development obligations related to this agreement. 1000000 0.161 0.033 936000 P2Y 0.50 0.75 1000000 0.50 8000000 0.75 1500000 1000000 P2Y 1100000 1000000 1000000 0 0 0 400000 0.20 0.20 0.075 P18M P12M 0.025 12 12 P15Y 75000 82000 Commitments and Contingencies<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Jupiter, Florida Headquarters</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700 in total. The lease expires on June 30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The Netherlands Office</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies a flexible office space for an annual rental rate of approximately $4,000. The lease expires on January 31, 2021, and thereafter, the Company will reconsider the leased space to align with the future operations of the Company.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">VTT Research Contract Extension</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 28, 2019, the Company extended its research contract (“Contract”) through June 2022 with VTT Technical Research Centre of Finland Ltd. (“VTT”). Under the terms of this Contract, Dyadic will pay VTT a total of EUR €2.52 million over the next three years to continue developing Dyadic’s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR €450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR €690,000 over the next 1.5 years to reinforce the glycoengineering work. On March 23, 2020, the Company further expanded the Contract to pay an additional EUR €700,000 over the next 19 months to accelerate the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days’ notice.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.</span></div> 4900 9700 4000 2520000 P3Y 450000 690000 P1Y6M 700000 P19M P90D Share-Based Compensation<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Equity Plans</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2011 Equity Incentive Plan (the “2011 Plan”) was adopted by the Company’s Board of Directors on April 28, 2011 and approved by the Company’s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company’s 2006 Stock Option Plan (the “2006 Plan”). Since the effective date of the 2011 Plan, all equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company’s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provisions of the 2011 Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on January 1, 2019 and 2020. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, the Company had 4,663,390 stock options outstanding and an additional 2,134,211 shares of common stock available for grant under the 2011 Plan. As of December 31, 2019, there were 3,860,390 stock options outstanding and 1,547,211 shares of common stock available for grant under the 2011 Plan. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan is ten years except for certain options granted to the CEO (five years) and contractors (<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZTNlOGNkMzU0ODRhMDk5YWRmNzFkZTMwZTRjMjkyL3NlYzo4NGUzZThjZDM1NDg0YTA5OWFkZjcxZGUzMGU0YzI5Ml80Ni9mcmFnOmE2ZTQ3NTc5OThiNDQwNmQ4ZDkwYzlhZThmNTg1OWJhL3RleHRyZWdpb246YTZlNDc1Nzk5OGI0NDA2ZDhkOTBjOWFlOGY1ODU5YmFfNTQ5NzU1ODE0Nzk0Ng_dd97cac1-5980-44b1-b31d-76735962e5ff">two</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZTNlOGNkMzU0ODRhMDk5YWRmNzFkZTMwZTRjMjkyL3NlYzo4NGUzZThjZDM1NDg0YTA5OWFkZjcxZGUzMGU0YzI5Ml80Ni9mcmFnOmE2ZTQ3NTc5OThiNDQwNmQ4ZDkwYzlhZThmNTg1OWJhL3RleHRyZWdpb246YTZlNDc1Nzk5OGI0NDA2ZDhkOTBjOWFlOGY1ODU5YmFfNTQ5NzU1ODE0Nzk2OQ_e956c64c-d28e-4c2d-afc3-057b53a88773">three</span> years).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend yield</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected stock price volatility.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected life of option. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for certain options granted to the CEO (five years) and contractors (<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZTNlOGNkMzU0ODRhMDk5YWRmNzFkZTMwZTRjMjkyL3NlYzo4NGUzZThjZDM1NDg0YTA5OWFkZjcxZGUzMGU0YzI5Ml80Ni9mcmFnOmE2ZTQ3NTc5OThiNDQwNmQ4ZDkwYzlhZThmNTg1OWJhL3RleHRyZWdpb246YTZlNDc1Nzk5OGI0NDA2ZDhkOTBjOWFlOGY1ODU5YmFfNzY5NjU4MTQwMzgxNA_dd97cac1-5980-44b1-b31d-76735962e5ff">two</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZTNlOGNkMzU0ODRhMDk5YWRmNzFkZTMwZTRjMjkyL3NlYzo4NGUzZThjZDM1NDg0YTA5OWFkZjcxZGUzMGU0YzI5Ml80Ni9mcmFnOmE2ZTQ3NTc5OThiNDQwNmQ4ZDkwYzlhZThmNTg1OWJhL3RleHRyZWdpb246YTZlNDc1Nzk5OGI0NDA2ZDhkOTBjOWFlOGY1ODU5YmFfNzY5NjU4MTQwMzgyMA_e956c64c-d28e-4c2d-afc3-057b53a88773">three</span> years). </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assumptions used in the Black-Scholes option pricing model for stock options granted during the three months ended March 31, 2020 are as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:58.761%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.239%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-Free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.25% - 1.72%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">39.94% - 51.22%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life of options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.75 - 6.25 Years</span></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activities during the three months ended March 31, 2020: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.795%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.290%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,860,390 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.76</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$13,287,932</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Granted</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">913,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Exercised </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(110,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.78 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,663,390 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$2.44</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$13,017,190</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,167,983 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.67</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$11,201,783</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Represents the following stock options granted:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Annual share-based compensation awards on January 2, 2020, including: (a) 525,000 stock options with an exercise price of $5.27 per share granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 325,000 stock options with an exercise price of $5.27 per share granted to the Board of Directors, vesting upon one year anniversary, (c) 23,000 stock options with an exercise price of $5.27 per share granted to employees, vesting annually in equal installments over four years, and (d) 15,000 stock options with an exercise price of $5.27 per share granted to a consultant, vesting upon one year anniversary. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">One-time awards on March 22, 2020, including 25,000 stock options to a contractor with an exercise price of $3.99 per share, vesting in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZTNlOGNkMzU0ODRhMDk5YWRmNzFkZTMwZTRjMjkyL3NlYzo4NGUzZThjZDM1NDg0YTA5OWFkZjcxZGUzMGU0YzI5Ml80Ni9mcmFnOmE2ZTQ3NTc5OThiNDQwNmQ4ZDkwYzlhZThmNTg1OWJhL3RleHRyZWdpb246YTZlNDc1Nzk5OGI0NDA2ZDhkOTBjOWFlOGY1ODU5YmFfNTQ5NzU1ODE0Nzk4Mg_6ae04982-682a-4bec-80db-030b41737cb9">six</span> months from the date of grant.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) Represents the following stock options exercised:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A total of 110,000 stock options exercised with a weighted average market price of $1.78, among which, 10,000 shares were issued in May 2020.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Compensation Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total non-cash stock option compensation expense was allocated among the following expense categories: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:61.917%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.673%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.674%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">380,251 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233,214 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,688 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,349 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">426,939 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 0 3000000 1500000 1500000 4663390 2134211 3860390 1547211 P10Y P5Y 0 P5Y <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assumptions used in the Black-Scholes option pricing model for stock options granted during the three months ended March 31, 2020 are as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:58.761%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.239%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-Free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.25% - 1.72%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">39.94% - 51.22%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life of options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.75 - 6.25 Years</span></div></td></tr></table></div> 0.0025 0.0172 0 0.3994 0.5122 P1Y9M P6Y3M <div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activities during the three months ended March 31, 2020: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.795%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.290%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,860,390 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.76</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$13,287,932</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Granted</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">913,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Exercised </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(110,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.78 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,663,390 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$2.44</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$13,017,190</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,167,983 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.67</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$11,201,783</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Represents the following stock options granted:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Annual share-based compensation awards on January 2, 2020, including: (a) 525,000 stock options with an exercise price of $5.27 per share granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 325,000 stock options with an exercise price of $5.27 per share granted to the Board of Directors, vesting upon one year anniversary, (c) 23,000 stock options with an exercise price of $5.27 per share granted to employees, vesting annually in equal installments over four years, and (d) 15,000 stock options with an exercise price of $5.27 per share granted to a consultant, vesting upon one year anniversary. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">One-time awards on March 22, 2020, including 25,000 stock options to a contractor with an exercise price of $3.99 per share, vesting in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZTNlOGNkMzU0ODRhMDk5YWRmNzFkZTMwZTRjMjkyL3NlYzo4NGUzZThjZDM1NDg0YTA5OWFkZjcxZGUzMGU0YzI5Ml80Ni9mcmFnOmE2ZTQ3NTc5OThiNDQwNmQ4ZDkwYzlhZThmNTg1OWJhL3RleHRyZWdpb246YTZlNDc1Nzk5OGI0NDA2ZDhkOTBjOWFlOGY1ODU5YmFfNTQ5NzU1ODE0Nzk4Mg_6ae04982-682a-4bec-80db-030b41737cb9">six</span> months from the date of grant.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) Represents the following stock options exercised:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A total of 110,000 stock options exercised with a weighted average market price of $1.78, among which, 10,000 shares were issued in May 2020.</span></div> 3860390 1.76 P5Y8M12D 13287932 913000 5.24 110000 1.78 0 0 0 0 4663390 2.44 P6Y4M24D 13017190 3167983 1.67 P5Y1M6D 11201783 525000 5.27 P1Y P4Y 325000 5.27 P1Y 23000 5.27 P4Y 15000 5.27 P1Y 25000 3.99 110000 1.78 10000 <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total non-cash stock option compensation expense was allocated among the following expense categories: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:61.917%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.673%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.674%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">380,251 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233,214 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,688 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,349 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">426,939 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 380251 233214 46688 76349 426939 309563 Shareholders’ Equity<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Issuances of Common Stock</span></div><div style="text-indent:54pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020, there were 100,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.78 per share. For the three months ended March 31, 2019, no shares were issued. </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"/><td style="width:20.633%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.024%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020 (Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,613 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,105,851 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,351,078)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,864,471 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">426,939 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">426,939 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,900 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">175,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,214,139)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,214,139)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,713 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,707,690 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,565,217)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,252,271 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019 (Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,385,230 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,043,113)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,451,169 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,175,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,175,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,694,793 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,218,371)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,585,474 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Treasury Stock </span></div>As of March 31, 2020 and December 31, 2019, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company. 100000 1.78 0 <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"/><td style="width:20.633%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.024%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020 (Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,613 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,105,851 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,351,078)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,864,471 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">426,939 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">426,939 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,900 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">175,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,214,139)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,214,139)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,713 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,707,690 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,565,217)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,252,271 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019 (Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,385,230 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,043,113)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,451,169 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,175,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,175,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,694,793 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,218,371)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,585,474 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table> 39613 -18929915 96105851 -41351078 35864471 426939 426939 100 174900 175000 -2214139 -2214139 39713 -18929915 96707690 -43565217 34252271 38967 -18929915 94385230 -33043113 42451169 309563 309563 -2175258 -2175258 38967 -18929915 94694793 -35218371 40585474 12253502 12253502 18900000 18900000 Subsequent Events <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management continues to actively monitor the COVID-19 pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through May 14, 2020, the date the consolidated financial statements were available to be issued. Management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</span></div> XML 43 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]    
Research and development expenses $ 590,452 $ 766,001
Legal expenses 9,782 26,994
Other 53,139 150,383
Accounts payable $ 653,373 $ 943,378
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Research Collaboration and Sub-licensing Agreements (Details)
€ in Thousands
 3 Months Ended
May 07, 2019
protein
antibody_and_vaccine
May 05, 2019
Jun. 30, 2017
EUR (€)
Jun. 30, 2017
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Apr. 26, 2019
Dec. 31, 2017
EUR (€)
Dec. 31, 2017
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Duration of agreement     2 years 2 years            
Payment for research and development agreement     € 1,000 $ 1,100,000            
Prepaid research and development         $ 0   $ 0      
Research and development - related party         0 $ 389,473        
Collaborative Arrangement | Serum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Number of antibodies and vaccines for development and commercialization | antibody_and_vaccine 12                  
Option to obtain exclusive commercial sub-license for number of proteins | protein 12                  
Research funding, milestone payments and royalties, period 15 years                  
Revenue from collaborative arrangement, recognized         75,000          
Revenue from collaborative arrangement, contract liability         $ 82,000          
Novovet                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Equity percentage               20.00%    
Alphazyme                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Equity percentage   7.50%                
Ownership interest consideration receivable upon extension of exclusivity period   2.50%                
Alphazyme | Collaborative Arrangement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Exclusivity period   18 months                
Option to extend exclusivity period   12 months                
RSA                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Payment for research and development agreement | €     € 1,000              
Payment for additional development and commercialization | €                 € 1,500  
RSA | Minimum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue sharing, percentage     50.00% 50.00%            
RSA | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue sharing, percentage     75.00% 75.00%            
RSA | BDI Holdings                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Equity interest acquired     16.10% 16.10%            
RSA | VLPbio                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Equity interest acquired     3.30% 3.30%            
RSA | BDI                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Duration of agreement     2 years 2 years            
Obligation for payment for research and development, minimum | €                 936  
Obligation for payment for research and development, maximum | €                 € 8,000  
RSA | BDI | Minimum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue sharing, percentage     50.00% 50.00%            
RSA | BDI | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue sharing, percentage     75.00% 75.00%            
SFA                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Duration of agreement     2 years 2 years            
Obligation for payment for research and development, minimum                   $ 1,000,000
Outstanding commitment                   $ 1,000,000
XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]    
Employee wages and benefits $ 162,310 $ 474,388
Research and development expenses 20,035 69,795
Other 57,658 21,820
Accrued expenses $ 240,003 $ 566,003
XML 47 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies - Textual (Details)
 3 Months Ended
Mar. 23, 2020
USD ($)
Oct. 25, 2019
EUR (€)
Jun. 28, 2019
EUR (€)
Mar. 31, 2020
USD ($)
ft²
Jun. 28, 2019
USD ($)
VTT Technical Research Centre of Finland Ltd          
Long-term Purchase Commitment [Line Items]          
Commitment to pay         $ 2,520,000
Commitment development period     3 years    
Commitment success bonus award | €     € 450,000    
Commitment to pay, expanded | €   € 690,000      
Commitment to pay, expanded, period   1 year 6 months      
Commitment to pay, additional $ 700,000        
Commitment to pay, additional coverage period 19 months        
Commitments, right to terminate contract notice period 90 days        
Jupiter, Florida Headquarters Lease          
Long-term Purchase Commitment [Line Items]          
Area of building rented | ft²       4,900  
Monthly rental rate       $ 9,700  
Netherlands Office Lease          
Long-term Purchase Commitment [Line Items]          
Rent expense       $ 4,000  
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation - Compensation Expense (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation $ 426,939 $ 309,563
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation 380,251 233,214
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation $ 46,688 $ 76,349
XML 49 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies - Textual (Details)
 3 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
Mar. 31, 2020
USD ($)
segment
customer
shares
Mar. 31, 2019
USD ($)
customer
shares
Dec. 31, 2019
USD ($)
customer
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Number of operating segments | segment   1    
Revenues   $ 315,372 $ 402,527  
Allowance for doubtful accounts receivable   0   $ 0
Income tax benefit, valuation allowance reversal   1,001,233    
Cash received from income tax refund   0 6,249  
Unrecognized tax benefits   0    
Provision for income taxes   0 $ 900  
Deferred tax assets, net   $ 9,600,000   $ 7,200,000
Deferred tax assets, valuation allowance coverage, percent   100.00%   100.00%
Antidilutive securities excluded from computation of earnings per share (in shares) | shares   4,663,390 4,541,890  
Tax Year 2018        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Cash received from income tax refund   $ 500,000    
Customer Concentration Risk | Revenue        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Concentration risk, number of customers | customer   5 6  
Customer Concentration Risk | Accounts Receivable        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Concentration risk, number of customers | customer       5
Outside of the United States | Customer Concentration Risk | Revenue        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Concentration risk, number of customers | customer   3    
Concentration risk, percentage   58.00% 69.70%  
Revenues   $ 183,000 $ 281,000  
Outside of the United States | Customer Concentration Risk | Accounts Receivable        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Concentration risk, number of customers | customer   8   4
Concentration risk, percentage   72.90%   69.50%
Accounts receivable   $ 378,000   $ 388,000
DuPont Danisco | Industrial Technology Business        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Proceeds from sales of business $ 75,000,000      
Contract Research Organizations | Customer Concentration Risk        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Concentration risk, percentage   100.00% 68.10%  
Contract Research Organizations | Customer Concentration Risk | Accounts Payable        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Concentration risk, percentage   91.20%   74.90%
Accounts payable   $ 596,000   $ 706,000
XML 50 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation
 3 Months Ended
Mar. 31, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation Share-Based Compensation
Description of Equity Plans
The 2011 Equity Incentive Plan (the “2011 Plan”) was adopted by the Company’s Board of Directors on April 28, 2011 and approved by the Company’s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company’s 2006 Stock Option Plan (the “2006 Plan”). Since the effective date of the 2011 Plan, all equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company’s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provisions of the 2011 Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on January 1, 2019 and 2020.
As of March 31, 2020, the Company had 4,663,390 stock options outstanding and an additional 2,134,211 shares of common stock available for grant under the 2011 Plan. As of December 31, 2019, there were 3,860,390 stock options outstanding and 1,547,211 shares of common stock available for grant under the 2011 Plan.
Stock Options
Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan is ten years except for certain options granted to the CEO (five years) and contractors (two or three years).
The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting
portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:
Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.
Expected dividend yield. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.
Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure.
Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for certain options granted to the CEO (five years) and contractors (two or three years).
The assumptions used in the Black-Scholes option pricing model for stock options granted during the three months ended March 31, 2020 are as follows:
Risk-Free interest rate
0.25% - 1.72%
Expected dividend yield— %
Expected stock price volatility
39.94% - 51.22%
Expected life of options
1.75 - 6.25 Years

The following table summarizes the stock option activities during the three months ended March 31, 2020: 
SharesWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
Outstanding at December 31, 20193,860,390  $1.765.7$13,287,932
Granted (1)
913,000  5.24  
Exercised (2)
(110,000) 1.78  
Expired —  —  
Canceled —  —  
Outstanding at March 31, 20204,663,390  $2.446.4$13,017,190
Exercisable at March 31, 20203,167,983  $1.675.1$11,201,783
_________________
Notes:
(1) Represents the following stock options granted:
•Annual share-based compensation awards on January 2, 2020, including: (a) 525,000 stock options with an exercise price of $5.27 per share granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 325,000 stock options with an exercise price of $5.27 per share granted to the Board of Directors, vesting upon one year anniversary, (c) 23,000 stock options with an exercise price of $5.27 per share granted to employees, vesting annually in equal installments over four years, and (d) 15,000 stock options with an exercise price of $5.27 per share granted to a consultant, vesting upon one year anniversary.
•One-time awards on March 22, 2020, including 25,000 stock options to a contractor with an exercise price of $3.99 per share, vesting in six months from the date of grant.
(2) Represents the following stock options exercised:
•A total of 110,000 stock options exercised with a weighted average market price of $1.78, among which, 10,000 shares were issued in May 2020.
Compensation Expenses
We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Total non-cash stock option compensation expense was allocated among the following expense categories: 
Three Months Ended March 31,
20202019
General and administrative$380,251  $233,214  
Research and development46,688  76,349  
Total $426,939  $309,563  
XML 51 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Schedule of Accounts Receivable
Accounts receivable consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Billed receivable $405,101  $432,546  
Unbilled receivable113,500  125,984  
$518,601  $558,530  
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Prepaid insurance$198,554  $173,890  
Prepaid expenses - various88,607  101,221  
Prepaid taxes1,334  2,888  
$288,495  $277,999  
Schedule of Accounts Payable
Accounts payable consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Research and development expenses$590,452  $766,001  
Legal expenses9,782  26,994  
Other53,139  150,383  
$653,373  $943,378  
Schedule of Accrued Expenses
Accrued expenses consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Employee wages and benefits$162,310  $474,388  
Research and development expenses20,035  69,795  
Other57,658  21,820  
$240,003  $566,003  
Schedule of Research and Development Costs Research and development costs, including related party, during the three months ended March 31, 2020 and 2019 were as follows:
Three Months Ended March 31,
20202019
(Unaudited)(Unaudited)
Outside contracted services$613,790  $585,487  
Contracted services - related party—  389,473  
Personnel related costs123,638  94,762  
Facilities, overhead and other18,025  12,121  
$755,453  $1,081,843  
JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dyai-20200331.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 114, "dts": { "calculationLink": { "local": [ "dyai-20200331_cal.xml" ] }, "definitionLink": { "local": [ "dyai-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "dyai-20200331.htm" ] }, "labelLink": { "local": [ "dyai-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "dyai-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml" ] }, "schema": { "local": [ "dyai-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 367, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 5, "http://www.dyadic.com/20200331": 1, "http://xbrl.sec.gov/dei/2019-01-31": 12, "total": 18 }, "keyCustom": 49, "keyStandard": 245, "memberCustom": 20, "memberStandard": 28, "nsprefix": "dyai", "nsuri": "http://www.dyadic.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.dyadic.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115104 - Disclosure - Commitments and Contingencies", "role": "http://www.dyadic.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Share-Based Compensation", "role": "http://www.dyadic.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124106 - Disclosure - Shareholders' Equity", "role": "http://www.dyadic.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128107 - Disclosure - Subsequent Events", "role": "http://www.dyadic.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables", "shortName": "Organization and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Cash, Cash Equivalent, and Investments (Tables)", "role": "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables", "shortName": "Cash, Cash Equivalent, and Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318303 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.dyadic.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325304 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.dyadic.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Textual (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i5a16553859f648c9ab82202fbb01c4a1_I20200331", "decimals": "0", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "dyai:ResearchAndDevelopmentInProcessCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "dyai:ResearchAndDevelopmentInProcessCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details)", "role": "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails", "shortName": "Cash, Cash Equivalent, and Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i169e0758172b44bdb3dcd08e63a36471_D20170630-20170630", "decimals": "-6", "first": true, "lang": "en-US", "name": "dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414408 - Disclosure - Research Collaboration and Sub-licensing Agreements (Details)", "role": "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "shortName": "Research Collaboration and Sub-licensing Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i169e0758172b44bdb3dcd08e63a36471_D20170630-20170630", "decimals": "-6", "first": true, "lang": "en-US", "name": "dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i3055226b434a416cae1fd4d0aa2a8294_I20190628", "decimals": "0", "first": true, "lang": "en-US", "name": "dyai:CommitmentToPay", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Commitments and Contingencies - Textual (Details)", "role": "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails", "shortName": "Commitments and Contingencies - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i3055226b434a416cae1fd4d0aa2a8294_I20190628", "decimals": "0", "first": true, "lang": "en-US", "name": "dyai:CommitmentToPay", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Share-Based Compensation - Textual (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails", "shortName": "Share-Based Compensation - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i09787b8e78bb40ff9ee60dacc92f1cb7_I20200331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ic3beb9a2f59744cc86b5a3718e2bee3d_D20200101-20200331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - Share-Based Compensation - Assumptions (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "shortName": "Share-Based Compensation - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ic3beb9a2f59744cc86b5a3718e2bee3d_D20200101-20200331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ie6703ef9c7484fcbb20ed8e491782a08_I20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i8110ba30c73e42228961b87d585fb173_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421412 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "shortName": "Share-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422413 - Disclosure - Share-Based Compensation - Stock Option Activity - Textual (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "shortName": "Share-Based Compensation - Stock Option Activity - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i4f16a958cfb74129b243a1db87d99a50_D20200501-20200514", "decimals": "0", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - Share-Based Compensation - Compensation Expense (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails", "shortName": "Share-Based Compensation - Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426415 - Disclosure - Shareholders' Equity - Textual (Details)", "role": "http://www.dyadic.com/role/ShareholdersEquityTextualDetails", "shortName": "Shareholders' Equity - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i8110ba30c73e42228961b87d585fb173_I20191231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427416 - Disclosure - Shareholders' Equity - Changes in Shareholders\u2019 Equity (Details)", "role": "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails", "shortName": "Shareholders' Equity - Changes in Shareholders\u2019 Equity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "0", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "ic4afe60152684cd188fd25055c0707db_I20181231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "role": "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i2eb7b845caa14f4abe5cc9ee63adba5e_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": "0", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies", "shortName": "Organization and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110102 - Disclosure - Cash, Cash Equivalent, and Investments", "role": "http://www.dyadic.com/role/CashCashEquivalentandInvestments", "shortName": "Cash, Cash Equivalent, and Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113103 - Disclosure - Research Collaboration and Sub-licensing Agreements", "role": "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreements", "shortName": "Research Collaboration and Sub-licensing Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20200331.htm", "contextRef": "i58780271760848d99f722f1d4df4fec6_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dyai_A2006PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2006 Plan [Member]", "label": "2006 Plan [Member]", "terseLabel": "2006 Plan" } } }, "localname": "A2006PlanMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_A2011PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2011 Plan [Member]", "label": "2011 Plan [Member]", "terseLabel": "2011 Plan" } } }, "localname": "A2011PlanMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_AccruedResearchandDevelopmentinProcessCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Research and Development in Process, Current", "label": "Accrued Research and Development in Process, Current", "terseLabel": "Research and development expenses" } } }, "localname": "AccruedResearchandDevelopmentinProcessCurrent", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "dyai_AlphazymeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alphazyme [Member]", "label": "Alphazyme [Member]", "terseLabel": "Alphazyme" } } }, "localname": "AlphazymeMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_BDIHoldingsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BDI Holdings [Member]", "label": "BDI Holdings [Member]", "terseLabel": "BDI Holdings" } } }, "localname": "BDIHoldingsMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_BDIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BDI [Member]", "label": "BDI [Member]", "terseLabel": "BDI" } } }, "localname": "BDIMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_CollaborativeArrangementDurationOfAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Duration Of Agreement", "label": "Collaborative Arrangement, Duration Of Agreement", "terseLabel": "Duration of agreement" } } }, "localname": "CollaborativeArrangementDurationOfAgreement", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "durationItemType" }, "dyai_CollaborativeArrangementEquityInterestAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Equity Interest Acquired", "label": "Collaborative Arrangement, Equity Interest Acquired", "terseLabel": "Equity interest acquired" } } }, "localname": "CollaborativeArrangementEquityInterestAcquired", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "dyai_CollaborativeArrangementExclusivityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Exclusivity Period", "label": "Collaborative Arrangement, Exclusivity Period", "terseLabel": "Exclusivity period" } } }, "localname": "CollaborativeArrangementExclusivityPeriod", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "durationItemType" }, "dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Maximum Obligation For Research And Development", "label": "Collaborative Arrangement, Maximum Obligation For Research And Development", "terseLabel": "Obligation for payment for research and development, maximum" } } }, "localname": "CollaborativeArrangementMaximumObligationForResearchAndDevelopment", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Minimum Obligation For Research And Development", "label": "Collaborative Arrangement, Minimum Obligation For Research And Development", "terseLabel": "Obligation for payment for research and development, minimum" } } }, "localname": "CollaborativeArrangementMinimumObligationForResearchAndDevelopment", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization", "label": "Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization", "terseLabel": "Number of antibodies and vaccines for development and commercialization" } } }, "localname": "CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "integerItemType" }, "dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Option To Extend Exclusivity Period", "label": "Collaborative Arrangement, Option To Extend Exclusivity Period", "terseLabel": "Option to extend exclusivity period" } } }, "localname": "CollaborativeArrangementOptionToExtendExclusivityPeriod", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "durationItemType" }, "dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins", "label": "Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins", "terseLabel": "Option to obtain exclusive commercial sub-license for number of proteins" } } }, "localname": "CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "integerItemType" }, "dyai_CollaborativeArrangementOutstandingCommitment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Outstanding Commitment", "label": "Collaborative Arrangement, Outstanding Commitment", "terseLabel": "Outstanding commitment" } } }, "localname": "CollaborativeArrangementOutstandingCommitment", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period", "label": "Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period", "terseLabel": "Ownership interest consideration receivable upon extension of exclusivity period" } } }, "localname": "CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Payment for Additional Development and Commercialization", "label": "Collaborative Arrangement, Payment for Additional Development and Commercialization", "terseLabel": "Payment for additional development and commercialization" } } }, "localname": "CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Payment for Research and Development Agreement", "label": "Collaborative Arrangement, Payment for Research and Development Agreement", "terseLabel": "Payment for research and development agreement" } } }, "localname": "CollaborativeArrangementPaymentforResearchandDevelopmentAgreement", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period", "label": "Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period", "terseLabel": "Research funding, milestone payments and royalties, period" } } }, "localname": "CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "durationItemType" }, "dyai_CollaborativeArrangementRevenueSharingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Revenue Sharing, Percentage", "label": "Collaborative Arrangement, Revenue Sharing, Percentage", "terseLabel": "Revenue sharing, percentage" } } }, "localname": "CollaborativeArrangementRevenueSharingPercentage", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "dyai_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangements And Noncollaborative Arrangement Transaction [Line Items]", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transaction [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionLineItems", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "dyai_CommitmentDevelopmentPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitment Development Period", "label": "Commitment Development Period", "terseLabel": "Commitment development period" } } }, "localname": "CommitmentDevelopmentPeriod", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "durationItemType" }, "dyai_CommitmentSuccessBonusAward": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Commitment Success Bonus Award", "label": "Commitment Success Bonus Award", "terseLabel": "Commitment success bonus award" } } }, "localname": "CommitmentSuccessBonusAward", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CommitmentToPay": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Commitment To Pay", "label": "Commitment To Pay", "terseLabel": "Commitment to pay" } } }, "localname": "CommitmentToPay", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CommitmentToPayAdditional": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Commitment To Pay, Additional", "label": "Commitment To Pay, Additional", "terseLabel": "Commitment to pay, additional" } } }, "localname": "CommitmentToPayAdditional", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CommitmentToPayAdditionalPeriodCoveage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitment To Pay, Additional Period Coveage", "label": "Commitment To Pay, Additional Period Coveage", "terseLabel": "Commitment to pay, additional coverage period" } } }, "localname": "CommitmentToPayAdditionalPeriodCoveage", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "durationItemType" }, "dyai_CommitmentToPayExpanded": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Commitment To Pay, Expanded", "label": "Commitment To Pay, Expanded", "terseLabel": "Commitment to pay, expanded" } } }, "localname": "CommitmentToPayExpanded", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CommitmentToPayExpandedPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitment To Pay, Expanded, Period", "label": "Commitment To Pay, Expanded, Period", "terseLabel": "Commitment to pay, expanded, period" } } }, "localname": "CommitmentToPayExpandedPeriod", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "durationItemType" }, "dyai_CommitmentsRightToTerminateContractNoticePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments, Right To Terminate Contract Notice Period", "label": "Commitments, Right To Terminate Contract Notice Period", "terseLabel": "Commitments, right to terminate contract notice period" } } }, "localname": "CommitmentsRightToTerminateContractNoticePeriod", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "durationItemType" }, "dyai_ConcentrationRiskNumberofCustomers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration Risk, Number of Customers", "label": "Concentration Risk, Number of Customers", "terseLabel": "Concentration risk, number of customers" } } }, "localname": "ConcentrationRiskNumberofCustomers", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "integerItemType" }, "dyai_ConsultantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consultant", "label": "Consultant [Member]", "terseLabel": "Consultant" } } }, "localname": "ConsultantMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_ContractResearchOrganizationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract Research Organizations", "label": "Contract Research Organizations [Member]", "terseLabel": "Contract Research Organizations" } } }, "localname": "ContractResearchOrganizationsMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_ContractorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contractor [Member]", "label": "Contractor [Member]", "terseLabel": "Contractor" } } }, "localname": "ContractorMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current", "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current", "terseLabel": "Short term investments, gross unrealized holding gain" } } }, "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent", "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent", "terseLabel": "Long term Investments, gross unrealized holding gain" } } }, "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current", "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current", "negatedLabel": "Short term investments, gross unrealized holding loss" } } }, "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent", "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent", "negatedLabel": "Long term Investments, gross unrealized holding loss" } } }, "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityFairValueCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Fair Value, Current", "label": "Debt Securities, Held-to-maturity, Fair Value, Current", "terseLabel": "Short term investments, fair value" } } }, "localname": "DebtSecuritiesHeldtomaturityFairValueCurrent", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_InvestmentsAndCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Fair Value, Noncurrent", "label": "Debt Securities, Held-to-maturity, Fair Value, Noncurrent", "terseLabel": "Long term Investments, fair value" } } }, "localname": "DebtSecuritiesHeldtomaturityFairValueNoncurrent", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Premium Paid on Purchase", "label": "Debt Securities, Held-to-maturity, Premium Paid on Purchase", "terseLabel": "Held-to-maturity, premium paid on purchase" } } }, "localname": "DebtSecuritiesHeldtomaturityPremiumPaidonPurchase", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Valuation Allowance Coverage, Percent", "label": "Deferred Tax Assets, Valuation Allowance Coverage, Percent", "terseLabel": "Deferred tax assets, valuation allowance coverage, percent" } } }, "localname": "DeferredTaxAssetsValuationAllowanceCoveragePercent", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "percentItemType" }, "dyai_DuPontDaniscoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DuPont Danisco [Member]", "label": "DuPont Danisco [Member]", "terseLabel": "DuPont Danisco" } } }, "localname": "DuPontDaniscoMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_EmployeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee [Member]", "label": "Employee [Member]", "terseLabel": "Employee" } } }, "localname": "EmployeeMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_ExecutivesandKeyPersonnelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Executives and Key Personnel [Member]", "label": "Executives and Key Personnel [Member]", "terseLabel": "Executives and Key Personnel" } } }, "localname": "ExecutivesandKeyPersonnelMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_IncomeTaxExpenseBenefitValuationAllowanceReversal": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income Tax Expense (Benefit), Valuation Allowance Reversal", "label": "Income Tax Expense (Benefit), Valuation Allowance Reversal", "terseLabel": "Income tax benefit, valuation allowance reversal" } } }, "localname": "IncomeTaxExpenseBenefitValuationAllowanceReversal", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_IncreaseDecreaseinPrepaidResearchandDevelopment": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Prepaid Research and Development", "label": "Increase (Decrease) in Prepaid Research and Development", "negatedTerseLabel": "Prepaid research and development" } } }, "localname": "IncreaseDecreaseinPrepaidResearchandDevelopment", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "dyai_IndustrialTechnologyBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Industrial Technology Business [Member]", "label": "Industrial Technology Business [Member]", "terseLabel": "Industrial Technology Business" } } }, "localname": "IndustrialTechnologyBusinessMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_InvestmentsandCashAmortizedCost": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investments and Cash, Amortized Cost", "label": "Investments and Cash, Amortized Cost", "totalLabel": "Cash and Investment, adjusted cost" } } }, "localname": "InvestmentsandCashAmortizedCost", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_JupiterFloridaHeadquartersLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Jupiter, Florida Headquarters Lease [Member]", "label": "Jupiter, Florida Headquarters Lease [Member]", "terseLabel": "Jupiter, Florida Headquarters Lease" } } }, "localname": "JupiterFloridaHeadquartersLeaseMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_NetherlandsOfficeLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Netherlands Office Lease [Member]", "label": "Netherlands Office Lease [Member]", "terseLabel": "Netherlands Office Lease" } } }, "localname": "NetherlandsOfficeLeaseMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_NovovetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Novovet [Member]", "label": "Novovet [Member]", "terseLabel": "Novovet" } } }, "localname": "NovovetMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_OperatingLeasesAnnualRentalRate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Leases, Annual Rental Rate", "label": "Operating Leases, Annual Rental Rate", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeasesAnnualRentalRate", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_OperatingLeasesMonthlyRentalRate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Leases, Monthly Rental Rate", "label": "Operating Leases, Monthly Rental Rate", "terseLabel": "Monthly rental rate" } } }, "localname": "OperatingLeasesMonthlyRentalRate", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_PrepaidResearchandDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Research and Development", "label": "Prepaid Research and Development", "terseLabel": "Prepaid research and development" } } }, "localname": "PrepaidResearchandDevelopment", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": 2.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Contracted Services, Related Party", "label": "Research And Development Expense, Contracted Services, Related Party", "terseLabel": "Contracted services - related party" } } }, "localname": "ResearchAndDevelopmentExpenseContractedServicesRelatedParty", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": 4.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Facilities, Overhead and Other", "label": "Research And Development Expense, Facilities, Overhead and Other", "terseLabel": "Facilities, overhead and other" } } }, "localname": "ResearchAndDevelopmentExpenseFacilitiesOverheadandOther", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Including Related Party", "label": "Research And Development Expense, Including Related Party", "totalLabel": "Research and development expense, related party, net" } } }, "localname": "ResearchAndDevelopmentExpenseIncludingRelatedParty", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseOutsideContractedServices": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": 1.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Outside Contracted Services", "label": "Research And Development Expense, Outside Contracted Services", "terseLabel": "Outside contracted services" } } }, "localname": "ResearchAndDevelopmentExpenseOutsideContractedServices", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": 3.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Personnel Related Costs", "label": "Research And Development Expense, Personnel Related Costs", "terseLabel": "Personnel related costs" } } }, "localname": "ResearchAndDevelopmentExpensePersonnelRelatedCosts", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentInProcessCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research And Development In Process, Current", "label": "Research And Development In Process, Current", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentInProcessCurrent", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchServicesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Research Services Agreement [Member]", "label": "Research Services Agreement [Member]", "terseLabel": "RSA" } } }, "localname": "ResearchServicesAgreementMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_ResearchandDevelopmentExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research and Development Expense, Related Party", "label": "Research and Development Expense, Related Party", "terseLabel": "Research and development - related party" } } }, "localname": "ResearchandDevelopmentExpenseRelatedParty", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_RevenueFromCollaborativeArrangementContractLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from Collaborative Arrangement, Contract Liability", "label": "Revenue from Collaborative Arrangement, Contract Liability", "terseLabel": "Revenue from collaborative arrangement, contract liability" } } }, "localname": "RevenueFromCollaborativeArrangementContractLiability", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_RevenueFromCollaborativeArrangementRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from Collaborative Arrangement, Recognized", "label": "Revenue from Collaborative Arrangement, Recognized", "terseLabel": "Revenue from collaborative arrangement, recognized" } } }, "localname": "RevenueFromCollaborativeArrangementRecognized", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Research and Development Costs [Table Text Block]", "label": "Schedule of Research and Development Costs [Table Text Block]", "terseLabel": "Schedule of Research and Development Costs" } } }, "localname": "ScheduleofResearchandDevelopmentCostsTableTextBlock", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "dyai_SerumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Serum [Member]", "label": "Serum [Member]", "terseLabel": "Serum" } } }, "localname": "SerumMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_ServiceFrameworkAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Service Framework Agreement [Member]", "label": "Service Framework Agreement [Member]", "terseLabel": "SFA" } } }, "localname": "ServiceFrameworkAgreementMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock Issued", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock Issued", "terseLabel": "Exercise of stock options, common stock issued (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "sharesItemType" }, "dyai_VLPbioMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VLPbio [Member]", "label": "VLPbio [Member]", "terseLabel": "VLPbio" } } }, "localname": "VLPbioMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_VTTTechnicalResearchCentreofFinlandLtdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VTT Technical Research Centre of Finland Ltd [Member]", "label": "VTT Technical Research Centre of Finland Ltd [Member]", "terseLabel": "VTT Technical Research Centre of Finland Ltd" } } }, "localname": "VTTTechnicalResearchCentreofFinlandLtdMember", "nsuri": "http://www.dyadic.com/20200331", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r40", "r65" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails", "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails", "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r88", "r119", "r121", "r215", "r217" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Information by billing status of receivables.", "label": "Billing Status, Type [Axis]", "terseLabel": "Billing Status, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r200", "r211" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableOtherCurrent": { "auth_ref": [ "r8", "r26" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable, Other, Current", "terseLabel": "Other" } } }, "localname": "AccountsPayableOtherCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r15", "r21", "r198", "r205" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r15", "r120" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r28" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Legal expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r126", "r128", "r153", "r154" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r128", "r148", "r152" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r37", "r91" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable", "terseLabel": "Allowance for doubtful accounts receivable" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of building rented" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r87", "r196", "r206" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r39" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r96" ], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": { "order": 2.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "totalLabel": "Investment, gross unrealized holding gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r97" ], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 4.0, "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent", "weight": 1.0 }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": { "order": 3.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTotalLabel": "Investment, gross unrealized holding losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r129", "r149" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BilledRevenuesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions.", "label": "Billed Revenues [Member]", "terseLabel": "Billed receivable" } } }, "localname": "BilledRevenuesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r66", "r85" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]", "terseLabel": "Organization and Summary of Significant Accounting Policies" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "auth_ref": [ "r192", "r193", "r194" ], "lang": { "en-US": { "role": { "documentation": "Information by project.", "label": "Project [Axis]", "terseLabel": "Project [Axis]" } } }, "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r24", "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 1.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r59", "r62", "r89" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r90", "r100" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Cash, Cash Equivalent, and Investments" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r54", "r58", "r61" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r54", "r183" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChiefExecutiveOfficerMember": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. In addition, the chief executive officer (CEO) may also be the chairman of the board or president.", "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Research Collaboration and Sub-licensing Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r107", "r201", "r209" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 4)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r106", "r108" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r109" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r80", "r81", "r178", "r179" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r80", "r81", "r178", "r179", "r214" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r80", "r81", "r178", "r179", "r214" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r76", "r203" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations and Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r80", "r81", "r178", "r179" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r80", "r81", "r178", "r179" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r115", "r116", "r120" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred research and development obligations" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r123", "r125" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r46" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Costs of research and development revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r45" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r79" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r166" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectorMember": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).", "label": "Director [Member]", "terseLabel": "Board of Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r113", "r155" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "verboseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per common share (USD per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r62", "r71", "r72", "r73" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r183" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee wages and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r123", "r124", "r125", "r174", "r188" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r123", "r124", "r125", "r174", "r189" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r123", "r124", "r125", "r174", "r190" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r180", "r181", "r182" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign currency exchange loss (gain), net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r180", "r181", "r182" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "negatedTerseLabel": "Foreign currency exchange loss (gain), net" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r62", "r182", "r184" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transaction Gain or Loss" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HeldToMaturitySecuritiesCurrent": { "auth_ref": [ "r95" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 2.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.", "label": "Debt Securities, Held-to-maturity, Current", "terseLabel": "Short-term investment securities", "totalLabel": "Short term investments, adjusted cost" } } }, "localname": "HeldToMaturitySecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesNoncurrent": { "auth_ref": [ "r95" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 3.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.", "label": "Debt Securities, Held-to-maturity, Noncurrent", "terseLabel": "Long-term investment securities", "totalLabel": "Long term investments, adjusted cost" } } }, "localname": "HeldToMaturitySecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r47" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income (Loss) Attributable to Parent, before Tax", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r105" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r64", "r86", "r168" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r62", "r160", "r161", "r164", "r165", "r167", "r169", "r216" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r34", "r199", "r212" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivableNoncurrent": { "auth_ref": [ "r12", "r204" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Noncurrent", "terseLabel": "Long-term income tax receivable" } } }, "localname": "IncomeTaxesReceivableNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedTerseLabel": "Interest receivable" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred research and development obligation" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "Increase (Decrease) in Income Taxes Receivable", "negatedTerseLabel": "Income tax receivable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable, Current", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfPremium": { "auth_ref": [ "r49" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization of purchase premium on nonoperating securities.", "label": "Investment Income, Amortization of Premium", "terseLabel": "Amortization of held-to-maturity securities, net" } } }, "localname": "InvestmentIncomeAmortizationOfPremium", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r27", "r62", "r98", "r99", "r102" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment Securities" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsAndCash": { "auth_ref": [ "r210" ], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": { "order": 1.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.", "label": "Investments and Cash", "totalLabel": "Cash and Investment, fair value" } } }, "localname": "InvestmentsAndCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]", "terseLabel": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Domain]", "terseLabel": "Lease Arrangement, Type [Domain]" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r197", "r208" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r54", "r55", "r57" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r41", "r42", "r43", "r57", "r72", "r202", "r213" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r67", "r68", "r69" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements Not Adopted and Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Outside of the United States" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r28" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r1", "r5" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid insurance" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": { "auth_ref": [ "r52", "r94" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.", "label": "Payments to Acquire Held-to-maturity Securities", "negatedTerseLabel": "Purchases of held-to-maturity investment securities" } } }, "localname": "PaymentsToAcquireHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r129", "r149" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (USD per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r22", "r23" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r2", "r5", "r103", "r104" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid expenses - various" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r3", "r5", "r103", "r104" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "auth_ref": [ "r55", "r60" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.", "label": "Proceeds from Income Tax Refunds", "terseLabel": "Cash received from income tax refund" } } }, "localname": "ProceedsFromIncomeTaxRefunds", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": { "auth_ref": [ "r50", "r94" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.", "label": "Proceeds from Sale and Maturity of Held-to-maturity Securities", "terseLabel": "Proceeds from maturities of investment securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "terseLabel": "Proceeds from sales of business" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r53", "r150" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProjectMember": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Planned program of work.", "label": "Project [Domain]", "terseLabel": "Project [Domain]" } } }, "localname": "ProjectMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesBillingStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.", "label": "Receivables Billing Status [Domain]", "terseLabel": "Receivables Billing Status [Domain]" } } }, "localname": "ReceivablesBillingStatusDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r21", "r62", "r92" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Research and Development [Abstract]", "terseLabel": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r156", "r218" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r62", "r156" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r110", "r207" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r117", "r118", "r119" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Research and development revenue", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r63", "r122" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Sales Revenue, Net [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Schedule of Cash, Available-for-sale Securities, Short-term and Long-term Investment Securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r157", "r158" ], "lang": { "en-US": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r141", "r142", "r143" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Activity [Table Text Block]", "terseLabel": "Schedule of non-cash stock option compensation expense" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r129", "r149" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r134", "r142", "r143" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of valuation assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "verboseLabel": "Schedule of stockholders equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Award requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-Free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-Free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under an established share-based compensation plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Approved (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercisable (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "verboseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r149" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r136", "r149" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending (in shares)", "periodStartLabel": "Outstanding, beginning (in shares)", "terseLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, outstanding, ending (USD per share)", "periodStartLabel": "Weighted average exercise price, outstanding, beginning (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Number of share instruments newly issued under a share-based compensation plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r127", "r132" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price, exercised (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, expired (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, canceled (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price, granted (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Compensation Award, Tranche One [Member]", "verboseLabel": "Period one" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Compensation Award, Tranche Two [Member]", "terseLabel": "Period two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r62", "r129", "r133" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r146", "r151" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r149" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term, outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r33", "r109" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r109", "r110", "r138" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r33", "r109", "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r18", "r19", "r93" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxYear2018Member": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Identified as tax year 2018.", "label": "Tax Year 2018 [Member]", "terseLabel": "Tax Year 2018" } } }, "localname": "TaxYear2018Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r36", "r111" ], "lang": { "en-US": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r32", "r111" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r32", "r111", "r112" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, shares held at cost", "terseLabel": "Treasury stock, shares held at cost" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnbilledRevenuesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.", "label": "Unbilled Revenues [Member]", "terseLabel": "Unbilled receivable" } } }, "localname": "UnbilledRevenuesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r159", "r163" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r74", "r75", "r77", "r78", "r82", "r83", "r84" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule for share-based compensation.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule for share-based compensation.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(a)(32))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5)(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1,2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r219": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r221": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r222": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r223": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r224": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2,12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "305", "URI": "http://asc.fasb.org/topic&trid=2122426" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5144-111524" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.M)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713" } }, "version": "2.1" } XML 53 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Organization and Summary of Significant Accounting Policies Organization and Summary of Significant Accounting Policies
Description of Business
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica (formerly Myceliophthora thermophila) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.
On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (“DuPont”), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.
After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is aiming to develop products such as innovative vaccines and drugs, biosimilars and/or biobetters.
Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”. Prior to the Company’s uplisting to the NASDAQ, the Company’s common stock traded on the OTCQX market.

Impact of COVID-19

The recent outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company’s employees, operations, and research projects.
To date, as a direct result of COVID-19, most of our employees are working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the response to curb its spread, currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.
The Company is currently working on several COVID-19 related vaccine and antibody opportunities. For example, the Israel Institute for Biologic Research (“IIBR”) is exploring the potential of Dyadic’s industrially proven C1 gene expression platform to express certain gene sequences and targets developed by IIBR into both an rVaccine candidate and mAbs that may potentially help combat the outbreak of the COVID-19 virus. The Company is also working with three scientists who are a part of the EU ZAPI initiative: Dr. Bosch at Utrecht University, Dr. Haagmans at Erasmus Medical Center, and Prof. Osterhaus at University of Veterinary Medicine Hannover, as well as with Dr. Erroba and Mr. Es-Sbai at clinical contract research organizations to develop and submit a proposal for funding to pharmaceutical organizations and governmental agencies. The objective of this proposal is to develop, and pre-clinically and clinically evaluate (in Phase I/II trials), a multimeric self-assembling SARS-CoV-2 Receptor Binding Domain vaccine candidate to rapidly respond to the COVID-19 pandemic. Another proposal was developed in conjunction with Ufovax, a spin-off vaccine company of Scripps Research, which was submitted to many of the same parties. In addition, the Company is pursuing other opportunities where it may be able to apply its C1gene expression platform to help combat the COVID-19 pandemic; however, there is no assurance that any of these opportunities will materialize or that the C1 technology or any product expressed from C1 or any of the various other steps in a vaccine or drug development process will perform, provide benefits, obtain governmental safety and regulatory approvals, be registered or gain market acceptance. In addition, our C1 technology has yet to be used to produce a vaccine, antibody or other biologic product that has entered the clinical trial phase, and we are competing with more experienced companies for grants or funding of this type. As a result, there is no assurance that we will receive these grants or funding resulting from these proposals.
We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs of our operations. We believe that we have sufficient cash, cash equivalents and investments to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing balances of cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.

Summary of Significant Accounting Policies

Basis of Presentation
The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2019, included in our Form 10-K which was filed with the SEC on March 30, 2020.
In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.
Use of Estimates
The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
Concentrations and Credit Risk
The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.
For the three months ended March 31, 2020 and 2019, the Company’s revenue was generated from five and six customers, respectively. As of March 31, 2020 and December 31, 2019, the Company’s accounts receivable was from eight and five customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations.
The Company generates a portion of its revenues from customers that are located outside of the United States. For the three months ended March 31, 2020, the Company had three customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 58.0% or $183,000 of total revenue. For the three months ended March 31, 2019, the Company had one customer outside of the United States (i.e. European customer) that accounted for approximately 69.7% or $281,000 of total revenue.
As of March 31, 2020, the Company had eight customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 72.9% or $378,000 of accounts receivable. As of December 31, 2019, the Company had four customers outside of the United States that accounted for approximately 69.5% or $388,000 of accounts receivable.
The Company uses a few contract research organizations (“CROs”) to conduct its research projects. For the three months ended March 31, 2020 and 2019, one CRO accounted for approximately 100% and 68.1% of total research services we purchased, respectively. As of March 31, 2020, approximately $596,000 or 91.2% of accounts payable was related to this CRO. At December 31, 2019, approximately $706,000 or 74.9% of accounts payable was to this CRO. The loss of business from this CRO or a combination of the Company’s CROs could adversely affect its operations.
Cash and Cash Equivalents
We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.

Investment Securities
The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).
The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of March 31, 2020 and December 31, 2019, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of March 31, 2020 or December 31, 2019.
Accounts Receivable
Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.
Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. There was no allowance for doubtful accounts as of March 31, 2020 and December 31, 2019.
Accounts receivable consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Billed receivable $405,101  $432,546  
Unbilled receivable113,500  125,984  
$518,601  $558,530  

Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Prepaid insurance$198,554  $173,890  
Prepaid expenses - various88,607  101,221  
Prepaid taxes1,334  2,888  
$288,495  $277,999  
Accounts Payable
Accounts payable consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Research and development expenses$590,452  $766,001  
Legal expenses9,782  26,994  
Other53,139  150,383  
$653,373  $943,378  
Accrued Expenses
Accrued expenses consist of the following:
March 31, 2020December 31, 2019
(Unaudited)(Audited)
Employee wages and benefits$162,310  $474,388  
Research and development expenses20,035  69,795  
Other57,658  21,820  
$240,003  $566,003  

Revenue Recognition
The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to grants and fundings: The Company may receive grants and fundings from governments, agencies, and other private and not-for-profit organizations. These grants and fundings are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred
research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

Research and Development Costs
Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.
Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three months ended March 31, 2020 and 2019 were as follows:
Three Months Ended March 31,
20202019
(Unaudited)(Unaudited)
Outside contracted services$613,790  $585,487  
Contracted services - related party—  389,473  
Personnel related costs123,638  94,762  
Facilities, overhead and other18,025  12,121  
$755,453  $1,081,843  

Foreign Currency Transaction Gain or Loss
The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.
Fair Value Measurements
The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 – Quoted prices in active markets for identical assets or liabilities.
•Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.
The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
Income Taxes
The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from 35% to 21% and repeal of the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended December 31, 2019.
The TCJA repealed the corporate AMT but permitted unused AMT credit carryforwards to be used to reduce the regular tax obligation in future years. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Subsequently, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), which was signed into law in March 2020, accelerated the full refund of any unused AMT credits from 2021 (as provided for in the TCJA) to 2018 or 2019, at the taxpayer’s election.

Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of March 31, 2020, we have received 50% or approximately a $0.5 million refund for tax year 2018 and we expect to receive the remaining portion in 2020 pursuant to the CARES Act.

For the three months ended March 31, 2020, there were no provision for income taxes and unrecognized tax benefits recorded.

Deferred tax assets as of March 31, 2020 and December 31, 2019 were approximately $9.6 million and $7.2 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of March 31, 2020 and December 31, 2019.
On June 20, 2019, the Company received a letter from the United States Internal Revenue Service (the “IRS”) informing the Company that its 2016 federal tax return was selected for examination. In August 2019, the Company had a meeting with the IRS agent and provided the IRS with all requested information. Thus far, the Company has not been informed of any assessment and we are unable to predict when the audit will be concluded or whether any assessment will be proposed.
Comprehensive Income (Loss)
Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.

Stock-Based Compensation

We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Net Loss Per Share
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average
number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method.
For the three months ended March 31, 2020 and 2019, the effect of the potential exercise of options to purchase 4,663,390 and 4,541,890 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.
Recent Accounting Pronouncements Not Adopted as of March 31, 2020
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2023. The Company does not expect ASU 2016-13 to have material impact on our consolidated financial statements.
Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.
Recently Adopted Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The ASU was effective for the Company beginning in the first quarter of 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
XML 54 R3.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Preferred stock, par value (USD per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (USD per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 39,722,659 39,612,659
Common stock, shares outstanding (in shares) 27,469,157 27,359,157
Treasury stock (in shares) 12,253,502 12,253,502